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The increase incidence of obesity and eating disorders represents a 
major health problem in developed countries. The low rate of 
success of treatments to prevent or reverse obesity, and overeating 
that causes it, highlights the important behavioural alterations that 
are associated to this disease. These alterations seem to be mediated 
by modifications in the reward circuits that mimic changes occurring 
during addictive behaviour. Moreover, like drugs of abuse, obesity is 
associated with abnormal intake habits when maintaining diet that 
can endure vulnerability to relapse. In the present thesis, we have 
first investigated the involvement of the endogenous opioid system 
in the neurobiological mechanism underlying drug and food 
reinstatement, as a potential therapeutic target in these behavioural 
disorders. Moreover, we have investigated the relationships between 
overeating and behavioural addiction. Indeed, we have demonstrated 
that repeated operant training with palatable food promotes 
behavioural alterations, as well as epigenetic, proteomic and 
structural plasticity changes in the reward circuit reminiscent to 
those observed with drugs of abuse. Finally, we identified the 
cannabinoid receptor 1 and the delta opioid receptor as common 








El aumento de la incidencia de la obesidad y de los trastornos de la 
alimentación representa un importante problema de salud en los 
países desarrollados. La baja tasa de éxito de los tratamientos 
disponibles para prevenir o revertir la obesidad y el fácil acceso a la 
comida obesogenica que lo causa, destacan la necesidad de encentrar 
dianas terapéuticas eficaces. Las importantes alteraciones 
conductuales que se asocian a esta enfermedad parecen estar 
mediadas por modificaciones en los circuitos de recompensa que 
imitan los cambios que ocurren durante el comportamiento adictivo. 
Por otra parte, al igual que las drogas de abuso, la obesidad se asocia 
con hábitos de ingesta anormales que pueden incrementar la 
vulnerabilidad a la recaída de búsqueda de comida. En la presente 
tesis, hemos investigado primero la implicación del sistema opioide 
endógeno en el mecanismo neurobiológico que subyace a la recaída 
del comportamiento de búsqueda de drogas y comida como una 
posible diana terapéutica en estos trastornos del comportamiento. En 
segundo lugar, hemos investigado las relaciones entre la sobre 
ingesta de comida palatable y la adicción conductual. De hecho, 
hemos demostrado que el entrenamiento operante repetido con 
comida palatable promueve alteraciones de la conducta, así como 
cambios epigenéticos, proteómicos y de plasticidad estructural en el 
circuito de la recompensa que recuerdan a los observados con las 
drogas de abuso. Es destacable señalar que hemos identificado el 
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receptor cannabinoide 1 y el receptor delta opioide como sustratos 




































2-AG 2: arachidonoylglycerol 
AEA: anandamide 
AMPK: 5' adenosine monophosphate-activated protein kinase 
AgRP: agouti-related peptide 
AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
ARC: arcuate hypothalamic nucleus 
BED: binge-eating disorders 
cAMP: cyclic adenosine-5'-monophosphate 
CART: cocaine- and amphetamine- regulated transcript 
CB1R: cannabinoid receptor type 1 
CB2R: cannabinoid receptor type 2 
CCK: colecistoquinina 
CRF: corticotropin-releasing factor 
CRH: corticotrophin-releasing hormone 
D1-4R: dopamine receptor type 1-4 
DA: dopamine 
DMH: dorsomedial hypothalamic nucleus 
DOR: delta opioid receptor 
KOR: kappa opioid receptor 
DSM: Diagnostic Statistical Manual of Mental Disorders 
ECS: endocannabinoid system 
EPSP: post synaptic potential 
FTO: fat mass and obesity associated gene 
GABA: γ-aminobutyric acid 
GLP-1: glucagon-like peptide 1 




ICD-11: International Statistical Classification of Diseases and Related Health Problems 11th Revision 
LHA: lateral hypothalamic area 
LTD: long-term depression 
LTP: long-term potentiation 
MCH: melanin-concentrating hormone 
MDMDA: 3,4-methylenedioxy-methamphetamine 
mGluR1‐8: metabotropic glutamate receptor 1-8 
MOR: mu opioid receptor 
MSH: melanocyte stimulating hormone 
NAc: nucleus accumbens 
NMDAR: N-methyl-D-aspartate receptor 
NPY: neuropeptide Y 
PDYN: prodynorphin 
PENK: proenkephalin 
PFC: prefrontal cortex 
PKA: protein kinase A 
POMC: proopiomelanocortin 
PP: pancreatic polypeptide 
PVH: paraventricular hypothalamic nucleus  
PYY: peptide YY 
THC: Δ9-tetrahydrocannabinol 
TRPV1: transient receptor potential cation channel subfamily V 
VMH: ventromedial hypothalamus 
VTA: ventral tegmental area 
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1.1. Addiction and relative diseases 
Addiction is a multifactorial brain disease that affects behavioural 
responses, in which neurobiological changes promoted by chronic 
exposure to a drug of abuse lead to compulsion to seek and take the 
drug, loss of control over intake despite consciousness of its 
negative consequences and relapse even after long periods of 
abstinence (American Psychiatric Association, APA 2013). 
Addiction is complex and has multifaceted symptoms, associated 
with dysfunctions in motivational, emotional, learning and 
behavioural control (Goldstein & Volkow 2011). A current triadic 
model proposes that the pathophysiology of addiction involves 
interactions between the drug, the environment and the vulnerable 
phenotype (Kreek et al. 2002). Indeed, genetic and environmental 
factors contribute to the development and progression of this 
maladaptive pattern of drug use leading to social and physical 
impairments (APA 2013). 
Clinically, this brain disease is diagnosed by several psychiatric 
manuals, such as the Diagnostic and Statistical Manual of Mental 
Disorders (DSM) of the APA or the International Classification of 
Diseases, 11th Revision (ICD-11; World Health Organization, 
WHO). Important revisions to the definitions and diagnosis of 
addiction were recognized in various versions of DMS during the 
last years. In particular, the DMS-III (1980) considered mainly the 






term exposure to drugs of abuse to diagnose addiction, using a 
physiological dependence approach ("assumption drug centered"). 
In the DSM-IV (1994), the term addiction was referred also to the 
psychological changes that the drug use can lead, with a 
psychological dependence approach (“assumption individual 
centered”) and in this line other 5 diagnostic criteria related to the 
loss of control of consumption were added. Indeed, tolerance and 
withdrawal were no longer necessary criteria to diagnose drug 
dependence and the diagnosis was given only when the patient met 
at least three of the seven criteria (see Table 1). In the last DSM-5 
edition (2013), the term addiction was also applied to compulsions 
that are not substance-related, taking into account the behavioural 
aspect of this disease, with an approach “behavioural centered”. In 
this line, gambling disorder was added as the only diagnosable 
condition in a new category of behavioural addictions since it 
resembles substance use disorder to a certain extent. In this last 
version, addiction combines the DSM-IV categories of substance 
abuse and substance dependence into a single disorder, named 
substance use disorder. Each specific substance is addressed as a 
separate use disorder, but nearly all substances are diagnosed based 
on the same overarching criteria (APA 2013). In addition, DSM-5 
includes criteria to specify the severity of substance use disorders, 
which results from merging the previous lists of dependence and 
abuse criteria into a single list of 11 criteria (see Table 1). 
Considering the pattern of drug-use and the related-symptoms of 
pathological intake, the threshold for substance use disorder 






Table 1. Comparison of the diagnosis items of drug use related disorders in 
DSM-III, DSM-IV and DSM-5, with their corresponding criteria measured in the 







2–3, mild; 4–5, moderate; ≥6, severe disorder. Classifications are 
categorical, i.e. a criterion is positive when present, independent of 
its intensity. To avoid the mislabelling of patients as dependent or 
addicted, tolerance and withdrawal do not count when the 
individual develops physiological dependence while adhering to a 
prescribed regimen (Compton et al. 2013).  
Therefore, transition to addiction was initially defined as the 
appearance of changes in drug effects (mainly tolerance and 
withdrawal), and it is currently described by changes in the 
modality of drug-taking from controlled drug use to loss of control. 
Thus, the occasional but limited use of a drug is clinically distinct 
from escalated drug use, loss of control over limiting drug intake, 
and the emergence of chronic compulsive drug-seeking that 
characterize addiction (Koob & Volkow 2010). Indeed, not all 
occasional drug users will became addict. For instance, out of 100 
people initiating cocaine use, 15–17 will develop addiction 
(Anthony et al. 1994). It is estimated that in the last years, drug use 
disorders affected around 27 million people (UNODC, World Drug 
Report 2015). No efficient cure for substance use disorders actually 
exists, and the available therapies are usually able to alleviate only 
withdrawal symptoms, but remain largely unsuccessful to promote 
control over drug intake (National institute of drug of abuse, NIDA 
1999). Indeed, relapse rate range between 50% and 90% for most of 
the drugs within the first year of treatment (Gonzales et al. 2010; 
Powell et al. 2010). This high rate of relapse to drug use after 
abstinence represents a major clinical problem, and understanding 
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the neurobiological basis of relapse constitutes a primary challenge 
of drug addiction research.  
1.2 Neurobiological substrate of addiction 
Current views recognize that drug addiction is based on 
pathological changes in brain functions produced by repeated 
pharmacological insult of drugs of abuse to specific brain circuits 
(Kalivas & O’Brien 2008). Drug-induced alterations in 
neurotransmitter systems disrupt the neuronal functions of the brain 
structures that compose the mesocorticolimbic system, and 
ultimately produce cognitive and emotional dysfunctions (Koob & 
Volkow 2010). In this line, drug addiction affects many areas of the 
brain reward system including nucleus accumbens (NAc), ventral 
tegmental area (VTA) and ventral pallidum, memory/learning-
conditioning circuits including amygdala and hippocampus (HCP), 
motivation /drive systems including orbitofrontal cortex, subcallosal 
cortex, dorsal striatum (ST) and motor cortex, inhibitory 
control/executive function including inferior frontal cortex (PFC), 
orbitofrontal cortex and anterior cingulate cortex and stress 
reactivity including habenula and amygdala (Volkow et al. 2011; 
Volkow & Baler 2013). This network of interacting circuits 
contributes to the complex set of pathological behaviours 
underlying addiction.  
An altered dopamine (DA) signalling has been implicated in all 
stages of drug addiction, from induction to maintenance and 



















Figure 1. Model of brain circuits implicated in drug addiction a) Schematic 
and oversimplified sagittal view of the main brain structures involved in 
addiction. b-c) Model proposing a network of interacting circuits in the non-
addicted and addicted brain: reward (red: located in the NAc and VP); motivation 
(green: located in OFC, DS, CG and mCTX); memory (gold: located in the Am 
and HCP); and executive control (blue: located in dorsolateral PFC, anterior CG, 
and inferior frontal cortex). In addition, these circuits also interact with circuits 
involved in the regulation of mood and stress reactivity (orange: HPA and Am); 
b) in non-addicted brain these circuits are balanced and the result is a proper 
inhibitory control and decision making; c) in the addicted brain the enhanced 
expectation value of the drug in the reward, motivation and memory circuits 
overcomes the control circuit, favoring a positive-feedback loop initiated by the 
consumption of the drug and perpetuated by the increased activation of the 
motivation/drive, memory and stress reactivity circuits. PFC, prefrontal cortex; 
CG, anterior cingulate cortex; OFC, orbitofrontal cortex; DS dorsal striatum; 
mCTX, motor cortex; Am, amygdala; Hip, hippocampus; NAc, nucleus 




mesolimbic DA pathway. Indeed, the DA projection from the VTA 
of the midbrain to the NAc is the major substrate of reinforcement 
for both natural rewards and addictive drugs (Schultz 1997). 
Addictive drugs directly or indirectly trigger exaggerated, but 
transitory increases in extracellular DA in the NAc. This increase 
positively correlates with the intensity of “pleasure” that subjects 
experience when taking drugs (Volkow et al. 2010). 
However, other DA pathways, such as the mesostriatal DA neurons 
in substancia nigra projecting to dorsal ST also contribute to drug 
reward (Wise 2009). Indeed, the nigrostriatal and mesolimbic DA 
systems have close anatomical relationships. Due to the proximity 
between substantia nigra and VTA (Wise 1981), these two areas 
have several functional overlaps. Thus, DA neurons of the 
substantia nigra respond similarly to rewards than DA neurons of 
the VTA (Apicella et al. 1991). Interestingly, the DA involvement 
in reward does not seem to equate only with hedonic pleasure, 
mediated in part by endogenous opioids and cannabinoids. Indeed, 
DA appears to encode prediction of rewards, imprinting incentive 
value to reinforcers and learning of reward associations by 
conditioning processes through modulation of subcortical and 
cortical brain regions (Volkow et al. 2012). 
Conditioning is one of the initial neuroadaptations that follows 
exposure to drugs and involves DA phasic signalling, 
predominantly though activation of DA receptor 1 (D1R), and 
synaptic changes in N-methyl-D-aspartate (NMDAR) and α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPAR)






underlie the intense desire for the drug that occurs when addicted 
subjects are exposed to drug cues that triggers the compulsive use 
of the drug. This hypothesis is supported by evidence showing that 
blockade of D1R or D2R activity in NAc shell and core prevents 
acquisition of conditioned learning tasks (Di Ciano et al. 2001). In 
the same direction, injection of D1R agonist or antagonist, 
respectively, enhances or decreases retention of memory in rodents 
(Morris et al. 2003), indicating also an important modulatory role of 
DA system in memory consolidation in the HCP. In addition, 
repeated experiences to a given stimulus lead to the shift of DA 
neurons activation from the presentation of the reward to the 
environmental cue that predicts its appearance. Therefore, it has 
been postulated that DA activity provides a predictor signal for the 
learning of stimulus through reward associations. Thus, DA cell 
firing is enhanced in response to the prediction of reward and not to 
reward itself, whereas DA cells fire decreases if the expected 
reward fails to materialise (Schultz 1997). 
DA signalling also modulates motivation to seek the drug through 
the regulation of several target regions including NAc, orbitofrontal 
cortex, dorsal ST and amygdala. Specifically, DA signalling is 
implicated in the motivation cost required to complete tasks that 
demand high levels of effort (Salamone et al. 2007). Dysregulation 
of the DA signalling is not only associated with an enhanced 
motivation (Volkow & Li 2005), but also contributes to the shift 
from impulsive to compulsive drug intake through the modulation 
of circuits involved in decision making and executive functions 
(Goldstein & Volkow 2002). Indeed, the PFC plays a crucial role in 
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inhibitory control, and an impaired PFC function is linked to the 
poor control and high compulsivity seen in addiction (Volkow & 
Baler 2013). Indeed, a decreased PFC activity associated with the 
reduction in striatal D2R levels has been reported during drug 
addiction (Volkow et al. 2007; Thanos et al. 2007). The decrease in 
D2R results in a hypofunctioning of the reward system, and 
“addicted” individuals compensate for decreased DA availability 
consuming large amounts of rewarding substances. This improper 
cortico-striatal DA signalling could underlie the impulsive 
behaviour and loss of control over drug intake (Volkow et al. 2000).  
Addictive drugs share the common feature to enhance DA activity 
and release in the mesocorticolimbic circuit by mimicking the 
effects of natural rewards. The potency of drugs as well as the 
mechanism, by which they increase DA, differs for the various drug 
classes. Indeed, addictive drugs can be distinguished into three main 
groups according to the way that they activate DA neurons in the 
mesocorticolimbic system (Lüscher & Ungless 2006).  
Class I:  
Drugs that bind to G protein–coupled receptors. This group 
includes the opioids (e.g. morphine, heroin, through mu opioid 
receptors, MOR), cannabinoids (e.g. Δ9-tetrahydrocannabinol, 
THC), through cannabinoid receptor 1, CB1R), and 
gamma‐hydroxy butyrate, through GABAB receptors). These drugs, 
acting on G protein-coupled receptors that are of the Gi/o family, 
inhibit mainly gamma‐aminobutyric acid (GABA) neurons in the 
VTA. As GABA neurons act as local inhibitory interneurons in the 
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VTA, their inhibition leads to a net disinhibition of DA neurons and 
increase DA release.  
Class II: 
Drugs that interact with ionotropic receptors or ion channels. 
This group includes nicotine (acetylcholine receptors), alcohol 
(GABAA and other receptors), and benzodiazepines (GABAA 
receptors). Mechanisms of these drugs are less clear but in general 
have a combined effect: inhibit GABA terminals in the VTA (e.g 
alcohol) and also directly modulate DA neurons activity in the VTA 
(e.g. nicotine) leading to enhanced release of DA. 
Class III: 
         Drugs that target monoamine transporters. This group 
comprises cocaine, amphetamines, and amphetamine derivates such 
as methylenedioxymetamphetamine (MDMA, ecstasy). Whereas all 
other drugs directly act on VTA neurons, these drugs block the 
re‐uptake of DA, or stimulate non‐vesicular release of DA in their 
projecting axons, causing an accumulation of extracellular DA in 
target structures, such as the NAc.  
As previously reported, addictive drugs also modulate other 
neurotransmitter/neuromodulator systems such as the opioid, the 
glutamatergic, the GABAergic and the endocannabinoid system 
(ECS), among others which also play key roles in drug rewarding 






The glutamatergic system plays an important role in drug addiction 
(Kalivas 2009). In particular, glutamatergic signalling in the 
mesocorticolimbic system, via its ionotropic (AMPAR, NMDAR 
and kainate receptor) and metabotropic (mGluR1‐8) receptors, has 
been considered an essential substrate for neuronal plasticity, 
learning and memory mechanisms involved in different aspects of 
the addictive process, such as reinforcement learning, drug 
sensitization and craving/relapse (Tzschentke & Schmidt 2003). 
Indeed, glutamatergic blockade in different parts of the 
mesocorticolimbic system prevents the acquisition of the operant 
self-administration behaviour to obtain natural rewards or drugs of 
abuse (Kelley et al. 1997; Kotlińska & Biała). These effects may 
rely on the capacity of the glutamatergic transmission to activate 
DA cells in the VTA and the following DA release in the NAc 
(Karreman et al. 1996). The glutamatergic system is also a key 
substrate for drug relapse (Knackstedt & Kalivas 2009). Imaging 
studies in human addicts have described that the presentation of the 
drug-related cue promotes drug relapse associated with increased 
glutamatergic activity in several brain structures, such as the 
amygdala and the PFC (Everitt and Wolf 2002).  
The GABAergic transmission is also involved in the mechanisms 
underlying drug addiction. GABA is the major inhibitory signalling 
in the central nervous system through the activation of its ionotropic 
GABAA and metabotropic GABAB receptors. In the VTA, the 
GABAergic system regulates DA transmission and modulates a 
variety of drug-related reinforcement and reward behaviours, 
through pre and post synaptic actions (Steffensen et al. 2009). Thus, 
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stimulation of the GABAB receptor prevents the reinforcing effects 
of cocaine (Shoaib et al. 1998), methamphetamine (Bartoletti et al. 
2004), nicotine (Paterson et al. 2008) heroin, morphine (Assadi et 
al. 2003) and ethanol (Maccioni et al. 2007). Similarly, stimulation 
of GABAA modulates the reinforcing effects of benzodiazepines 
(Shinday et al. 2013), barbiturates (Winger et al. 1975), cocaine, 
amphetamine (Meririnne et al. 1999), and ethanol (Davies 2003). 
Indeed, cocaine self-administration (Negus et al. 2000; Goeders et 
al. 1993; Barrett et al. 2005; Karler et al. 1995) and cocaine and 
amphetamine-induced conditioned place preference (Meririnne et 
al. 1999; Reynolds et al. 2003; Rush et al. 2004) are inhibited by 
agonists or positive modulators of GABAA. Moreover, systemic 
administration of GABAA antagonists such as bicuculline and 
picrotoxin and the inverse agonist Ro 15-4513, reduces ethanol self-
administration (Chester & Cunningham 2002). Similarly, GABAA 
receptor antagonist SR 95531 administrated into specific brain 
regions such as central nucleus of the amygdala, bed nucleus of the 
stria terminalis, and shell of the NAc, also reduces ethanol 
responding in a free-choice operant task (Hyytiä & Koob 1995). 
The effect of GABAA agonists on ethanol self-administration is less 
clear (Chester & Cunningham 2002) and may be region-specific, 
since site-specific injections of muscimol into dorsal and median 
raphe nuclei (Tomkins et al. 1994) or into NAc (Hodge et al. 1995) 
increase and decrease ethanol self-administration respectively. 
However, it is not clear why the administration of both, a GABAA 
receptor agonist (Hodge et al. 1995) and a GABAA receptor 
antagonist (Hodge et al. 1995) into the NAc reduces ethanol self-
Introduction 
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administration. This result may depend on the affinity to a specific 
GABAA subunit. Indeed, knockout mice lacking the delta subunit of 
the GABAA receptor consumed less ethanol compared with wild-
type mice in a free-choice operant procedure (Mihalek et al. 2001). 
Furthermore, GABAA agonists, like benzodiazepines, also improve 
the manifestations of the withdrawal symptoms to ethanol (Prater et 
al. 1999; Miller & Gold 1998) and psychostimulants (Miller & Gold 
1998). In this line, the activation of both GABA receptors 
diminishes the reinstatement of alcohol (Malcolm 2003) and other 
drugs of abuse such as nicotine (Lubbers et al. 2014; Fattore et al. 
2009) and cocaine (Torregrossa & Kalivas 2008).  
The ECS and the opioid system also exert a common role in the 
neurobiological mechanisms underlying drug addiction, as reported 
in chapters 3 and 4. 
In summary, behavioural dysfunctions in addictive disorders have 
been mainly related to drug-induced alterations in DA and 
glutamatergic systems in the mesocorticolimbic circuit. However, 
other neurochemical systems, such as the GABAergic, endogenous 
cannabinoid and opioid system also play important roles in the 
addictive process. A remaining critical issue not yet fully clarified is 
to understand how these alterations lead to persistent physiological 
changes in the different brain reward areas leading to the 
development and maintenance of addiction. 
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1.3 Genetic and environmental influence: effects on 
vulnerability to addiction 
Addiction disorder is a complex disease mainly resulting from 
interactions between genetic and environmental factors combined 
with drug induced changes in the brain. Other factors also influence 
the vulnerability to addiction as the gender and the individual 
comorbidity with other mental disorders. Gender is an important 
factor influencing addiction. Indeed, men have more probability 
than women to become addicted, possible due to hormonal 
differences (Mitchell & Potenza 2015) and progesterone may 
attenuate drug-rewarding effects (Quinones-Jenab & Jenab 2010). 
In the same line, drug addiction is often developed in individuals 
suffering from psychiatric disorders, such as depression, anxiety or 
schizophrenia. The high prevalence of these comorbidities does not 
mean that one condition causes the other, even if one appears first. 
In fact, there are at least three scenarios that should be considered: 
1) Mental illnesses can lead to drug abuse. Patients may abuse drugs
as a form of self-medication. For example, the use of tobacco 
products by patients with schizophrenia is believed to lessen the 
symptoms of the disease and improve cognition (AhnAllen et al. 
2015); 
2) Drugs of abuse may bring to another mental illness. The
increased risk of psychosis in vulnerable marijuana users suggests 
this possibility (Caspi et al. 2005); 
3) Both drug use disorders and other mental illnesses could be
caused by shared risk factors such as genetic vulnerabilities, and/or 
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environmental triggers, like early exposure to stress or trauma (Nee 
2013).  
Moreover, the involvement of similar brain regions is also a 
determinant factor for the comorbidity of these diseases (NIDA, 
2010). 
It is estimated that the risk to progress from recreational use to 
substance related disorder is around 15-17% for cocaine, 31% for 
tobacco (Anthony et al. 1994) and 10% for cannabis users (Lopez-
Quintero et al. 2011). Therefore, risk factors influencing the 
transition to addiction are of fundamental relevance. Addiction as a 
polygenic disease hinges a vast number of genes able to influence 
brain development, neurotransmitter systems, drug metabolic 
pathways, neuronal circuitry and behavioural patterns (Drgon et al. 
2010) that could contribute to brain changes leading to transition 
from controlled to compulsive drug use. Indeed, several 
polymorphic variations have been demonstrated to affect the 
addiction vulnerability (Bierut et al. 2006; Greenwald et al. 2013; 
Heath & Picciotto 2009). An example is the genetic variant of DA 
family receptors (Le Foll et al. 2009). Since DA is a critical 
modulator in the reward area, it is not surprising that many facets of 
the addiction phenotype are influenced by genetic variability in the 
DA system. In a similar way, polymorphisms of the CB1R (Zhang 
et al. 2004) or the MOR and DOR (LaForge et al. 2000) might 















Figure 2. Risk factors in addiction disease.  The overall risk for addiction is 
impacted by the biological makeup of the individual and the surrounding social 
environment with a consequent influence of brain development and function, 
which in turn will influence behaviour (NIDA, 2014). 
 
 
Addiction is not only due to the risk conveyed by genes themselves, 
but also the added impact of the environment on these genes. 
Environmental risk factors are conditions in person’s surroundings 
that could predispose an individual to become addicted to drugs. A 
person may have many environments of influence such as the 
community, family, school, and friends. The risk of addiction can 
develop in any of these domains. Thus, environmental conditions 
influence the expression of genes and could contribute to the 
initiation of addictive drug use and to the transition from controlled 
use to addiction. Indeed, human behaviour is the product of intricate 
networks involving thousands of genes working in the concert with 
multiple developmental and environmental events. In this line, 
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epigenetic regulations represent important adaptive changes linked 
with a dynamic environment that have emerged as critical elements 
for understanding how chronic drug exposure is connected to long 
lasting neuronal changes (Robison & Nestler 2011). Indeed, chronic 
cocaine and alcohol treatments activate and repress many genes 
such as FosB, cyclin-dependent kinase 5, and brain-derived 
neurotrophic factor, where their epigenetic dysregulation, at the 
chromatin level, contributes to the development and maintenance of 
addiction (Biliński et al. 2012; Levine et al. 2005). Similarly, 
repeated exposure to heroin leads to a DNA hypermethylation on 
the gene promoter of MOR which, in turn, follows a reduced 
transcription and consequently decreased MOR protein levels 
(Nielsen et al. 2012). In addition, intermittent subcutaneous nicotine 
administration in rats increases the expression of D1R mRNA in 
PFC, and this increase seems related to changes in histone H4 
acetylation of the D1R gene promoter (Gozen et al. 2013). 
In summary, addiction is viewed as a multifactorial and complex 
disease resulting from a combination of genetic and environmental 
factors that influence brain functions and behaviours (Hamer 2002). 
Understanding the various contributions of these factors will help to 
develop more effective prevention and treatment interventions for 
this disease. 
1.4 Different stages of the addiction process 
The occasional use of a drug is clinically distinct from compulsive 
drug seeking and uncontrolled intake that characterize addiction. 
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The switch from an occasional use to a compulsive habit is a key 
diagnostic feature of addiction and this only emerges after a 
prolonged substance use history. This transition to addiction is 
composed by several steps leading to changes in the modality of 
drug-taking from controlled drug-use to loss of control (Piazza & 
Deroche-Gamonet 2013). The transition to addiction involves 
neuroplasticity changes in some brain structures that may begin 
with modifications in the mesolimbic DA system and a cascade of 
neuroadaptations from ventral to dorsal ST and orbitofrontal cortex 
and eventually dysregulations of the PFC, cingulate gyrus and 
extended amygdala (Koob & Volkow 2010).  
This transition results from three sequential and independent 
phases: (1) initial drug use, when a drug is voluntary taken due to its 
hedonic effects, (2) drug harmful use, when a drug is chronically 
consumed to avoid negative emotional state and finally (3) drug 
addiction, when drug intake becomes compulsive and uncontrolled 
(Koob & Nestler 1997; Koob & Volkow 2010).  
Initially, the individual learns to take drugs during his recreational 
activities, and the primary reinforcing effects of the drug is the 
major reason of the initial drug use (Piazza & Deroche-Gamonet 
2013). This sporadic drug use activates the same brain substrates 
that mediate the positive reinforcing effects of natural rewards, i.e. 
increased DA release in the NAc shell (Di Chiara & Imperato 
1988). 
The repeated and increasing pattern of drug intake leads the drug 
use extremely likeable, due to the DA release (Bassareo & Di 
Chiara 1997) and the motivational effects of drugs related to 
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adaptations that also include the DA system (Hooks et al. 1992; 
Anagnostaras & Robinson 1996). Sensitization of the DA 
transmission in the NAc is considered a crucial factor of the 
neurobiological mechanisms leading to transition to addiction 
(Piazza & Deroche-Gamonet 2013). Another well-documented 
mechanism is the impaired PFC function, leading to reduced ability 
to inhibit excessive drug taking (Volkow et al. 2011). The increased 
activity of DA neurons in the NAc is consistent with an enhanced 
desire to take drugs, whereas the impairment of the PFC function is 
mainly related to increased impulsivity (Jentsch & Taylor 1999). 
Afterwards, drugs progressively shift from being strongly wanted to 
also strongly needed. The establishment of sustained drug intake 
induces an allostatic state associated with a less sensitive reward 
system that needs stronger stimulation to achieve the same level of 
reward and this state will progressively bring the non-drug state out 
of the comfort zone. Accordingly, a negative emotional state that 
includes dysphoria, anxiety or even physical withdrawal symptoms 
appears when the drug is not available. This negative reinforcement 
promotes even more the consumption of the drug (Koob 2009; 
Hyman et al. 2006; Kosten & George 2002). The mechanism 
underlying the negative reinforcement is hypothesized to derive 
from dysregulation of key neurochemical elements involved in 
reward and stress functions within the basal forebrain structures 
involving the ventral ST and extended amygdala (Koob 2009). This 
stage includes not only a diminished reward neurotransmission, 
such as decreased DA and serotonin levels in the ventral ST, but 
also activation of brain stress systems, such as corticotropin 
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Figure 3. Phases of the transition to addiction: (1) Recreational, sporadic (ReS) 
drug use, in which drug intake is sporadic and still one among many recreational 
activities of the individual. (2) Intensified, sustained, escalated (ISuE) drug use, 
in which drug intake intensifies and frequent and becomes the principal 
recreational activity of the individual; although some decreased societal and 
personal functioning start appearing, behaviour is still largely organized. (3) Loss 
of control (LoC) of drug use and full addiction that results in disorganization of 
the addict’s behaviour; drug-devoted activities are now the principal occupations 






-releasing factor (CRF) in the extended amygdala that regulates the 
induction of anxiety-like behaviours (Koob 2009). Indeed, the 
hypothalamic-pituitary-adrenal axis and the brain stress system 
mediated by CRF are dysregulated by chronic administration of all 
major drugs of abuse, with a common response of elevated 
adrenocorticotropic hormone, corticosterone, and amygdala CRF 
during acute withdrawal to all the prototypical drugs of abuse (Delfs 
et al. 2000; Olive et al. 2002). Although these mechanisms are 
shared substrates for the majority of drugs of abuse, others appear to 
be drug-specific. Indeed, increased sensitivity of opioid receptor 
transduction mechanisms is revealed in the NAc during opiate 
withdrawal (Stinus et al. 1990), decreased GABAergic and 
increased NMDA glutamatergic transmission during alcohol 
withdrawal (Weiss et al. 1996), and differential regional changes 
are reported in nicotine receptor functions (Dani & Heinemann 
1996). In addition, the somatic manifestations of the withdrawal 
symptoms are different depending on the drug used. 
Moreover, the sustained drug use induces compulsive seeking-
behaviours and loss of control of drug intake, a persistent state in 
which drug use escapes control even when serious negative 
consequences ensue (Hyman & Malenka 2001). The behavioural 
alteration is characterized by a loss of long term depression (LTD) 
of synaptic plasticity in reward areas (Kasanetz et al. 2013) 
mediated by NMDAR-dependent LTD and accompanied by the 
appearance of an impaired mGluR 2/3-mediated LTD in the cortex 
of addicted rats (Piazza & Deroche-Gamonet 2013). Moreover, 






quickly in the VTA, then in the NAc and later in the PFC (Lüscher 
& Malenka 2011). This loss in synaptic plasticity and the fault in 
maintained adaptive behavioural responses to changes in 
environmental contingencies (Neiman & Loewenstein 2013) 
produce a kind of crystallized behaviour around one unique goal, 
the compulsive drug seeking and intake (Piazza & Deroche-
Gamonet 2013). More studies are needed to understand the 
genetic/epigenetic, cellular, and molecular mechanisms that mediate 
the transition from occasional drug use to the loss of behavioural 




Persistent drug overstimulation causes long-lasting cellular, 
molecular and neurochemical adaptations in the brain that seem to 
be involved in the high vulnerability to relapse after cessation of 
drug use (Kalivas & Volkow 2011; Kalivas 2009). Relapse can be 
defined as the return to drug-seeking and drug-taking behaviour 
after a period of abstinence. The high rate of relapse to drug use is 
recognized as the most difficult clinical problem in the treatment of 
addiction (O’Brien 1997). 
Three main stimuli have been identified to trigger relapse in 
humans: (1) the reexposure to drugs of abuse (Everitt et al. 2003), 
(2) drug-associated environmental cues (Carter & Tiffany 1999b) 
and (3) stress (Shaham et al. 2000; Shalev et al. 2000). Neuronal 
mechanisms underlying drug priming-, cue- or stress-induced 
relapse involve different brain areas and neurotransmitters. 
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Functional brain imaging studies in humans (Daglish & Nutt 2003; 
Goldstein & Volkow 2002) have demonstrated an interconnected 
set of cortical and limbic brain regions in associative learning 
underlying relapse. Indeed, learned associations that occur during 
the process of repeated drug use can later manifest as trigger factors 
in relapse to renewed drug-seeking and drug-taking behaviour. The 
relapse of drug seeking and taking by re-exposure to drugs of abuse 
Figure 4. Diagram showing the primary circuits and neurotransmitters implicated 
in drug-induced reinstatement. VTA, ventral tegmental area, cell body regions of 
mesocorticolimbic DA pathway; NAc, nucleus accumbens; medial PFC, medial 
prefrontal cortex; VP/SNr, ventral pallidum/substantia nigra reticulata; PPT/LDT, 







is a robust phenomenon in humans. Neuroanatomical studies 
indicate that relapse depends on the re-activation of the 
mesocorticolimbic system toward the reward. Indeed, circuits and 
main neurotransmitters implicated in drug-induced relapse were 
identified. These include DA projections from the VTA to the NAc 
and medial PFC, and glutamatergic inputs from medial PFC to the 
VTA, the peduncular pontine, the laterodorsal tegmental nuclei and 
the NAc. There is general agreement that activation of the DA 
pathway from the VTA to the medial PFC contributes significantly 
to the reinstatement of drug seeking (McFarland & Kalivas 2001; 
Sun & Rebec 2005; Capriles et al. 2003). Indeed, increased DA 
release in the medial PFC appears to promote cocaine seeking by 
stimulating the glutamatergic projection from the medial PFC to the 
NAc (McFarland et al. 2003; Park et al. 2002). Accordingly, 
cocaine, amphetamine or DA administered into the dorsal PFC 
reinstates cocaine seeking (McFarland & Kalivas 2001; Park et al. 
2002). The VTA projects to the dorsal medial PFC and, in turn, this 
region projects back directly to the VTA or indirectly through the 
peduncular pontine and laterodorsal tegmental nuclei (Kalivas & 
McFarland 2003; Shaham et al. 2000). The mesocorticolimbic DA 
system plays a critical role in drug-induced reinstatement. 
Activation of these midbrain DA neurons by local morphine 
infusions (Di Chiara & North 1992) or other compounds known to 
increase the firing rates of DA neurons such as NMDA (Karreman 
et al. 1996) reinstates heroin and cocaine seeking (Stewart 1984; 
Vorel 2001). In addition, reversible inactivation of the VTA blocks 
cocaine priming-induced reinstatement of drug seeking (McFarland 
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& Kalivas 2001). Medial PFC glutamate and VTA DA projections 
to the NAc serve as the final common pathway for all events 
inducing relapse (Kalivas & McFarland 2003). In this context, the 
NAc core, but not the shell, is primarily responsible for modulating 
cocaine priming-induced reinstatement of drug seeking (Kalivas & 
McFarland 2003; McFarland & Kalivas 2001). Indeed, reversible 
inhibition of the core by GABAA and GABAB agonists attenuates 
cocaine-seeking behaviour induced by a cocaine prime (McFarland 
& Kalivas 2001). In addition, the ventral portion of the HCP, known 
as the ventral subiculum, is innervated by DA projections from the 
VTA and stimulation of the ventral subiculum activates DA cell 
bodies in the VTA and subsequently leads to increased DA 
transmission in the NAc (Legault et al. 2000). Interestingly, 
electrical stimulation of the ventral subiculum reinstates cocaine or 
amphetamine seeking in rats (Taepavarapruk & Phillips 2003; Vorel 
2001). At present, little is known about the role of DA or glutamate 
in brain areas other than the VTA, NAc and medial PFC in drug-
induced reinstatement. Inactivation by GABAA and GABAB 
agonists of the ventral pallidum attenuates cocaine-induced 
reinstatement, whereas this GABAergic blockade of the substantia 
nigra, central and basolateral nuclei of the amygdala and the 
mediodorsal thalamus has no effect (McFarland & Kalivas 2001; 
Schmidt et al. 2005). 
Contexts or environmental stimuli that are repeatedly associated 
with the drug consumption are known to promote compulsive drug 
taking and craving and are a primary trigger of relapse (Carter & 
Tiffany 1999a; Shalev et al. 2002; See 2002). Discrete stimuli such 
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as odours and sounds, among others, can have similar effects. The 
mechanisms underlying this kind of relapse include activation of 
mGluR2, mGluR3, D1R, CB1R, and MOR, all of which contribute 
to relapse of heroin, cocaine, alcohol, and food seeking induced by 
Figure 5. Diagram showing the primary circuits and neurotransmitters implicated 
in cue-induced reinstatement. VTA, ventral tegmental area, cell body regions of 
mesocorticolimbic DA pathway; NAc, nucleus accumbens; medial PFC, medial 
prefrontal cortex; VP/SNr, ventral pallidum/substantia nigra reticulata; PPT/LDT, 
peduncular pontine and laterodorsal tegmental nuclei; BLA, basolateral 
amygdala; HIPP, HCP. Grey, DA; black, glutamate, (Stewart 2008). 
environmental contexts (Crombag et al. 2008; Nair et al. 2009; 
Ciccocioppo et al. 2001). Principal regions associated with relapse 
induced by environmental contexts are the basolateral amygdala, 






from the VTA to basolateral amygdala, medial PFC and NAc, and 
glutamatergic inputs from the basolateral amygdala and PFC to the 
NAc and the VTA respectively, are involved in this kind of relapse 
(Bossert 2004; Bossert et al. 2006; Fuchs et al. 2007). Cue-induced 
relapse primarily involves enhanced glutamate transmission from 
the dorsal medial PFC to the NAc (Kalivas et al. 2003). Indeed, 
previous animal studies have suggested an important role of the 
NAc core in this type of reinstatement (Di Ciano et al. 2008; Di 
Ciano & Everitt 2004). Furthermore, the dorsomedial PFC sends 
direct and indirect projections to the ventral striatopallidal 
pathways, that may allow planning and executing an appropriate 
motor response (Salinas & McGaugh 1996), and to VTA and the 
raphe nuclei (Uylings & van Eden 1990). In turn, DA projections 
from the VTA to the NAc, medial PFC, and basolateral amygdala 
acting on D1R would be able of stimulating glutamate projection 
neurons in the amygdala and medial PFC (See et al. 2001; Sun & 
Rebec 2005; Alleweireldt et al. 2006; See 2009), whereas DA 
acting on both D1R and D2R in the NAc shell (Anderson et al. 
2003; Bachtell et al. 2005; Schmidt et al. 2006) could act in concert 
with AMPAR to reduce GABAergic transmission to the ventral 
pallidum (O’Connor 2001; Torregrossa et al. 2008). In addition, 
basolateral amygdala and dorsal HCP are key structures involved in 
the reconsolidation of drug context memories (Wells et al. 2011) 
and HCP and amygdala inputs to the NAc can modulate reward-
related behaviours. Moreover, the projection from the basolateral 
amygdala to the dorsomedial PFC (Pitkanen 2000) may allow the 
amygdala to provide relevant information to the PFC about the 
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affective significance of drug-associated stimuli. The PFC 
integrates this information and guides purposeful behaviour relevant 
to the salience of drug-associated stimuli (Everitt & Robbins 2000). 
Previous research indicates that the dorsomedial PFC, basolateral 
amygdala and HCP exhibit neuronal activation concomitant with 
cocaine-seeking behaviour in a cocaine-paired environment 
(Neisewander et al. 2000), and lesions of these structures impair 
place conditioning, a task dependent on context-reward learning 
(Tzschentke & Schmidt 1999; Ferbinteanu & McDonald 2001; 
Meyers et al. 2003). However, inactivation of the HCP abolished 
contextual reinstatement, but failed to alter explicit cue-induced 
reinstatement of cocaine-seeking behaviour (Fuchs et al. 2005). 
Stress leads to state-related changes in brain reward circuits 
resulting in a greater sensitivity to the reinforcing properties of 
drugs particularly in vulnerable individuals (Piazza & Le Moal 
1998). Several stressors have been reported to reinstate drug 
seeking behaviour and different systems mediate this behaviour.  
The reward system is the first system involved, principally through 
glutamatergic projections from the PFC to the VTA, the NAc, 
basolateral amygdala, the peduncular pontine and the laterodorsal 
tegmental nuclei, and DA projections from the VTA to several brain 
structures such as PFC, NAc and basolateral amygdala. Thus, stress 
induces activation of the DA projections from VTA to medial PFC 
(Thierry et al. 1976). This activation involves D1R which, in the 
medial PFC, is expressed on pyramidal cells promoting excitability 
primarily by increasing NMDAR-mediated effects (Lewis & 
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O’Donnell 2000; Seamans et al. 2001). Moreover, glutamatergic 
projections from dorsal medial PFC to NAc core (Sesack et al. 
1989) and potentially GABAergic projections from NAc shell to 
VTA (the ‘direct’ striatal pathway) (Zahm et al, 2001) and to 
ventral pallidum (the ‘indirect’ pathway) have also a role in this 
reinstatement. Other different pathways are also involved in stress-
induced reinstatement. Thus, several studies have reported the 
involvement of the adrenergic neurotransmission from neurons in 
the lateral tegmental nucleus to the bed nucleus of the stria 
terminalis and central amygdala nucleus, as well as the CRF 
projection from the central amygdala to the bed nucleus of the stria 
terminalis (Shaham et al. 2000). Moreover, CRF projections from 
the bed nucleus of the stria terminalis to VTA (Rodaros et al. 2007) 
are also involved in stress-induced reinstatement of drug seeking. 
The bed nucleus of the stria terminalis is also activated by 
adrenergic projections (Aston-Jones et al. 1999). The bed nucleus of 
the stria terminalis and central amygdala are both considered 
components of the extended amygdala, which is a continuum of 
interconnected nuclei that also includes the shell of the NAc and 
ventromedial aspect of the ventral pallidum, and has been 
postulated to function as an integrated structure in modulating 
emotional responses (Zahm & Heimer 1993; Koob et al. 1993). 
CRF system is known to be activated in response to stressors and to 
mediate a wide variety of physiological and behavioural responses 
to stress, including fear and anxiety (Schulkin et al. 2005; Davis 
2006). Indeed, CRF can be released into the VTA in a stress 






between the CRF-containing cell groups and the DA neurons in the 
















Figure 6. Diagram showing the primary circuits and neurotransmitters implicated 
in stress-induced reinstatement. VTA, ventral tegmental area, cell body regions of 
mesocorticolimbic DA pathway; NAc, nucleus accumbens; medial PFC, medial 
prefrontal cortex; VP/SNr, ventral pallidum/substantia nigra reticulata; PPT/LDT, 
peduncular pontine and laterodorsal tegmental nuclei; BLA, basolateral 
amygdala; HIPP, HCP; CeA, central nucleus of the amygdala; BNST, bed 
nucleus of the stria terminalis. Dark grey, DA; black, glutamate; light grey, CRF 
(Stewart 2008). 
 
modulate seeking behaviour (Prasad et al. 1995; Piazza & Le Moal 
1996). Furthermore, alpha 2-adrenergic agonists, such as clonidine, 
have been found to reduce stress-induced relapse to drug seeking 
(Erb et al. 2000; Shaham et al. 2000) suggesting that noradrenergic 
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activation also mediates stress-induced drug seeking and relapse 
(Shaham 1996; Erb et al. 1998). In addition, hypocretin/orexin 
signalling is also critically involved in relapse of drugs-seeking 
behaviour, such as nicotine. Hypocretin 1 reinstates nicotine- 
seeking through a mechanism independent of corticosterone 
releasing factor activation (Plaza-Zabala et al. 2013). Furthermore, 
hypothalamic arginine vasopressin and its V1b receptor, plays also 
an important role in response to stress. High arginine vasopressin 
mRNA levels have been found in medial/basolateral amygdala 
during stress-induced reinstatement of heroin seeking-behaviour. 
Thus, enhanced amygdalar arginine vasopressin expression may be 
related to individual vulnerability to reinstatement of drug-seeking 
in stress conditions (Zhou et al. 2015). Similarly, substance P may 
play a role in addictive behaviours, including stress-induced relapse, 
due to its interaction  with specific areas of the reward system, such 
as the VTA, amygdala, bed nucleus of the stria terminalis and NAc 
(Commons, 2010). The cholinergic projections from the NAc to the 
basolateral amygdala contain the substancia P receptor, NK1 (Bell 
et al. 1998), suggesting that this receptor can contribute to the 
consolidation of emotionally-motivated learning underlying relapse 
(McGaugh 2004). In addition, substance P likely interacts with the 
CRH system in mediating stress-activated relapse, since substance P 
and NK1 receptors are co-localized with central CRH and CRH 
receptors (Commons, 2010). Moreover, KOR/dynorphin system 
participates in stress-induced reinstatement of cocaine seeking 
(Mantsch et al. 2015) due to its critical involvement in the 






GABA receptors have been extensively investigated in diminishing 
stress responses. In this line, benzodiazepines attenuate the 
withdrawal symptoms of psychostimulants, opiates, and alcohol 
(Paine et al. 2002), which activate stress systems and are a primary 
initiator of relapse (Breese et al. 2005). Relieving these symptoms 
may decrease the probability of a relapse event (See & Waters, 
2010). In addition, leptin has also a role in stress-induced 
reinstatement of heroin seeking, although this effect since limited to 
relapse promoted by food deprivation as a stressor event (Shalev et 
al. 2001).  
 
1.6 Animal models to study drug addiction 
 
Animal studies have been crucial in understanding the 
pathophysiology of drug addiction. Although animal models of 
addiction do not entirely emulate the human condition, important 
features of the drug addiction process can be reliably measured in 
animal studies with having variables controlled. The validity of 
animal models is typically assessed using three validation criteria: 
face, construct and predictive validity (Sanchis-Segura & Spanagel 
2006). Face validity indicates that a model recapitulates important 
anatomical, biochemical, neuropathological or behavioural features 
of a human disease (Nestler & Hyman 2010). Construct or etiologic 
validity refers to the fact that biological mechanisms underlying the 
disorder are similar in both humans and animals. In the ideal 
situation, researchers would achieve construct validity by recreating 
in an animal the etiologic processes that cause a disease in humans 
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and thus replicate neural and behavioural features of the illness 
(Nestler & Hyman 2010). Predictive or pharmacological validity 
signifies that a model responds to treatments in a way that predicts 
the effects of those treatments in humans (Nestler & Hyman 2010).  
Regarding the validity in the drug addiction field, traditional self-
administration procedures have firmly established that drugs of 
abuse function as reinforcers in animals (Bozarth 1990). Studies on 
contingent and noncontingent drug intake in animals have already 
provided important advances and have contributed to understand the 
mechanisms involved in the initiation and maintenance of drug 
consumption. However, drug intake is just the first step of the 
complex addiction process and it is becoming evident that other 
factors are involved in the development of this disease. Indeed, 
addiction is influenced by genetic predisposition, environmental 
risk factors, and the interaction between both variables. A strong 
effort has been devoted to increase the knowledge about the 
molecular, cellular, and behavioural adaptations regulating these 
interactions to understand the mechanisms mediating addictive-like 
behaviour. 
Different models have been used to characterize the neurobiological 
substrates underlying the rewarding effects of drugs of abuse, the 
aversive aspects of drug withdrawal as well as some long-lasting 
behavioural alterations associated to repeated drug exposure. 
Examples of models able to measure these specific features include 
the intracranial electric self-stimulation techniques, place 
conditioning methods and self-administration parading among 
others (Sanchis-Segura & Spanagel 2006). 
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1.6.1 Intracranial self-stimulation 
The intracranial self-stimulation procedure provides unique ways to 
investigate the anatomical basis of reward and motivation and is an 
important tool for the assessment of the reward-facilitating and 
withdrawal effects of drugs of abuse (Vlachou et al. 2011). Several 
brain sites support intracranial self-stimulation, including the lateral  
Figure 7. A simplified example of intracranial self-stimulation in rats. Animals 
are implanted with electrodes into a specific brain site of the reward circuit. The 
functioning of the brain reward circuit is often assessed by measuring the minimal 
electrical current intensity for which animals will perform an easy response, such 
as pressing a lever, to receive the stimulation. The minimal current intensity that 
the subject is willing to self-deliver is the reward threshold. 
hypothalamus, medial forebrain bundle, and VTA among the sites 
that produce the most vigorous intracranial self-stimulation 
responding (Olds & Milner 1954). In this model, animals previously 
implanted with intracranial electrodes into specific regions of the 
brain reward pathways are trained to maintain operant behaviour to 






sessions, the threshold of the minimal current needed to promote 
intracranial self‐stimulation is estimated. Typically, rewarding 
stimuli, such as drugs of abuse decrease the self-stimulation 
threshold, whereas aversive drugs or stimuli, such as drug 
withdrawal, elevate the threshold for self-stimulation (Markou et al. 
1993).  
 
1.6.2. Place conditioning 
 
Conditioned place preference is a procedure for assessing the 
rewarding efficacy of drugs using a classical Pavlovian conditioning 
paradigm. In this paradigm, the animal is exposed to a drug or non-
drug treatment that has appetitive or aversive properties in a 
previously neutral environmental context. Following several 
pairings of the unconditioned stimulus with the distinct 
environmental cues (conditioned stimulus), only the presence of the 
context will evoke approach or avoidance behaviour (conditioned 
response) (Tzschentke 2007). 
The simplest version of the place conditioning apparatus consists of 
two environments that can differ in characteristics, such as colour, 
texture, pattern, in which the animal explore freely both 
compartments. One of the environments is paired with the drug and 
the other with the vehicle administration. After conditioning 
sessions, animals, in a drug-free state, are allowed to explore freely 
both environments, and the time spent in the drug-paired 
environment is considered an index of the rewarding value of the 






information about the motivational state created by the drug. A drug 
with rewarding properties will typically induce place preference, 











Figure 8 Place conditioning. Mice are placed in two discrete environments, and 
are then injected with a drug in one environment and with saline in the other 
environment. In a drug-free state, the animal is allowed access to both 
environments, and the amount of time spent in each environment is recorded. A 
positively reinforcing effect of the drug is apparent if the mouse spends more 
time in the environment in which the drug was administered (place preference) 
than in the one in which saline was administered (adapted from Camí & Farré, 
2003). 
 
drug administration will mainly produce place aversion. Although 
drug consumption in humans can induce conditioned 
approach/avoidance to specific drug-related stimuli, conditioned 
place preference and conditioned place aversion are not intended to 
model any particular feature of human behaviour (Sanchis-Segura 






These paradigms mainly represent an indirect measure of the 
rewarding or aversive effects of a drug by measuring the response 
of the animal towards the conditioned stimulus and can be also used 
to model relapse by re-exposing the animal to this paradigm that 
mimics drug associated-cues (Aguilar et al. 2009). 
 
1.6.3. Operant drug self-administration  
 
The operant model of self-administration is considered to be the 
most reliable and predictive model of drug use in rodents in the 
addiction field. Indeed, it mimics human drug seeking/taking and 
the neurobiological substrates related to drug effects appear to be 
similar in humans and experimental animals (Sanchis-Segura & 
Spanagel 2006). This animal model is widely used in the preclinical 
research to directly evaluate the primary reinforcing effects of drugs 
of abuse as well as the relapse after periods of abstinence.  
In drug self-administration procedures, the reinforcer can be 
delivered by different routes of administration. The most common 
routes of administration are intravenous and oral, but 
intracerebroventricular, intracranial, inhalation, intragastric and 
intramuscular routes have also been used. Studies commonly use 
the route of administration that is most similar to the route used in 
humans for that particular drug. In this procedure, animals learn to 
perform an instrumental response to obtain the reinforcer in 
experimental chambers provided with an active and an inactive 
lever/nose poke. Responding on the active lever/nose poke will 
activate a pump/dispenser delivering the reinforcer. Active 
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manipulandum pressing can be paired with unconditioned stimuli, 
such as a light or a tone, which improves learning of the operant 
behaviour. Activation of the inactive malipulandum will have no 
consequences, but will provide important control procedures for 
nonspecific motor and motivational actions, such as increases in 
exploratory activity and locomotion. The use of different schedules 
of reinforcement can provide information of the reinforcing 
properties of the drug. Reinforcement is known as behaviour which 
tends to be repeated and strengthened, thus it increases the 
probability of the behaviour being expressed. The simplest schedule 
Figure 9. Intravenous self-administration procedure for drugs. Animal 
implanted with an intravenous catheter in the jugular vein and trained to self-
administer drug. The chamber is provided with two levers/nose pokes. The 
number of responses in each lever/nose poke will be recorded by equipments. 
Responses on the active lever/nose poke will deliver a drug infusion and 
activate a light (cue), while responses of the inactive lever/nose poke will have 
no consequences. 
of continuous reinforcement used is the fixed ratio schedule, where 
the drug is delivered each time a preselected number of responses is 
completed. After each reinforcer delivery, a time-out period 
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(usually 10 sec) occurs in which operant responses are not 
rewarded. This period aimed to avoid any potential drug overdoses 
and can also serve to evaluate impulsive-like behaviour (Diergaarde 
et al. 2009). Additional information about the motivational effects 
for a drug reward can be obtained by using a progressive-ratio 
schedule, in which the required ratio to deliver a drug increases 
following an arithmetic progression. The work requirement is raised 
until responding ceases. This maximum work level, the “breaking-
point”, refers to the highest response rate accomplished to obtain a 
single reinforcer. Thus, the “breaking-point” is considered to be a 
measure of the motivation for the drug and can be compared 
between drugs to assess relative reinforcing efficacy or strength. 
After the acquisition and maintenance of drug self-administration 
behaviour in operant conditioning chambers, extinction procedures 
can provide measures of the persistence of drug-seeking behaviour 
in the absence of response-contingent drug availability. When the 
reinforcing element is no longer present, first there is an increase of 
the response (burst pattern) followed by a gradual reduction in 
operant responses results in eventual cessation or “extinction” of the 
operant behaviour (Yan & Nabeshima 2009). Extinction testing 
sessions are identical to training sessions except that no drug is 
delivered and the environmental cue is not presented after 
responding in active manipulandum. Resistance to extinction and 
high responding rate on active manipulandum are related to high 
persistence to seek the drug. Interestingly, the resistance to 
extinction in mice is similar to the case in human addicts (Childress 
et al. 1993; Gilpin et al. 1997; McKay et al. 2001), although the 
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possible mechanism underlying the resistance to extinction in mice 
remains unclear (Yan & Nabeshima 2009). 
The reinstatement model has been widely used to study relapse in 
animals. Reinstatement refers to the reinitiating of drug seeking in 
animal after the extinction of the previous drug administration 
(Shalev et al. 2002). After the extinction of drug-reinforced 
behaviour, the ability of drug priming, drug-associated stimuli, and 
stress to trigger reinstatement of drug-seeking behaviour can be 
evaluated (Yan & Nabeshima 2009). 
Figure 10. A typical cue-induced reinstatement experiment. The reinstatement 
model of relapse is divided in 3 phases: acquisition of self-administration 
behaviour, extinction and reinstatement. The cartoon above depicts a typical cue-
induced reinstatement procedure (De Vries & Schoffelmeer 2005). 
Drug priming effects on reinstatement have been reported in 
cocaine-, amphetamine-, heroin-, ethanol-, MDMA- and nicotine-






Nestler 1998; McClung et al. 2010; Daza-Losada et al. 2009), 
among others. 
Reinstatement induced by environmental stimuli (cue) associated to 
drug administration has also been described. There are different 
types of drug associated experimental cues: “discrete cues” paired 
with drug infusions during self-administration training (See 2002), 
as the cue-light stimuli; “discriminative cues” that become 
predictors of drug availability during the acquisition of the drug 
self-administration behaviour (Weiss 2005); and “contextual cues” 
associated with drug delivery as familiar environment in the 
Skinner box (Crombag & Shaham 2002). In drug-associated cues or 
conditioned reinforcers, responses on the active lever result in the 
presentation of a brief stimulus (light or tone) followed by drug 
delivery. This previously neutral stimulus can acquire conditioned 
reinforcing properties and evoke drug-seeking behaviour in 
experimental animals. Indeed, subsequent re-exposure after 
extinction to drug-associated stimuli produces strong recovery of 
responding at the active lever in the absence of any further drug 
availability (Yan & Nabeshima 2009). Cue-induced effect on 
reinstatement has been reported in cocaine-, amphetamine-, heroin-, 
ethanol-, nicotine-, MDMA-, cannabinoid- and food-trained animals 
(Ball & Slane 2014; Fattore et al. 2010; Martín-García et al. 2009; 
Soria et al. 2008; Shaham et al. 2003; Ball et al. 2007), among 
others.  
Stress-induced reinstatement of drug seeking has been most often 
induced by intermittent footshock stimuli, pharmacological agents 
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that induce stress (e.g. yohimbine), and food deprivation (Shalev et 
al. 2010). Stressor, such as electric footshock, could generate an 
internal condition partly similar to the state induced by drugs of 
abuse, which would reinstate drug-seeking behaviour in absence of 
further drug availability (Ahmed & Koob 1997; Shaham et al. 2003; 
Yan & Nabeshima 2009). Stress-induced reinstatement has been 
reported in cocaine-, amphetamine-, morphine-, heroin-, ethanol-, 
food- and nicotine-trained animals (Ahmed & Koob 1997; 
Economidou et al. 2006; Erb et al. 1998; Ghitza et al. 2006; Plaza-
Zabala et al. 2012; Shaham 1996; Cruz et al. 2010; Shaham et al. 
2003), among others.  
i. Drug addiction model
The voluntary intake of drugs of abuse is a behaviour largely 
conserved throughout phylogeny (Deroche-Gamonet et al. 2004). 
The possibility of studying these behaviours in other species than 
humans has helped to understand the neurobiological basis of drug 
taking (Nestler 1997). Several symptoms of the addictive-like 
behaviour have been shown to occur in experimental animals, such 
as escalation of drug use, cognitive deficits, resistance to extinction, 
increased motivation for drugs, preference for drugs over nondrug 
rewards, and resistance to punishment (Belin & Deroche-Gamonet 
2012; Deroche-Gamonet et al. 2004). Although first attempts to 
develop models of sustained and escalated drug use occurred in the 
mid-seventies (Johanson et al. 1976; Bozarth & Wise 1985), models 
with several facets of the addiction disorder have just recently 
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appeared (Deroche-Gamonet et al. 2004; Belin & Deroche-Gamonet 
2012; Vanderschuren & Everitt 2004). These models considered 
interindividual differences in drug responses and the concept of 
vulnerability was introduced for the first time in the preclinical 
research. Researchers attempted to capture facets of the addiction-
like behaviour by the operational translation of the seven diagnostic 
criteria of the DSM-IV. These seven items were grouped into three 
behavioural pillars considered the hallmarks of substance 
dependence, able to represent completely the loss of control over 
drug intake (Deroche-Gamonet et al. 2004). Indeed, the items 3 and 
4 of DSM-IV (see Table 1) indicate a difficulty to limit drug use, 
the items 5 and 6 indicate a high motivation for the drug and the 
item 7 refers to the drug use maintained despite its negative 
consequences. Thus, these points can be reproducible in animal 
models and correspond respectively to: 1) Persistence in drug-
seeking, measured by the persistence of drug seeking during a 
period of signalled drug nonavailability. 2) Motivation for the drug, 
measured by the breakpoint in the progressive ratio schedule of 
reinforcement 3) Resistance to punishment, measured by the 
persistence of the animals’ responding when the drug delivery was 
associated with a punishment, an electric footshock (Deroche-
Gamonet et al. 2004). In humans, the diagnosis of addiction is 
performed by counting the number of diagnostic criteria met by a 
subject. A similar approach was used in rats after long-term drug 
exposure, by scoring them for each of the three addiction-like 
behaviours. Different and extreme subpopulations according to the 
number of positive criteria met were found and the group which 
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reached all three criteria was defined as “addicted”. A prominent 
percentage of rats, around the 20%, showed loss of control over 
drug-intake (Piazza & Deroche-Gamonet 2013). The addict rats did 
not differ significantly from the no addict rats in terms of initial 
rates of cocaine self-administrated (Belin et al. 2008; Deroche-
Gamonet et al. 2004). However, they showed escalation of cocaine 
intake when given long access to the drug and a high vulnerability 
to relapse (Belin et al. 2009) that can be greatly reduced by a pre-
treatment with a mGluR2/3 agonist (Cannella et al. 2013), 
confirming the contribution of glutamatergic mechanisms to drug 
addiction. At the neurobiological level, addicted rats are 
characterized by an impairment in synaptic plasticity in the ventral 
ST (Kasanetz et al. 2010) and in the medial PFC (Kasanetz et al. 
2013), suggesting that addiction, at least to cocaine, is associated 
with impaired fronto-striatal connectivity in rats. These findings are 
also in agreement with a demonstration that altered synaptic 
plasticity in the prelimbic cortex supports compulsive drug-seeking 
behaviour in rats (Chen et al. 2013). The relationships between 
different dimensions of the seeking behaviour traits and stages of 
addiction, from vulnerability to drug self-administration initiation to 
compulsive intake were also reported. It was argued that seeking 
behaviour in rats predicts vulnerability to use cocaine, and high 
impulsive seeking behaviours predict vulnerability to shift from 
controlled to compulsive cocaine use, that is, addiction (Belin & 
Deroche-Gamonet 2012). 
This model of addiction may help to identify the 
neuropharmacological and molecular mechanisms underlying 
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individual addiction vulnerability and provide an important 
advancement to better approximate the physiological and 
behavioural aspects of drug addiction in humans. 
1.7 Neuronal plasticity 
Brain is a sophisticated information processing and storage system. 
Neurons accomplish these processes by integrating internal and 
external inputs and by modifying their morphology and/or 
functioning in response to these stimuli. Storage of information by 
changes in brain structures and functions is known as plasticity. 
More specifically, plasticity can be defined as the ability of neural 
circuitries to undergo adaptations consequent to experience which, 
in turn, influence the behaviour. Plasticity mechanisms include the: 
(a) modification of the strength or the efficacy of synaptic
transmission (synaptic plasticity) and (b) modification in dendritic 
complexity associated to the growth of new synaptic connections or 
the pruning away of existing ones (structural plasticity) (Malenka 
2003). 
1.7.1 Synaptic plasticity 
Synaptic plasticity is the cellular phenomenon by which synapses 
can undergo permanent changes in their properties consequent to 
specific patterns of activity. Synaptic plasticity can be divided in:  
1) Short-term plasticity that allows a rapid and reversible




2) Long-term plasticity, involving changes that last for hours to
underpin learning and memory (Martin et al. 2000); 
3) Homeostatic plasticity of synapses and neurons to maintain
appropriate levels of excitability despite continuous occurrence of 
short- and long-term plasticity (Pérez-Otaño & Ehlers 2005). 
 Synaptic plasticity may encompass a long-lasting strengthen or 
weaken in the efficacy of synaptic transmission, referred as long-
term potentiation (LTP) and long-term depression (LTD) 
respectively. LTP and LTD have been found to occur in neurons 
that release various neurotransmitters, although the most common 
neurotransmitter involved is the glutamate, the principal excitatory 
neurotransmitter in the brain. 
LTP that persistently enhances the synaptic strength is often 
measured in terms of the magnitude of excitatory post synaptic 
potential (EPSP) enhancement at a given time-point after induction. 
LTP is widely studied in the CA1 region of the HCP (Bliss & 
Collingridge 1993; Reymann & Frey 2007) involved in memory 
storage. Long-term plasticity at glutamatergic synapses is mediated 
by NMDA-receptor. Glutamate ionotropic receptors (NMDAR, 
AMPAR and kainate) present on the postsynaptic membrane are the 
initial triggers for the ensuing postsynaptic calcium (Ca
2+
)
signalling mechanism responsible for the induction of LTP. 
Receptors allow the transduction of electrical events at the 
postsynaptic membrane into chemical signals which, in turn, 
activate both pre and postsynaptic mechanisms to generate a 
persistent increase in synaptic strength. Glutamate binding to the 
AMPAR leads to a sodium (Na
+
) influx into the postsynaptic
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compartment leading to depolarization, removing Mg
2+
 that plays a
role as blocker of the NMDAR. The removal of Mg
2+
 blockade




conduct into the cell. Ca
2+
 influx activates several important
signalling pathways involving different protein, kinases and 
phosphatases (Figure 11). One of the kinases activated is 
Ca
2+/
calmodulin dependent protein kinase II, which is known as the
memory molecule. The Ca
2+
 influx through NMDAR also activates
the adenyl cyclase, which generates cAMP in the postsynaptic 
compartment. This second messenger triggers a series of 
downstream signalling mechanisms, which function in LTP 
maintenance by the activation of the protein kinase A (PKA) that 
regulates gene expression. PKA can modify transcription by 
phosphorylating several transcription factors, one of which is the 
cAMP response element binding protein. The final effect of this 
process is the rapid insertion into the postsynaptic membrane of 
AMPARs that is the major mechanism underlying LTP expression. 
In addition, a mechanism that requires a retrograde signal (perhaps 
NO) spreading from the postsynaptic region to the 
presynaptic terminal is considered to be partly involved in the 
modulation of the neurotransmitter release (Purves et al. 2001). The 
activation of mechanisms that require the synthesis and expression 
of new proteins and/or genes, leads to the stabilization of these 
synaptic changes for hours, days or weeks (Malenka & Bear 2004). 
A measure of postsynaptic changes in synaptic strength is evaluated 
Introduction 
50 
Figure 11.  
Schematic diagram 
of the induction and 
expression of 
NMDAR-dependent 
LTP observed in the 
rodent brain: 1) 
glutamate is released 
from activated pre-
synaptic neurons, 2) 
glutamate binds with 
both AMPAR and 
NMDAR, 3) binding 
opens AMPAR 
channels leading to 




synaptic neurons, 4) binding opens gate of NMDAR channels but Mg
2+ 
still 












 second-messenger pathway, 7a) second-messenger pathway 
promotes phosphorilation and insertation of additional AMPAR into post-
synaptic membrane, increasing its sensitivity to glutamate, 7b) second-messenger 
pathway also triggers release of retrograde paracrine (likely nitric oxide) that 
stimulates long-lasting increase in glutamate release by presynaptic neuron, 7c) 
second-messenger modifies transcription by phosphorilation of several 
transcription factors, such as cAMP response element binding protein. 
by the ratio between AMPARs and NMDARs in 
electrophysiological studies. The ratio is defined as the peak 
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synaptic AMPAR current relative to the peak synaptic NMDAR and 
indicates that the modification in synaptic transmission is caused by 
enhanced or decreased AMPAR transmission respect to the 
NMDAR transmission. 
Another subclass of glutamate receptors, mGluRs, is also involved 
in LTP induction (Bashir et al. 1993). Specifically, activation of 
mGluRs1 or mGluRs5 produces LTP-like effects by increasing 
Ca
2+/
calmodulin dependent protein kinase II levels and
phosphorylation of AMPAR receptor GluR1 subunits, which in turn 
promotes an enhancement of AMPAR number and channel 
conductance (Delgado & O’dell 2005; Jia et al.1998). 
The inverse mechanism of LTP is the LTD. LTD can be defined as 
a long lasting decrease in the synaptic response of neurons 
following a long patterned stimulus (Collingridge et al. 2010). LTD 
occurs principally when postsynaptic cells are depolarized to 
reverse LTP at saturated synapses and to reduce circuit excitability, 
but LTD could also occur at synapses that are not potentiated. 
Although a major form of LTD is mediated by NMDARs, the 
ultimate direction of change in synaptic efficacy is brought by 
changes in AMPAR function (Collingridge et al. 2010). Ca
2+
 influx
through the NMDAR is crucial for the induction of both LTP and 
LTD. LTD is triggered by postsynaptic Ca
2+
 entry after activation
by presynaptic stimulus. If the postsynaptic depolarization is weak, 
it cannot activate NMDARs completely. The partial removal of 
Mg
2+
 block results in the reduction of Ca
2+
 entry. This mechanism
activates particular phosphatases, such as calcineurin and protein 
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phosphatase (PP1) with the final effect of AMPARs 
dephosphorylation and their removal from the post-synaptic 
membrane, thus resulting in weakens synaptic transmission and 
LTD induction. Since the induction of LTD is controlled by the 
postsynaptic glutamate receptors, presynaptic components are 
required as retrograde messengers to modulate the transmission, 
such as endocannabinoids (Bliss & Cooke 2011). Upon stimulation, 
endocannabinoids are released from postsynaptic neurons and travel 
across the synaptic cleft to activate CB1R on presynaptic terminals, 
resulting in depression of synaptic transmission. Another form of 
LTD depends on mGluR1. Glutamate binding to mGluR initiates a 
signalling cascade, which involves the breakdown of the membrane 
lipid phosphoinositol 4, 5–bisphosphate by phospholipase C to the 
important signalling molecules inositol trisphosphate and 
diacylglicerol able to induce calcium mobilization. This leads to the 
activation of the calcium sensitive kinase protein kinase c that, in 
turn, dephosphorylates AMPAR and causes receptor internalization 
resulting in weaken synaptic transmission. Activation of mGluR1 
could be involved in opposed downstream signalling pathways that 
may both enhance or depress the synaptic transmission. However, 
synaptic depression mediated by mGluR1 has been the most 
commonly observed (Delgado & O’dell 2005). Indeed, mGluR-
mediated EPSPs/EPSCs are only evoked following high stimulus 
intensity or brief high frequency stimulation (Anwyl 1999). 
mGluR1 activation can lead to either LTP or LTD, depending on 
the frequency and intensity of stimulation (Bortolotto et al. 1994). 
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Figure 12. Diagrams of the induction and expression of LTD in the rodent 
HCP region. NMDAR-dependent LTD is triggered by Ca
2+
 entry through 
postsynaptic NMDAR channels, leading to the increase in the activity of the 
protein phosphatases. The primary expression mechanism involves internalization 
of postsynaptic AMPARs and a down regulation of NMDARs by an unknown 
mechanism (adapted from Isaacson, 2013). 
1.7.2 Structural plasticity 
Persistent changes in behaviour and psychological functions are due 
to the reorganization of synaptic connections (structural plasticity) 
that remove or create new connectivity patterns between neurons in 
relevant brain circuits. Functional plasticity and structural plasticity 
are strikingly associated. Indeed, LTD promotes spines shrinkage or 
synapse elimination (Bastrikova et al. 2008). In contrast, induction 
of LTP has been associated with an increase in spine turnover, 




formation or also in spine elimination (Engert & Bonhoeffer 1999; 
Nägerl et al. 2004; De Roo et al. 2008). At the molecular level, LTP 
or LTD trigger changes in signalling pathways that lead to the re-
organization of cytoskeletal proteins, such as actin and transynaptic 
adhesion molecules (Kasai et al. 2003). Rho GTPases and their 
downstream effectors have an important role in regulating the 
cytoskeleton, and consequently in regulating spines and dendritics 
morphology in response to extracellular stimulation. The 
morphological adaptation induced by LTP or LTD includes changes 
in the size of body cells, dendritic three arborizations or spines 
number and shape, affecting different partners and taking place on 
different time scales (minutes to days).  
High morphological variability of dendritic spines reflects the 
different stage of maturation of excitatory synapses (Bourne & 
Harris 2008). Small spines are recognized as immature spines with 
low stability and easily turned into other spines or eliminated (Kasai 
et al. 2002). Conversely, large spines, mainly referred to mushroom 
type of spines, are associated with mature, stable spines that have 
been strengthened through a process of activity- or plasticity-
mediated enlargement. Small spines are less likely than larger ones 
to contain smooth endoplasmatic reticulum, spine apparatus and 
have few or no polyribosomes. In comparison, most of the larger 
spines contain smooth endoplasmatic reticulum, spine apparatus, 
polyribosomes and have larger post-synaptic density than small 
ones (Nimchinsky et al. 2002). As the size of post-synaptic density 
correlates with the number of post-synaptic receptors, large spines 
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have shown to contain more AMPARs and to be more sensitive to 
glutamate stimulation than small spines (Takumi et al. 1999).  
Figure 13. Morphological classification of dendritic spines. They are 
commonly classified into four different categories: stubby, thin, mushroom or 
filopodia. Stubby spines are devoid of a neck and are particularly prominent 
during postnatal development. Thin spines are most common and have a thin, 
long neck and a small bulbous head, whereas mushroom spines are those with a 
large head. Lastly, dendritic filopodia are typically longer, normally have no clear 
head, and often represent immature spines (Yuste & Bonhoeffer 2004).  
Other types of spines have been reported. Thin spines are elongated 
and stable structure with a small bulbous head and are relatively 
young, with newly formed synaptic structure (Bourne & Harris 
2007a). Another type of protrusion is named filopodia, usually 
characterized by the absence of enlargement at the tip. Filopodia 
protrusions are believed to represent precursors of dendritic spines 
(Petrak et al. 2005; Toni et al. 2007) and they have been mainly 
seen during early stages of neurodevelopment although their 
function remains largely unclear as the majority of filopodia just 
appear and disappear without transforming into spine synapses (Zuo 
et al. 2005; De Roo et al. 2008). They seem to be implicated in 
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synaptogenesis mechanisms due to their elongated morphology that 
can facilitate axodentritic synaptic contacts (García-López et al. 
2010). 
1.7.3 Drug-induced neuronal plasticity 
Despite their chemical diversity and individual molecular targets, 
the major substrates of drugs of abuse are hypothesized to be 
molecular and cellular mechanisms that underlie long-term 
associative memories in several forebrain circuits mainly involving 
the ventral and dorsal ST and PFC, which receive inputs from 
midbrain DA neurons (Hyman et al. 2006). The basolateral 
amygdala and NAc core are also key structures within limbic 
cortical-striatal circuitry where reconsolidation of cue-drug 
memories occur (Theberge et al. 2010). Thus, addictive drugs 
increase plasticity mechanisms involved in learning and memory 
processes in these circuits responsible for reward. A single exposure 
to several drugs of abuse triggers LTP of AMPAR-mediated 
currents at excitatory synapses into VTA DA neurons (Niehaus et 
al. 2010). Accordingly, AMPAR/NMDAR ratio is significantly 
increased in the VTA in response to single exposure of different 
drugs of abuse, which seems to reflect an initial form of adaptive 
synaptic plasticity for all addictive drugs (Mameli et al. 2011). 
Hence, drug-evoked changes in the VTA may constitute an initial 
step in many of the behavioural changes that define addiction. 
These initial changes in the VTA are confirmed by the fact that 
pharmacological inhibition of NMDAR in the VTA blocks drug-
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evoked synaptic plasticity, behavioural sensitization (Dunn et al. 
2004), and acquisition of morphine-conditioned place preference 
(Harris et al. 2004). Moreover, prolonged cocaine self-
administration reduces excitatory synaptic responses in the NAc 
shell (Schramm-Sapyta et al. 2006) associated with an inability to 
elicit LTD in both the core and the shell of the NAc (Martin et al. 
2006). In this context, only a modest proportion of rats develop 
behaviours analogous to human addicts following prolonged 
cocaine self-administration while all animals develop impaired LTD 
in the NAc (Kasanetz et al. 2010). Interestingly, LTD was impaired 
in all animals two weeks following the cessation of cocaine self-
administration, although the ability to generate LTD slowly 
recovered only in “non-addicted” animals. In contrast, “addicted” 
animals expressed persistently impaired LTD (Kasanetz et al. 
2010). Therefore, long-lasting impairment of LTD induced by 
chronic cocaine intake results in a persistent deficit in synaptic 
plasticity that may contribute to the transition to addiction.  
Drug-induced synaptic adaptation in the NAc occurs also during 
cue-induced reinstatement of cocaine seeking after protracted 
withdrawal (Grimm et al. 2001). Increased AMPAR surface 
expression and AMPAR/NMDAR ratio associated to a consistent 
increase in excitatory synaptic strength in NAc are reported during 
prolonged withdrawal periods (Russo et al. 2010; Lüscher & 
Malenka 2011). However, internalization of AMPAR cell surface in 
the NAc (Boudreau et al. 2007) and decrease in the 
AMPAR/NMDAR ratio associated to a reduction of excitatory 
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synaptic strength in the NAc shell have been shown after priming- 
and cue-induced reinstatement (Rothwell et al. 2011). 
Synaptic adaptations are not the only mechanisms by which drugs 
of abuse can modify the reward DA system circuitry to cause long-
lasting behavioural changes. Indeed, addictive drugs activate 
complex intracellular signalling cascades, including transcription 
factors, that change intrinsic membrane excitability and modify 
dendrite and spine structures (Kalivas 2009). Indeed, neuroplastic 
changes after repeated drug use lead to a reorganization of 
mesocorticolimbic synaptic connectivity due to adaptations that 
counteract chronic brain insults, but their undesirable counterpart is 
the subsequent increase of drug consumption (Hyman et al. 2006). 
Many studies have shown that chronic administration of most drugs 
of abuse (mainly amphetamine, cocaine, nicotine and morphine) 
induces structural plasticity changes in reward areas (Russo et al. 
2010). Thus, repeated exposure to psycostimulants and nicotine has 
been associated with changes in postsynaptic AMPAR and the 
consequent increase of total denditric spine density in the NAc, 
VTA and medial PFC (Robinson & Kolb 2004). Conversely, 
chronic exposure to opiates decreases the number of denditric 
spines in the same areas (Robinson et al. 2002) and decreases the 
soma size of the VTA DA neurons (Mazei-Robison & Nestler 
2012). Indeed, chronic morphine induces changes in 
phosphatidylinositol 3′-kinase signalling that contribute to the 
morphological modifications of the soma size. This global change 
in the VTA DA architecture could participate in the decreased DA 
release in the NAc (Mazei-Robison & Nestler 2012). These 
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morphological changes vary in parallel with drug-induced 
behavioural changes and their extent seems to be correlated to the 
magnitude of the “addictive state”. In fact, rats with a longer 
cocaine exposure dramatically escalate their drug intake, present 
high motivation and show an increase in spines density in the NAc 
core (Ferrario et al. 2005). For the majority of the drugs, these 
structural changes have been maintained long after the 
discontinuation of chronic drug administration (Kolb et al. 2003; 
González-Forero et al. 2004). 
In summary, changes in strength of synaptic connections and in 
structural spine morphology have been demonstrated in neural 
reward circuits after repeated administration of drugs of abuse and 
might contribute to maladaptive learning of addictive behaviours. A 
clear understanding of the molecular substrates that mediate these 
adaptations could help in ravelling new targets for the development 
of efficient therapies for drug addiction. 
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2. EATING ADDICTION: LESSON LEARNED
FROM DRUG ADDICTION
2.1 Common insights with drug addiction 
Empirical and experimental evidence indicates that certain 
individuals can develop maladaptive patterns of consuming 
behaviours that are essential for survival, including food intake 
(Gold et al. 2009). Indeed, the decision to eat is not only influenced 
by the internal state of the caloric equation of calories intaken and 
the calories expended, but also by non homeostatic factors, such as 
food palatability. Palatable food is very pleasurable and is readily 
overconsumed despite the resulting health consequences. This 
behaviour is due to the intrinsic rewarding effects of foods. Indeed, 
a food rewarding experience contributes to motivation to repeat the 
experience and, under certain circumstances or in vulnerable 
individuals, results in the development of loss of control over food 
intake. This maladaptive pattern of food overconsumption 
resembles in certain aspects that undertaken by individuals using 
drugs of abuse. Indeed, several studies suggest commonalities 
between overeating and drug addiction, such as reinforcement 
effects of rewards, motivation and external cues to eat or use drugs, 
among others. Similar to drugs, the reinforcing effects of food are 
mediated by its ability to increase DA levels in the limbic system. 
Indeed, palatable food activates the brain reward circuitry through 






such as raising glucose concentration in blood and brain, whereas 
drugs activate these same pathways directly or indirectly (Koob & 
Volkow 2010) stimulating DA release in the NAc (Di Chiara & 
Imperato 1988; Kilts et al. 2001). However, the magnitude of the 
DA response to food is much smaller than the DA response to drugs 
(Pandit et al. 2011). The increase of DA release due to the repeated 
stimulation of reward pathways triggers neurobiological adaptations 
that may make the behaviour compulsive leading to further loss of 
control over intake (Pelchat 2009). Interestingly, decreased D2R 
levels in the ST have been reported in obese individuals (Wang et 
al. 2001). These findings suggest that low DA activity could be the 
mechanism of vulnerability to obesity as individuals with fewer 
D2Rs have to eat more in order to experience the rewarding 
properties of food intake. The improper striatal regulation by D2R 
signalling is associated with decreased activity in prefrontal regions 
involved in salience attribution (orbitofrontal cortex), inhibition 
(anterior cingulate cortex), and decision making (dorsolateral PFC) 
(Volkow et al. 2007) that could underlie the enhanced incentive 
motivational value of drugs or food and the difficulty in resisting 
their consumptions (Volkow et al. 2008). In addition, impairments 
in orbitofrontal cortex and anterior cingulate cortex are associated 
with impulsive and compulsive behaviours. Thus, impaired 
modulation of DA in these regions is likely to contribute to the shift 
from impulsive to compulsive patterns of drug or food intake 







Molecular and functional interactions between the homeostatic and 
reward pathways in food intake regulation have been reported. 
Specifically, several hormones and neuropeptides involved in 
energy homeostasis influence the DA reward pathway (Volkow et 
al. 2013a), such as glucagon-like peptide-1 (GLP1) (Alhadeff et al. 
2012), ghrelin (Abizaid et al. 2006), leptin (Figlewicz et al. 2003), 
insulin (Figlewicz et al. 2008), orexin (Fadel & Deutch 2002) and 
melanocortin receptors (Davis et al. 2011). Consistent with 
preclinical studies, imaging studies have also shown that 
anorexigenic peptides (e.g., insulin, leptin, peptide YY, PYY) 
decrease the sensitivity of the brain reward system to food reward, 
whereas orexigenic peptides (e.g., ghrelin,) increase this sensitivity 
(Volkow et al. 2011).  
 
2.2 Food intake control 
  
Availability of palatable food is a crucial environmental factor 
promoting overeating. In this context, the term of “non-homeostatic 
feeding” refers to eat for pleasure, as opposed to “homeostatic 
feeding”, where food intake is restricted to satisfy biological needs 
(Pandit et al. 2011). However, homeostatic and hedonic neural 
circuits are closely interlinked, and both respond to metabolic 
signalling. The control of food intake and energy metabolism is 
therefore a complex process that depends on the ability of the brain 
to receive and integrate a wide range of external and internal signals 
in order to produce appropriate responses in terms of food intake, 






 2.2.1 Homeostatic regulation of food intake 
 
The homeostatic control of appetite is mediated by the biological 
need to maintain body's energy stores, which is achieved by 
increasing the motivation to eat following depletion of stores. It 
requires reciprocal communication between peripheral organs that 
provide information about the nutrient status and energy stores of 
the body, and the brain that integrates all this information and 
advises about the availability of food in the external environment 
(Berthoud 2006; 2007). 
 
 i. Central regulation 
 
Central regulation of food intake is an organized mechanism 
involving humoral signals and afferent neuronal pathways mainly 
acting in hypothalamic neuronal circuits, and descending commands 
using vagal and spinal neurons (Palkovits 2003). Hypothalamic 
nuclei regulate an enormous number of homeostatic functions and, 
among them, of particular importance are the control of hunger and 
satiety closely related to energy balance control. The hypothalamus 
is organized in anatomically discrete neuronal nuclei that form 
interconnected circuits via axonal projections. The arcuate nucleus 
(ARC), paraventricular nucleus (PVH), dorsomedial hypothalamic 
nucleus (DMH), lateral hypothalamus nucleus (LHA) and 
ventromedial hypothalamus nucleus (VMH) are among the most 
relevant hypothalamic sites modulating the homeostatic processes 






(insulin, leptin, ghrelin and others), nutrients signalling and 
neuronal inputs from different peripheral locations (mainly 
stomach, liver, pancreas, muscle and white and brown adipose 
tissue) (Figure 14). The LHA functions as a hunger center while the 
VMH functions as a satiety center. Indeed, the LHA contains 
subpopulation of orexin and melanin-concentrating hormone 
(MCH) neurons promoting feeding behaviour (Li et al. 2014), while 
the VMH contains a high density of oxytocin receptors that 
negatively regulate energy balance acting to reduce feeding and 
increase energy expenditure (Noble et al. 2014). The ARC contains 
functionally discrete populations of neurons, such as the orexigenic 
(neuropeptides, NPY and agouti-related peptide, AgRP) and 
anorexigenic neuropeptides (proopiomelanocortin, POMC; the 
precursor of melanocyte peptides stimulating hormone, α-, β-, γ- 
MSH, adrenocorticotropic hormone, and cocaine- and 
amphetamine- regulated transcript, CART) (Elias et al. 1998), that 
indicate the nutritional status (Harrold et al. 2012). The PVH 
integrates signals from many neuronal pathways that regulate 
energy intake. These pathways include NPY/AgRP and 
POMC/CART neurons of the ARC and orexin neurons of the LHA 
area (Schwartz 2000). The DMH receives circadian information 
from the suprachiasmatic nucleus and senses leptin and other 
feeding signalling (Bellinger & Bernardis 2002). Hypothalamus 
activates these orexigenic/anabolic or anorexigenic/catabolic 







• Orexigenic/anabolic pathway: it is activated in response to a 
low energetic state and produces the release of orexigenic 
peripheral signals, such as ghrelin, stimulates NPY and 
AgRP expression within the ARC, and the subsequent 
release of MCH and hypocretins by the lateral 
hypothalamus. These neuronal responses lead to the 
sensation of hunger and the motivation to seek food that 
initiates a feeding episode. 
• Anorexigenic/catabolic pathway: the release of anorectic 
peripheral signals, such as insulin and leptin, stimulates the 
activity of POMC and CART expressing neurons within the 
ARC. This activation promotes the release of anorexigenic 
neurotransmitters, such as corticotrophin-releasing hormone 
(CRH), thyrotropin-releasing hormone and oxytocin, leading 
to increase metabolic rate and promote satiety, which finish 
the episode of eating. 
 
Moreover, the dorsal vagal complex that consists of the dorsal 
motor nucleus, the area postrema, and the sensory nucleus of the 
tractus solitarius have been classically associated with feeding 
behaviours owing to the vago-vagal reflex, linking the central 
nervous system with the peripheral tissues (Schwartz et al. 2000). 
Subnuclei of the nucleus tractus solitarius are the first central 
neurons to process ingestion-related vagal afferent signals, overall 
from the gastrointestinal tract. Indeed, the ingestion of food gives 
rise to mechanical and chemical stimulation of the gastrointestinal 






cholecystokinin (CCK) and GLP-1, among others, that mediated the 
control of energy status and meal consumption (Berthoud 2008; 
Vrang et al. 2007). These events activate vagal afferent neurons, 
which projections stimulate the nucleus tractus solitarius and 
central–visceral afferent pathways, including neurons located in the 




Figure 14. Hypothalamic regulation of body energy balance and metabolism. 
Specific nuclei in the hypothalamus respond to alterations in food availability, 
energy stores and nutritional requirements and communicate hormonally and via 
the autonomous nervous system to elicit functional changes in a range of 
organs/tissues including the liver, pancreatic cell, muscle, white adipose tissue 







direct effect on the brainstem, acting locally via the activation of 
CCK receptor 1 on nucleus tractus solitarius neurons, with the final 
effect of suppressing food intake (Preedy et al. 2011; Hisadome et 
al. 2011). Central processing of these signals is widely regarded as 
the primary determinant of the reduced food intake that follows 
meal consumption (Grill & Hayes 2009). 
 
ii. Peripheral regulation 
 
Gut and fat-derived hormones are released in response to 
homeostatic and hedonic signals facilitating the regulation of 
feeding by providing feedback information about energy 
consumption. These hormones include leptin, insulin, glucagon, 
adiponectin, ghrelin, pancreatic polypeptide (PP), CCK, PYY and 
GLP-1, among others (Banks 2006; Yu et al. 2006). 
Leptin, mainly derived from adipocytes, circulates in concentrations 
proportional to body fat content (Maffei et al. 1995). Leptin 
concentration is decreased by food restriction and restored by 
refeeding. Centrally and/or peripherally administration of leptin 
decreases food intake, increases energy expenditure and causes 
weight loss, whereas deficiencies in leptin are associated with 
obesity (Friedman & Halaas 1998). Leptin directly affects 
melanocortin neurons in the ARC of the hypothalamus and the 
anorectic effects of leptin are generally attributed to signal 
transduction in the hypothalamus (Zhang et al. 2005). Recent 






via activation of its receptor on VTA DA neurons (Billes et al. 
2012).  
Insulin is produced by β cells in the islets of Langerhans in the 
pancreas and also circulates in the bloodstream in proportion to 
body fat content (Bagdade et al. 1967). Insulin acts directly in the 
liver to regulate the synthesis of glucose in post prandial condition 
and stimulates the increase of glucose uptake in most peripheral 
tissues. At the central level insulin acts on KATP channels in 
hypothalamic neurons to control hepatic glucose production. The 
activation of these channels normally restrains hepatic 
gluconeogenesis (Pocai et al. 2005). In contrast to this critical role 
that happens mainly during meals, insulin also provides an ongoing 
message to the brain proportional to the total body fat. In this line, 
insulin reduces food intake by acting in the mediobasal 
hypothalamus (Woods et al. 2006; Gerozissis 2004). Indeed, insulin 
receptors are highly expressed in the ARC and here, they are co-
expressed with the anorexigenic neuropeptides POMC and CART, 
as well as with the orexigenic neuropeptides NPY and AgRP 
(Benoit et al. 2002). Changes in the expression of these 
hypothalamic neuropeptides have been regarded as the pivotal 
mechanism mediating insulin anorexigenic effects via inhibition of 
NPY/AgRP neurons and activation of POMC neurons (Plum et al. 
2006). 
Glucagon hormone is synthesized and secreted from α-cells of the 
islets of Langerhans (Kieffer & Habener 1999). Glucagon metabolic 
functions are in many respects opposite to those of insulin. The 






glucose blood levels. It stimulates glucose production via hepatic 
glycogenolysis or gluconeogenesis, thereby helping maintain 
euglycemia during states of rapid glucose utilization or fasts, 
respectively. Pancreatic glucagon is also secreted as food is 
ingested, and provides a satiety signal reaching the brain via 
sensory axons of the vagus nerve and leading to termination of the 
meal (Geary 1990).  
Adiponectin is a hormone that modulates a number of metabolic 
processes, including enhanced glucose use and regulation of fatty 
acid oxidation in the skeletal muscle and liver (Díez & Iglesias 
2003) via receptor-dependent activation of the 5′-AMP–activated 
protein kinase (AMPK) (Lancaster & Febbraio 2011; Yamauchi et 
al. 2002). This hormone is exclusively secreted from adipose tissue 
and is inversely correlated with body fat percentage in adults 
(Ukkola & Santaniemi 2002). In the central nervous system, 
adiponectin stimulates food intake via direct activation of AdipoR1 
in the ARC (Kubota et al. 2007). 
Ghrelin is mainly synthesised by endocrine cells in the stomach. 
Ghrelin levels increase before expected meals and rapidly decrease 
after food intake, which suggests a role in meal initiation (Williams 
& Cummings 2005). Ghrelin generally increases food intake by 
modulating the expression of hypothalamic peptides after binding 
its receptor in the hypothalamus. Indeed, peripheral and 
intracerebroventricular ghrelin injections increase food intake, 







PP is secreted from the pancreas and its level is directly 
proportional to the caloric load consumed. At the peripheral level, 
PP inhibits further food intake by modulating the rate of gastric 
emptying during meal. On the other hand, at central level it 
presumably modulates gastrointestinal function via stimulation of 
NPY receptors, such as Y5 or Y4 receptors in the dorsal vagal 
complex, including the area postrema, nucleus tractus solitarius and 
dorsal motor nucleus of the vagus (Whitcomb et al. 1997). 
Activation of these receptors produces a moderate increase in food 
intake. Thus, PP seems to be an anorexigenic signal in the periphery 
and an orexigenic signal in the central nervous system. However, 
the mechanism of the regulation of food intake induced by PP 
remains to be determined (Katsuura et al. 2002).  
Meal termination and satiety factors include CCK, mainly released 
from the gastrointestinal tract, which besides controlling gall 
bladder contraction, pancreatic secretion, and gut motility, also 
inhibits food intake via brainstem neurons (Chaudhri et al. 2006). 
Endocrine cells in the distal intestine produce PYY and GLP-1, 
which both inhibit feeding (Chaudhri et al. 2006; Druce & Bloom 
2006). PYY is released into the circulation in response to the meal 
composition and in proportion to the calories ingested (Adrian et al. 
1985). PYY slows the gastric emptying, increases efficiency of 
digestion and nutrient absorption after a meal, and inhibits food 
intake. Peripheral administration of PYY reduces food intake in rats 
(Chaudhri et al. 2006).  
GLP-1 enhances insulin sensitivity (Miki et al. 2005) and inhibits 






release and promotes an increase in pancreatic β-cell mass (Edvell 
& Lindström 1999). Due to these effects, the acute infusion of GLP-
1 in humans reduces both appetite and food intake (Verdich et al. 
2001).  
 
2.2.2 Hedonic control of food intake 
 
Environmental cues, rewarding stimuli and emotional factors play 
an important role in food intake in humans, which may override 
homeostatic requirements during periods of relative energy 
abundance by increasing the desire to consume foods (Berthoud 
2006). In this context, food palatability represents an important 
component involved in liking, wanting, and learning to acquire 
food, and each of these aspects has separate but overlapped 
neuropsychological substrates.  
The hypothalamus is highly connected to crucial brain areas 
involved in the hedonic pleasure, emotion and memory and these 
structures are strongly activated in response to the presentation of 
food stimuli (Kelley, Baldo & Pratt 2005; Volkow et al. 2012). 
Even though the mesolimbic pathways are responsible for the 
reward control of feeding behaviour, the orbitofrontal cortex 
regulates gustatory, olfactory, visual, somatosensory and sensory 
functions, such as taste and smell, and has an important role in 
reward related feeding (Rolls 2011). 
Brain sites playing the most prominent role in the hedonic control 
of food intake include the NAc, amygdala, PFC, VTA and HCP. 






including palatability and pleasure that are arguably the most 
powerful motivators of food intake.  
Figure15. Interaction of the homeostatic and hedonic system in the control of 
food intake. Schematic diagram showing neural systems and flow of information 
involved in the control of food intake and regulation of energy balance. The 
traditional regulatory circuitry using neural and hormonal feedback from the 
internal milieu acting on hypothalamus and brainstem is shown on the bottom 
(dark-grey boxes). Sensory and cortico‐limbic brain areas used for processing 
information from the environment are shown in the upper half (light gray boxes). 
The broken lines with open arrows on the left indicate modulation of sensory, 
cognitive, and reward processes by circulating signals of fuel availability, such as 
leptin, ghrelin, and glucose. The full lines/open arrows indicate modulation by 
nutritionally relevant neural signals such as taste and visceral sensory 
information, as well as signals originating from the hypothalamus. Full 
lines/closed arrows represent neural interconnections, and dotted lines/full arrows 
represent subconscious behavioural, autonomic, and endocrine output/effector 






These neuronal circuits are involved in learning, allocating attention 
and effort toward food rewards, setting the incentive value of 
stimuli in the environment and integrating information about energy 
stores and gut contents with information about food availability 
(Dagher 2009). 
DA reward pathway from VTA to NAc is responsible not only for 
motivating food consumption, but also for the pleasurable feeling 
that eating produces (Wang et al. 2009). In this line, a distinction 
between `wanting', more associated with DA, and `liking', more 
associated with opioids, is often made (Berridge 2009). Liking 
refers to the hedonic value, palatability or pleasurable feeling 
associated with food, while wanting is considered to be a desire that 
stimulates goal-directed behaviour to obtain the food and is 
therefore often regarded as motivation. These two components often 
overlap and depend on each other.  
Other mesocorticolimbic structures, different from the NAc, have 
shown to tightly control eating behaviour. In particular, the 
projections from PFC, amygdala and HCP to hypothalamus play an 
important role in cognitive suppression of metabolic satiation 
signals (Berthoud 2002). The amygdala influences reward-related 
food intake since a reciprocal connection between the central 
nucleus of the amygdala and the NAc is involved in opioid-
mediated eating (Kim et al. 2004) and connections between the 
basolateral amygdala and forebrain regions appear to play a role in 
cue-potentiated feeding and in assessing food palatability (Petrovich 
et al. 2007; Balleine et al. 2003). Moreover, HCP and PFC are also 






lesions showed increased appetitive behaviour (Davidson et al. 
2007) and alteration of PFC activity in rodents, which causes 
hyperphagia and enhances preference for sweet palatable foods 
(Mena et al. 2011). 
Metabolic signalling can also directly act on the brain reward circuit 
adding a motivational meaning to the energetic feeling of hunger 
and satiety. Indeed, anorexigenic peptides decrease the sensitivity of 
the brain reward system to the hedonic effects of food, whereas 
orexigenic peptides increase this sensitivity (Zheng et al. 2007). A 
close relationship between these signals and DA activity has been 
reported (Domingos et al. 2011). Thus, the activation of the leptin 
receptor in VTA DA neurons (Figlewicz et al. 2003) stimulates the 
intracellular JAK-STAT pathway leading to a reduction in DA 
firing rate and a decrease of food intake (Hommel et al. 2006).  
In summary, increasing evidence underlines the important 
contribution of the mesocorticolimbic circuit in the control of eating 
behaviour and dysregulation in this circuit is likely to contribute to 
the physiopathology of some eating disorders. 
 
2.3 Eating disorders 
 
According to the DSM-5, eating disorders are characterized by a 
persistent disturbance of eating or eating-related behaviour resulting 
in the altered consumption of food that significantly impairs 
physical health, psychosocial function and emotions. Individuals 
suffering from eating disorders typically have unusual concern 






several millions people, most often women between the ages of 12 
and 35. They are associated with a wide range of adverse 
psychological, physical, and social consequences. While past 
findings have described the causes of eating disorders as primarily 
environmental and sociocultural, new studies have uncovered 
evidence of a prevalent genetic/heritable aspect. Indeed, numerous 
studies have demonstrated a possible genetic predisposition toward 
eating disorders (Mazzeo & Bulik 2009). Epigenetic mechanisms 
leading to environment-alter gene expression seem to be also 
implicated (Frieling et al. 2010). These mechanisms will be 
discussed in section 2.4.3. Eating disorders are difficult to treat with 
many remissions and recurrences (Berkman et al. 2007; Shapiro et 
al. 2007) and, at the present, the treatment consists mainly in 
cognitive behavioural therapy while the pharmacotherapy still 
remains a challenge. 
Obesity and eating disorders share some similarities. Indeed, some 
forms of obesity are driven by an excessive motivation for food and 
by the inability to restrain from eating despite the desire to do so. In 
this line, standard interventions based on promoting lifestyle 
changes to decrease excessive food consumption and increase 
physical activity are effective in normalizing body weight if 
followed rigorously, but they are difficult to sustain (Volkow & 
O’Brien 2007). These issues highlight the behavioural underpinning 
in obesity disease and lead to suppose that obesity is not only a 
metabolic disorder, but also a mental and behavioural alteration 
(Volkow & Wise, 2005). In agreement with this assumption, a 






obesity and other psychiatric alterations, including mood and 
anxiety disorders.  
In spite of the partial overlap between eating disorders and obesity, 
these disorders also differ in several aspects. Firstly, obesity is the 
consequence of varying interactions between individual and 
environmental factors resulting in a diversity of obesity phenotypes 
(Marcus & Wildes 2009). Some obesity phenotypes may be caused 
by mental disorders, such as those generally associated to binge-
eating disorder (BED). However, not every person who is obese or 
overweight has an eating disorder. In fact, the vast majority of 
obese individuals do not have BED and, although BED is generally 
associated with overweight, not every person suffering from BED 
will become obese (Bruce & Wilfley 1996; Telch & Agras 1994). 
Moreover, excluding the subset of those meeting diagnostic criteria 
for BED, most obese people do not show signs of dramatic 
abnormalities in eating behaviour similar to those described in 
anorexia, bulimia or BED. Indeed, eating disorders are generally 
characterized by an acute sense of loss of control during binge-
eating episodes, whereas some forms of obesity may be associated 
to a more generalized pattern of uncontrolled eating. Mostly, obese 
individuals present lower responsiveness to internal satiety cues and 
higher responsiveness to external food cues that are likely to confer 
vulnerability to overeating in environmental conditions where the 
food supply is palatable and accessible (Carnell & Wardle 2008; 
O’Rahilly & Farooqi 2008). In addition, individuals with eating 
disorders show distress and feelings of guilt and disgust after food 






evolve in “inappropriate” compensatory behaviours (DSM-5). In 
contrast, these feelings do not necessarily characterize obese 
patients.  
Currently, obesity is not included in the eating disorder category of 
the DSM-5 due to the little evidence in support that obesity is a 
mental disease. Indeed, there are wide ranges of genetic, 
behavioural and environmental factors that vary across individuals 
contributing to the development of obesity. Thus, obesity is a 
heterogeneous condition with a complex and incompletely 
understood etiology that cannot be considered per se in the 
psychiatric nomenclature. The relationship between obesity and 
numerous psychiatric disorders highlight both the heterogeneity of 
obesity and the limitations inherent in descriptive diagnostic 
categories. 
 
2.3.1 Conceptualization in the DSM-5 
 
Different types of eating disorders have been reported. Bulimia 
nervosa and anorexia nervosa are the most common specific forms 
of eating disorders. Other main eating disorders include BED and 
other atypical disorders that did not fit entirely in the previous 
categories and received a diagnosis of “specified feeding or eating 
disorder”. According to the DSM-5, eating disorder symptoms 
resemble to those types typically endorsed by individuals with 
substance use disorders, such as craving and compulsive use. These 
similarities may reflect the participation of similar neural systems, 






Indeed, neuroimaging studies suggest altered function of reward 
circuitry in patients with eating disorders (Harrison et al. 2010). 
Thus, this similar symptomology can support the inclusion of eating 
disorders as addiction disorders. However, empirical evidence 
suggests that other patterns of food consumption more properly 
share salient features with substance use disorder. Indeed, the 
concept of “being addicted to food” has developed progressively 
and become popular in recent years. However, the existence of 
eating addiction as a clinical disorder that leads to loss of control 
over food intake is still under critical view due to the fact that food 
is essential to survival and, as a result does not figure in the DSM-5 
at present. Nevertheless, behavioural similarities between eating 
addiction and the recognized eating disorders have been found, 
together with many shared psychological and biological risk factors 
(Davis et al. 2011). In this line, compulsive food consumption 
underlying eating addiction also characterizes binge eating 
episodes, which generally occur in bulimia, BED and in binge 
eating/purging type of anorexia nervosa. These similarities are 
consistent although they are only partial, as later discussed for BED. 
Indeed, the addiction model used to understand eating disorders 
(Szmukler & Tantam 1984; Marrazzi & Luby 1986) has been 
widely criticized for being over simplistic and for lack parsimony in 
its explanations of eating disorder symptoms. Moreover, the 
addiction model does not distinguish between BED, bulimia and 
anorexia, three brain disorders with different etiology and 
symptoms. Thus, although the exploration of eating addiction is 






disorder different from anorexia, bulimia and BED may be helpful 
in identifying the mechanisms underlying the development, 
maintenance, prevention, and treatment of problematic eating. 
 
2.3.2 Eating disorder currently recognized in medical manuals 
 
The following eating disorders are specified as mental disorders in 
standard medical manuals, such as ICD-11 and DSM-5: 
 
i. Anorexia nervosa  
 
This disorder is characterized by food restriction, odd eating habits 
or rituals due to an obsessive fear of gaining weight and an 
unrealistic perception of low body weight. Indeed, patients with 
anorexia usually experience “fat phobia" that influences their self-
evaluation and/or brings them in denial of the seriousness of their 
current low body weight (APA, 2013). The disease manifests itself 
in two distinct forms: a restricted type or a binge eating/purging 
type (Pinhas et al. 2011). In the first case, the weight loss is 
accomplished primarily through dieting, fasting and/or excessive 
exercise. Individuals with anorexia nervosa tend to exhibit high 
activity levels, as well as mental alertness, during their weight loss 
from food restriction (Casper et al. 1991; Klein et al. 2007). This in 
turn drives them to engage in excessive exercises, creating a 
detrimental positive feedback/reward cycle (Klein et al. 2007). In 
the second case the individual has engaged in recurrent episodes of 






control over food intake followed by laxative abuses or vomiting. 
Anorexia nervosa is most commonly found in young women with 
18 being the average onset (Fairburn & Harrison 2003). 
Because no single factor has been shown to be either necessary or 
sufficient for causing anorexia nervosa, a multifactorial model 
might be most appropriate (Connan et al. 2003), even thought risk 
factors are associated with the individual temperament, 
environmental, genetic and psychological aspects. Indeed, the onset 
of this disorder is often associated with stressful environmental 
events during life. Biological and/or genetic component influences 
are also reported in many cases. A recent genome-wide association 
study confirmed several risk genes in the mesocorticolimbic system 
involved in anorexia (Brown et al. 2007). Genes coding for 
serotonin (5-HT) and DA are implicated in the altered reward 
modulation in people with anorexia (Kaye et al. 2009). Indeed, low 
levels of 5-HT and DA metabolites are found in the cerebrospinal 
fluid of these patients (Kaye et al. 1984). Modifications in the 
expression of genes coding for 5-HT1A, 5-HT2A receptors and 5-
HT transporter have also been reported in the cortex and dorsal 
raphe of anorexic patients (Bailer et al. 2005; Kaye et al. 2005). 
Moreover, evidence supports the involvement of polymorphisms 
within gene encoding DOR on human chromosome 1 in the genetic 
susceptibility to anorexia, especially to the restricting type (Brown 
et al. 2007; Bergen et al. 2003). Indeed, a disturbance in DOR gene 
can facilitate the development of addictive-like behaviour to fasting 






Psychological aspects are also crucial in the development of this 
disorder. Indeed, an association between major depression and 
anorexia nervosa has been widely reported in clinical studies (Wade 
et al. 2000). Additionally, patients with anorexia nervosa show 
comorbidities with intellectual disability and dissociative disorders 
(Mammen et al. 2007), and demonstrate elevated levels of suicide, 
making anorexia nervosa a deadly mental illness (Wade et al. 2000). 
 
ii. Bulimia nervosa  
 
This disorder is characterized by recurrent binge-eating followed by 
compensatory behaviours such as purging (self-induced vomiting), 
excessive use of laxatives/diuretics, or excessive exercise. Bulimia 
nervosa shares similar behavioural substrates with anorexia 
although the framework of both diseases is different. Indeed, 
anorexics are underweight, whereas bulimics tend to be normal or 
overweight, due to the calories consumed during binges. Moreover, 
anorexia is characterized by restriction of eating, the opposite 
behaviour observed in bulimia. Furthermore, the DSM-5 explicitly 
requires for a diagnosis of bulimia nervosa a subjective sense of 
loss of control over eating to define a binge-eating episode (APA, 
2013). Bulimia nervosa also shares many clinical symptoms with 
BED, even though, according to the DSM-5, they have distinct 
diagnostic criteria, such as lack of compensatory behaviour (e.g., 







The neurobiological mechanisms in this disease are still not 
understood. It has been suggested that bulimia nervosa is the 
behavioural manifestation of a decreased activity of serotonin 
and/or DA transmission (Steiger 2004; Galla et al, 1995). Bulimia 
commonly begins in adolescence or young adulthood. Comorbidity 
with mental disorder is common in individuals with bulimia nervosa 
and an increased frequency of bipolar and depressive disorders has 
been reported. Indeed, nearly 87% of patients with bulimia have 
moderate to severe depressive symptoms (Stunkard et al. 2006) and 
significantly elevated risk for mortality (2%) by committing suicide 
has been reported (DSM-5).  
 
iii. Binge Eating Disorder (BED) 
 
BED is characterized by recurrent episodes of consumption of large 
quantities of food accompanied with a sense of loss of control over 
eating, as described by DSM-5 (APA, 2013). DSM-5 criteria 
specify that individuals must experience at least three of the 
following impaired control behavioural indicators for the diagnosis 
of BED: (1) eating rapidly, (2) eating until uncomfortably full, (3) 
eating large amounts of food when not hungry, (4) eating alone due 
to embarrassment, (5) feeling depressed, disgusted, or guilty after 
overeating. An occurrence of excessive food consumption must be 
accompanied by a sense of lack of control that is reported as the 
inability to refrain from eating or to stop eating once started. The 
type of food consumed during binges varies across individuals and 






more by an abnormality in the amount of food consumed than by 
craving for a specific nutrient. 
Epidemiological studies indicate that BED is much more common 
in the general population than other eating disorders. It mainly 
occurs in normal/weight/overweight and obese individuals (Bruce 
& Wilfley 1996; Spitzer et al. 1993), although it could also be 
present in anorexia nervosa (Swanson et al. 2011). A positive 
correlation has been observed between BED and psychological 
distress, depression, interpersonal problems and low self-esteem 
(Telch & Agras 1994). Moreover, these patients have higher 
lifetime rates of panic and personality disorders compared with 
individuals that do not meet these criteria (Yanovski et al. 1993). 
Women are 1.5 times more likely than men to be diagnosed with 
BED (Spitzer et al. 1993).  
Pharmacotherapy research of bulimia nervosa and BED is currently 
in early stages. Fluoxetine is the only medication with regulatory 
approval in bulimia nervosa, and no medication has been approved 
for BED. Many of the available pharmacotherapy studies in bulimia 
nervosa and BED are limited by small sample size, high placebo 
response and dropout rates, and unclear generalizability of findings 
to real world clinical situations (McElroy et al. 2012). 
 
iv. Other specified feeding or eating disorder  
 
This category includes eating or feeding disorder that does not meet 
full DSM-5 criteria for anorexia, bulimia, or BED, but they cause 






It is important to note that this category is not an indication of a less 
severe eating disorder, simply a different expression of symptoms. 
Examples of these eating disorders include individuals with atypical 
anorexia nervosa, who meet all criteria for anorexia nervosa except 
being underweight, despite substantial weight loss; atypical bulimia 
nervosa, who meet all criteria for bulimia nervosa except that 
bulimic behaviours are less frequent or have not been ongoing for 
long enough; purging disorder; and night eating syndrome. 
 
2.3.3 Eating disorders not currently recognized in clinical 




Obesity is a complex metabolic disorder defined as an excess of 
accumulation of fat in adipose tissue to an extent that can negatively 
affect the person’s health (James et al. 2001; Garrow 1988). The 
most common method for defining obesity is the Body Mass Index 
(BMI) strongly associated with adiposity and obesity-related 
morbidity, and category thresholds have been established. Indeed, 
overweight is commonly set in a BMI range between 25 and 29.9 
and obesity in a BMI of 30 or above (James et al. 2001; WHO, 
2004). The weakness of this definition is that it does not distinguish 
muscle weight from fatness and does not account for the wide 
variation in body fat distribution (James et al. 2001; WHO, 2004). 






15% of women) was obese in 2014 and this percentage will tend to 
increase (WHO; 2014). 
The etiology of this disease is multifactorial involving a multitude 
of genetic, neural, physiological hormonal, nutritional, social, and 
psychological factors, which can interact to promote weight gain 
under numerous conditions (Bray & Champagne 2005). In many 
cases obesity is conceptualized as the imbalance of energy-intake 
and energy-expenditure. However, the cause appears much more 
complex. Indeed, food availability, environmental cues and 
alterations in dietary patterns with a prevalence of energy-dense fat 
and sweet foods contribute to the high prevalence of obesity (Rolls 
2011; Young & Nestle 2002). The evidence strongly confirms that 
the rewarding properties of palatable food appearing to override 
homeostatic processes. Sedentary activities, by reducing energy 
expenditure, also have high influences in obesity (Zhang & Wang 
2004). Overconsumption of food along with a sedentary lifestyle is 
an association appropriate for ensuring of weight gain.  
A crucial importance in the obesity framework is the combination 
of genetic and environmental factors that are likely to interact in 
diverse ways among individuals (Freedman & Stern 2004). 
Important candidate gene variants are the polymorphisms in the “fat 
mass and obesity-associated” (FTO) locus that seem to confer risk 
of obesity through increasing energy intake and reducing satiety 
(Hetherington & Cecil 2010). In addition, monogenic mutations 
have been discovered in genes that play essential roles in the 
appetite control, food intake, and energy homeostasis, primarily in 






opiomelanocortin, and the melanocotin-4 receptor, among others 
(Hu 2008). Moreover, variations of genes involved in DA 
neurotransmission, such as D2R Taq I A1 allele (Blum et al. 1996), 
as well as the gene coding for CB1R (Schleinitz et al. 2010) have 
also been associated with obesity. Other candidate genes have been 
studied and the number of genes involved in this disorder continues 
to expand. Polymorphisms of genes implicated in the adipocyte 
metabolism such as the gene of fatty acid binding protein 2 
(Shabana & Hasnain 2015), insulin induced gene 2 (Liu et al. 2015), 
Niemann-Pick protein, type C1 for the intracellular lipid transport, 
MAF involved in adipogenesis and insulin-glucagon regulation 
(Hofker & Wijmenga 2009) could also play a role in the 
development of obesity. In addition, polymorphisms of the 
glucocorticoid receptor have also been associated to fat 
accumulation, particularly in the central abdomen, and obesity 
(Cellini et al. 2010). Other possible candidates for the genetic 
substrate of obesity include genes coding for apoliproteins, 
adrenergic receptors, insulin, insulin receptors, insulin-like grow 
factor, glucose transport proteins and CCK, among others 
(Bouchard 1994). 
Another important cause factor affecting the development of obesity 
is stress (Pickering 1999). Data support the notion that humans 
experiencing stress seek comfort by consuming palatable foods that 
are high in fat and sugar (Pecoraro et al. 2004). These types of 
foods have powerful reinforcing properties and repetitive rewards 
can alleviate feelings of anxiety and discomfort (Dallman et al. 






2004). Other pathophysiological factors contribute to the obesity 
prevalence. Indeed, the number of depressive episodes positively 
predicts the risk of developing obesity, suggesting that mood is the 
main driver of emotional eating (Björntorp 2001; Scott et al. 2008).  
In turn, obesity has been considered an important risk factor for 
mortality and morbidity because it exacerbates the deleterious 
effects of other diseases. Indeed, obesity is associated with many 
comorbidities, such as cardiovascular diseases, type II diabetes 
mellitus and certain cancers (Bray 2004), and increases the risk of 
stroke, hypertension, and dyslipidemia (Must et al. 1999; Must & 
Strauss 1999).  
Several neurochemical systems have been reported to be involved 
in the mechanisms underlying obesity. As already reported, the 
endogenous opioid, DA and ECS have a crucial role in the 
development of obesity. However, treatment options for obesity 
remain quite limited. Lifestyle changes in the form of dieting and/or 
exercise do not generally produce sustainable weight loss (Leblanc 
et al. 2011), whereas effective psychological therapies, such as 
cognitive behavioural therapy, cannot easily be delivered on a mass 
scale (Wing et al. 2006) and long-term results are disappointing. 
Bariatric surgery is much more effective in terms of weight loss, 
comorbidity reduction and enhanced survival (Kral & Näslund 
2007; Sjöström et al. 2007). However, these procedures tend to be 
reserved for the morbidly obese considering the concerns about 
perioperative mortality, surgical complications and the frequent 
need for reoperation (Field et al. 2009). Pharmacological agents that 






the absorption of nutrients, or increase energy expenditure. In the 
past, drug therapies available have included thyroid hormone, 
dinitrophenol and amphetamines, followed by amphetamine 
analogues such as aminorex, fenfluramines (Ioannides-Demos et al. 
2005), CB1R antagonist as rimonabant and the 5-HT and 
noradrenalin (NA) uptake inhibitor, sibutramine. Unfortunately, 
those were withdrawn for the market due to an important risk of 
adverse consequences (Janero et al. 2011). Other agents have been 
trialled though only orlistat (a gastrointestinal lipase inhibitor) was 
approved for long-term use ( ≥ 24 weeks) in obese patients 
(Ioannides-Demos et al. 2011). It does not directly act on appetite as 
other obesity pharmacotherapies, rather it decreases fat absorption 
by binding to pancreatic lipase, the principle enzyme that 
hydrolyses triglycerides (Padwal & Majumdar 2007). Liraglutide 
and exenatide, GLP-1 analogues, were developed for the treatment 
of type 2 diabetes associated to obesity (Vilsbøll et al. 2007). 
Liraglutide was approved in the 2014 by Food and Drug 
Adminisration agency and demonstrated beneficial weight loss in 
obese patients by increasing the secretion of leptin, which results in 
suppressed appetite, decreased energy intake and a delay in gastric 
emptying (Astrup et al. 2009). In the same line, metformin is the 
first-line drug of choice for the treatment of type 2 diabetes that can 
also be used in overweight and obese patients since contributes to 
weight loss. Lorcaserin is a selective 5-HT2 receptor agonist used 
as a weight-loss drug approveted by Food and Drug Administration 






supposed to activate POMC production and consequently promotes 
weight loss through satiety mechanisms (Helmut 2010). 
A number of polipharmacological treatments have been reported to 
be effectively ‘polytherapies’, such as Contrave® and Qnexa®. 
Contrave® is a fixed-dose combination of naltrexone and 
bupropion. Qnexa® formulation contains doses of the 
amphetamine-analogue phentermine that are 1/10 to 1/2 the doses 
used for obesity and doses of topiramate that are 1/16 to 1/4 the 
doses used as an anticonvulsant (Bello & Campbell 2012).  
 
ii. Eating addiction 
 
Certain pathologic patterns of food consumption bear a striking 
resemblance to substance use disorders, associated with increased 
risk for comorbidity complications and relapse. The commonalities 
existing between compulsive eating and drugs of abuse, such as 
behavioural alterations, external cue-control of appetite or excessive 
motivation for reinforcement suggest that compulsive food 
consumption could be conceptualized as a mental addictive-like 
disorder. In this view, eating addiction is defined as a compulsive 
overeating syndrome accompanied by strong craving and extreme 
difficulty in abstaining from palatable food, which leads to a high 
risk of relapse (Davis et al. 2013). The idea that a person can be 
addicted to food has recently gotten more approval and may play an 
important role in obesity epidemic. However, normal-weight people 
exposed to high-fat, high-calorie foods may also be vulnerable to 






responsiveness to “unhealthy” food environments (Hetherington & 
Cecil 2010). This observation emphasizes the importance of 
avoiding simple use of BMI as a general marker for compulsive 
overconsumption. At present, it is discussed whether or not these 
specific patterns of food consumption should be viewed as addictive 
processes. In this line, opinions in favour and against the existence 
of eating addictive-like behaviour are currently discussed. Indeed, 
several models reject the eating addiction concept underlining the 
fact that food is essential to survival and it is normal to eat 
repeatedly and to look forward to eating for pleasure. These 
opinions also highlight the matter that eating depends on different 
peripheral and central factors, while drug addiction depends just on 
central factors.  
Conversely, other authors support the eating addiction construction 
highlighting that core components of addiction, across substances 
and reinforcing behaviours are reported in overeating (see Table 1). 
However, controversies concerning the possible classification of 
eating addiction as a “chemical” (substance-based) or a 
“behavioural” (non substance-based) addiction (Ifland et al. 2015; 
Albayrak et al. 2015) under the current DSM-5 criteria have been 
recently reported. Regarding chemical addiction, several models 
propose that some foods, containing specific “substances” such as 
high-fat and/or sugar, are capable of promoting addiction-like 
behaviour and neuronal changes under certain conditions (Corwin 
& Grigson 2009) similar to those promoted by an addictive drug 
such as nicotine, alcohol among others. Accordingly, the use of the 






the word “food” connotes the use of a substance that engages 
addictive processes. 
In contrast to chemical addiction, other models conceptualize food 
overconsumption as a behavioural addiction in predisposed 
individuals under specific environmental circumstances (Hebebrand 
et al. 2014). The term “eating addiction”, similar to compulsions 
that are non substance-related (i.e. gambling), more properly 
underscores the behavioural addiction to eating (Hebebrand et al. 
2014). In this context, the use of the term “food addiction” has been 
criticized because it appears more like a passive process which 
simply befalls an individual and does not emphasize on the 
behavioural component. 
Although the concept of eating addiction has received considerable 
attention from the popular media, it is still not clinically recognized 
in the DSM-5 and other manuals.  
In summary, the question of whether eating addiction is a valid 
concept is still subject of debate. Although findings provide support 
for eating addiction as a clinically relevant phenomenon, more 
scientific research is needed to its acceptance in clinical settings. 
Another point to be clarified is whether eating addiction should be 
considered as a substance use or as a behavioural disorder and thus 
diagnosed with the substance use disorder criteria or with those 











2.4 Eating addiction: perspective 
 
2.4.1 Chemical addiction or “food addiction” 
 
Labelling a food or nutrient as addictive implies that it possesses an 
inherent property with the capacity of making susceptible 
individuals addicted to it. As already reported, chemical addiction 
would refer to a kind of food, or its constituent, that engages 
specific neuronal mechanisms and produces behavioural adaptations 
comparable to those engendered by drugs. The growing legitimacy 
of food addiction concept has been heavily influenced by the 
premise that hyper-palatable foods have the potential to foster 
excessive consumption and a state of dependence (Davis & Carter 
2014). Past evidence in animal models reports that food can trigger 
addictive processes, although it should be essential to learn which 
constituent of foods might be responsible. Food is nutritionally 
complex and it could be difficult to suppose that under normal 
physiological circumstances humans crave specific foods to ingest a 
specific “substance”. In this view, several studies have focused on 
some specific nutrients such as sugar, fat and salt that, akin to 
addictive-substances, can alter the brain reward system. However, 
addiction to a particular substance or a nutrient profile, including 
high sugar content or combinations of high sugar and high fat, have 
been previously described only in animal studies (Colantuoni et al. 
2001; Berner et al. 2008; Ifland et al. 2009). Previous rodent models 
of addiction to food have typically used behavioural paradigms 
based on analogues inspired on substance dependence criteria 






eating behaviours using sugar and high palatable food have been 
shown in the conditioned place preference test and in operant self-
administration paradigms (de Jong et al. 2013; Velázquez-Sánchez 
et al. 2015). Compulsive food-seeking were evaluated in these 
models (Johnson & Kenny 2010; Avena et al. 2008) by measuring 
the animal motivation for palatable foods despite facing potentially 
harmful consequences. Indeed, an increased motivation to obtain a 
sucrose reward under a PR schedule after chronic exposure to high-
fat and high-sucrose choice diet was shown (Morgan et al. 2006). 
Conditioned aversion paradigm has been used to show that 
palatable food seeking can become resistant to punishment (Johnson 
& Kenny 2010; Latagliata et al. 2010). Models of reinstatement of 
extinguished palatable food-seeking behaviour induced by cues 
stimuli have also been described in mice (Martín-García et al. 2011) 
and rats (Ghitza et al. 2007).  
Sugar and fat seem to alter the brain reward system in a similar way 
in rats (Avena et al., 2008; Carrillo et al., 2003). Thus, changes in 
DA, acetylcholine and opioid levels in sugar–bingeing rats are 
similar to those observed with some drugs of abuse (Avena et al. 
2009). A similar addictive-like state may emerge with fat. Indeed, a 
binge of fat also modifies the DA and enkephalin system activity 
(Liang et al. 2006). However, these models cannot yet go beyond 
relating addiction to broad categories of high-fat, high-sugar or 
hyperpalatable foods and it is still unknown whether a particular 
concentration of nutrient(s) might engender the addictive process 
(Ziauddeen & Fletcher 2013). Evidence in rats showing preference 






However, the role of salt in directly increasing the rewarding value 
of food is relatively unexplored. Some studies have described a link 
between salt intake and activation of reward brain areas in rodents, 
although little evidence exists about the intrinsic reinforcing 
properties of salt (Tekol 2006). Recent studies described that rats 
exposed to “cafeteria diet” (composed of numerous nutrient 
combinations) also develop compulsivity toward palatable food, 
indicating that is not a single substance which possesses reinforcing 
properties (Johnson & Kenny 2010). Netherless, there is not 
currently evidence at present that these nutrient components or very 
simple combinations of them can elicit a substance use disorder in 
humans. 
In summary, past evidence in rodents suggests that addictive-like 
behaviour can be manifested toward foods composed by specific 
nutrient components, such as fat, sugar or salt (Kaplan 1996). 
However, there is insufficient evidence to label fat, sugar or salt as 
addictive as drugs of abuse, according to current DSM-5 diagnostic 
criteria, although these nutrient components have rewarding 
properties and are highly palatable.  
 
2.4.2 Behavioural addiction or “eating addiction” 
 
Addictive-like responses may be attributed not just to substances 
but also to behaviours. Thus, the recent DSM-5 has acknowledged 
the existence of behavioural addiction for the first time. In this 
edition, the conceptual model of “substance” addiction has been 






substance use rather than the chemical properties of the substances 
themselves (Gawin 1991). This change leads to an overlap in 
psychological characteristics between ‘chemical’ and ‘behavioural’ 
addictions, and the common properties of addictive substances or 
activities. In this line, eating addiction might be viewed mainly as a 
specific form of behavioural addiction and could be categorized 
alongside conditions like gambling addiction, especially when the 
psychological compulsion to eat is driven by the positive feelings 
that the brain associates with the act of eating. Eating addiction 
patterns could be the result of learning rather than a substance-
driven form of addiction.  
Researchers have stressed the behavioural component of this 
disorder proposing that the addictive pattern of eating may spring 
by the way in which the food is consumed, rather than its sensory 
and nutritional properties. Thus, palatable food is typically 
considered “forbidden” due to the high calorie content. This could 
indeed lead to a restricted pattern of consumption of the high-
energy food that may engage addictive processes (Corwin & 
Grigson 2009). In fact, evidence suggests that the state of 
prohibition could stimulate even more the consumption of palatable 
food (Pelchat 2009).  
As eating addiction, other excessive behaviours related to internet, 
sex, exercise, and shopping have been considered for the inclusion. 
However, none was deemed to have sufficient evidence for the 
identification as a mental health problem (Potenza 2014). Currently, 
pathological gambling is the only one listed in the newly labelled 






behaviour was included because it activates similar reward systems 
that are targeted by drugs of abuse, and because it produces 
behavioural symptoms that overlap with those produced by 
substance use disorders.  
In summary, the DSM-5 currently does not allow the classification 
of an “eating addictive disorder” within the diagnostic category 
substance-related and addictive disorders. However, similar to other 
behaviours, eating could become an addiction in predisposed 
individuals under specific environmental circumstances. 
Conversely, there is little evidence that humans can develop a 
specific nutrient use disorder. More evidence is also needed to 
confirm the existence of eating addictive like-behaviour in humans 
before its consideration as formal disorders. 
 
2.4.3 Diagnosis of “food addiction” in human 
 
The Yale Food Addiction Scale (YFAS) (Gearhardt et al. 2009b) 
can be viewed as the first questionnaire to assess the severity and 
frequency of symptoms of dependence in relation to individual food 
consumption based on similarities between certain aspects of 
overeating and the DSM-IV criteria for substance dependence 
(APA, 1994). This questionnaire was create in 2009 and it is to date 
use in expectation to clarify the concept of eating addiction disorder 
and to eventually come up with stringent diagnostic criteria 
according to those of the DSM-5. YFAS consists of a series of 25 
questions which address individual’s eating habits during the past 






criteria, the YFAS demonstrated good validity with other measures 
of eating problems and clearly focuses on the assessment of eating 
behaviour and not on substance based addiction (Hebebrand et al. 
2014). The questionnaire includes items related to foods containing 
different substances and a diagnosis of food addiction as a 
substance use disorder is therefore not possible using this 
questionnaire (Hebebrand et al. 2014). However, further 
modifications for the YFAS diagnosis of eating addiction are 
needed to better capture the cognitive and behavioural aspects of 
eating addiction.  
The YFAS criteria have been used to explore the prevalence of food 
addiction in obese subjects (Davis 2013b), in clinical population 
with and without BED (Gearhardt et al. 2013; Lent et al. 2014) and 
in a population of below normal weight (Flint et al. 2014). Studies 
using YFAS scale found prevalence rates of food addiction of about 
5-10% in people of normal weight and about 15-25% in obese 
participants (Meule 2012; Meule 2011). To date, several studies 
have found substantial comorbidity between BED and YFAS food 
addiction. Indeed, 56.8% of people with BED met YFAS criteria for 
food addiction (Gearhardt et al. 2013).  
 
2.4.4 Individuals vulnerabilities and risk factors of eating 
addiction 
 
Multiple factors are implicated in the propensity to develop eating 
addictive-like behaviours. These factors include genetic 






other mental disorders and negative emotions. Individual 
differences seem to play an important role in eating addiction. As 
previously described, genetic variations involved in drug addiction 
such as polymorphisms of the CB1R and MOR could also be 
predisposing factors leading to eating addiction. Other genetic 
factors could also play a role in the personality traits that are 
associated with increased overconsumption, such as novelty seeking 
and impulsiveness (Albayrak et al. 2012). On the other hand, 
environmental factors including food availability and advertising 
also have an important impact on the development of eating 
addiction. Availability is important since people cannot become 
addicted to something that they cannot find. Moreover, the repeated 
exposure to cues, such as advertising, may condition craving and 
the exposure to these environmental factors at a young age appears 
to have an important impact on the development of the addiction 
process (Picherot et al. 2010). As previously explained, the 
interaction of individual vulnerability and environmental factors is 
also crucial in the development of the eating addict phenotype.  
An interesting phenomenon that remains to be elucidated is the 
differential gender implication in eating addiction. Indeed, 
compulsive food consumption affects females more often than 
males (Davis 2013a; Liang et al. 2013). In spite of this prevalence, 
drug addiction seems to principally affect men. It is hypothesized 
that such differences are due to hormonal reasons since estrogens 
can modulate DA signalling and thus drug and food response (Roth 






In addition, patients with psychiatric comorbidity with mood, 
anxiety, conduct disorders and depression have a high risk to 
engage in this behaviour (Gearhardt et al. 2012). 
As previously described in the case of obesity disease, physiological 
stressors such as overloaded work, interpersonal issues or self-pride 
increase the motivation to engage in overeating behaviours. Indeed, 
stressors have been associated with an increased high-fat food 
intake or extra snacking between meals (O’Connor et al. 2009). 
 
2.4.5 Clinical implication 
 
i. Eating addiction and BED 
  
BED shares many characteristics with addictive behaviours (Gold et 
al. 2009) and scientific literature supports the addiction 
conceptualization of this eating disorder. Loss of control becomes a 
crucial part in the diagnosis of BED. Indeed, several 
diagnostic/research criteria for the bingeing-related eating disorders 
approximate the criteria for substance use disorders, such as 
diminished control over intake, high motivation, continued use 
despite negative consequences and diminished ability to cut down 
(Davis & Carter 2009; Gearhardt et al. 2009). Moreover, BED and 
addiction share neuronal correlate, such as similar patterns of DA 
activity in response to cue stimuli (Avena et al. 2008; Schienle et al. 
2009). Like eating addiction, BED also occurs in normal weight 
individuals albeit less frequently than in overweight or obese 






Despite similarities, BED and addiction also differ in important 
concepts. First, the loss of control over consumption occurs 
differently in BED and addiction. Indeed, BED diagnosis specifies 
that an episode of out-of-control over eating could occur during a 
discrete period of time, referring to a limited food consumption 
period during the day. Conversely, the impaired control in eating 
addiction is not necessarily experienced during a single episode of 
overeating, but it could persist throughout the day and does not 
necessarily include eating binges. In addition, binge-eating episode 
occurs at least once a week according to the DSM-5, whereas the 
loss of control over drug intake in addiction could occur with high 
frequency of consumption during days and weeks. In this line, 
addict individuals spend an abnormal amount of time in using the 
drug, as well as in obtaining and recovering from the effect of the 
drug. All these items have not been demonstrated in BED, in which 
the substance-focused activities could occur infrequently and the 
patient does not spend a great deal of time in obtaining and using 
food (Gearhardt et al. 2009). Moreover, addiction diagnosis places a 
greater emphasis on the contribution of the substance (addictive 
potential of drug) while BED diagnosis does not consider specific 
types of food consumed, but merely the amount (Gearhardt et al. 
2011; Gearhardt et al. 2014). Clinical studies reveal that although 
only 1-4% of the population meets diagnostic criteria for BED, 
episode of uncontrolled eating are also seen in nonclinical 
populations (Gearhardt et al. 2009b) suggesting that eating 
addiction may also be linked to other patterns of eating behaviours 






conditions are sufficiently different in etiology and clinical course is 
an important step to warrant classification as separate pathological 
eating disorders. 
 
ii. Eating addiction and Obesity 
 
Obesity is not considered at present a mental illness and is not 
included in the psychiatric manuals (e.g. DSM). However, there are 
robust associations between some types of obesity and a number of 
psychiatric disorders such as BED, depression, bipolar disorder and 
schizophrenia (DMS-5). In this context, recent opinions 
conceptualize obesity and overeating as disorders related to 
addictive-like processes. Indeed, some forms of obesity strongly 
resemble to drug addiction, both at the behavioural level and in 
terms of underlying neural processes (Ziauddeen et al. 2012). 
Indeed, obese individuals are driven by an excessive motivation for 
food and by a compulsive pattern of eating even though obeses 
make frequent, yet unsuccessful, efforts to control it. These obese 
individuals continue to overeat despite knowledge that their 
behaviour causes negative health consequences that could reduce 
the individual ability to participate in a full range of social, 
occupational, and recreational activities. Thus, it seems that the face 
value of eating addiction construct is strong when it is applied to 
certain individuals with obesity. 
Obesity and addiction has also a strong neurobiological common 
substrate. Indeed, addiction and obesity share several traits such as 






rewards (Volkow & Wise 2005). Indeed, the ST hypofunction that 
characterizes both obesity and drug addiction has been well 
documented (Volkow et al. 2011). These parallelisms have 
generated interest in understanding also the shared vulnerabilities 
between addiction and obesity. Indeed, some obese and drug-addict 
patients could be linked to similar genetic polymorphisms. The 
most widely studied polymorphism has been the Taq1A minor 
allele of the DA D2R, which is associated with alcoholism (Munafò 
et al. 2007) cocaine (Noble 1993), opioid dependence (Doehring et 
al. 2009) and also obesity (Davis et al. 2009).  
Although similarities between obesity and addiction have been 
described, there are also important differences according to clinical 
evidence. An addiction model of obesity assumes that overeating is 
the primary cause of obesity, just as compulsive drug use causes 
addiction. However, although obesity is generally associated with 
food overconsumption, other factors may also contribute to body 
weight gain (Blair & Nichaman 2002). Moreover, eating addiction 
has also been diagnosed in lean patients (Gearhardt et al. 2009). 
Thus, despite similarities between addicted and obese phenotypes, 
the overlap between these two disorders is only partial (Ziauddeen 
et al. 2012). 
In summary, obesity is a heterogeneous condition with a complex 
and incompletely understood etiology and is not considered a 
mental disorder per se. The hypothesis that overeating and obesity 
could be understood under the addiction framework has fuelled a 













3. THE OPIOID SYSTEM 
 
3.1 Components and physiological role 
 
The endogenous opioid system is integrated by three different 
families of endogenous opioid peptide precursors, 
proopiomelanocortin (POMC), proenkephalin (PENK) and 
prodynorphin (PDYN), and three main different opioid receptors, 
mu (MOR), delta (DOR) and kappa (KOR), widely distributed in 
the central nervous system and peripheral tissues. Within the central 
nervous system, opioid receptors are found in many areas, including 
the cortex, the limbic system and the spinal cord. 
The distribution of MOR, DOR and KOR is similar in several 
aspects. They are located at the same components of the limbic 
system, such as the NAc and amygdala, explaining the role of these 
receptors in mood and reward. In addition, MOR is predominantly 
localized in the VTA, habenula and thalamic nuclei and is also 
highly present in cortex, brainstem and reticular core nuclei. DOR is 
prominent in cerebral cortex and HCP, indicating the involvement 
of this receptor in cognition and memory, and is also highly 
expressed in the olfactory tubercle and caudate-putamen. The MOR 
and DOR location at the cortex, periaqueductal gray, 4th ventricle 
and substantia gelatinosa of the spinal cord reveals the involvement 
of these receptors in the control of nociceptive stimuli. In contrast, 







Figure 16. Schematic distribution of opioid receptors in the a) brain (sagittal 
plane) and b) spinal cord. Densities are represented by symbols of different 
sizes, from low to high. Localization of opioid receptors is determined by ligand 
autoradiography in main areas. Amb, nucleus ambiguus; AD, anterodorsal 
thalamus; AL, anterior lobe, pituitary; AON, anterior olfactory nucleus; Arc, 
arcuate nucleus, hypothalamus; BLA, basolateral nucleus, amygdala; BNST, bed 
nucleus of the stria terminalis; CeA, central nucleus, amygdala; Cl, claustrum; 
CL, centrolateral thalamus; CM, centromedial thalamus; CoA, cortical nucleus, 









hypothalamus; DMR, dorsal and medial raphé; DTN, dorsal tegmental nucleus; 
En, endopiriform cortex; Ent, entorhinal cortex; FrCx, frontal cortex; G, nucleus 
gelatinosus, thalamus; G/VP, globus pallidus/ventral pallidum; HbL, lateral 
habenula; HbM, medial habenula; HPC, hippocampus; IL, intermediate lobe, 
pituitary; IP, interpeduncular nucleus; LC, locus coeruleus; LD, laterodorsal 
thalamus; LG, lateral geniculate, thalamus; LH, lateral hypothalamus; LRN, 
lateral reticular nucleus; MD, mediodorsal thalamus; Me, median eminence; 
MEA, median nucleus, amygdala; MG, medial geniculate; MM, medial 
mammillary nucleus; MV, medial vestibular nucleus; NAc, nucleus accumbens; 
NL, neuronal lobe, pituitary; NRGC, nucleus reticularis gigantocellularis; NTS, 
nucleus tractus solitarius; OCx, occipital cortex; PAG, periaqueductal gray; PCx, 
parietal cortex; Pir, piriform cortex; PN, pontine nucleus; PnR, pontine reticular; 
PO, posterior thalamus; POA, preoptic area; PPTg, pedunculopontine nucleus; 
PrS, presubiculum; PV, paraventricular thalamus; PVN, paraventricular 
hypothalamus; RE, reuniens thalamus; RN, red nucleus; RM, raphé magnus; 
SON, supraoptic nucleus; SN, substancia nigra; SNT, sensory trigeminal nucleus; 
STN, spinal trigeminal nucleus; TCx, temporal cortex; Th, thalamus; Tu, 
olfactory tubercle; Tz, trapezoid nucleus; VL, ventrolateral thalamus; VM, 
ventromedial thalamus; VMH, ventromedial hypothalamus; VPL, 
ventroposterolateral thalamus; VTA, ventral tegmental area; ZI, zona incerta. 
(adapted from Le Merrer et al. 2009a).  
 
 
nuclei, important sites in sensory processing and homeostasis. It is 
also highly present in cortex, caudate-putamen, olfactory tubercle, 
amygdala and brainstem (George et al. 1994; Mansour et al. 1994; 
Le Merrer et al. 2009a). In the peripheral nervous system, these 
receptors are expressed in both the myenteric plexus and 
submucous plexus of the wall of the gut and are responsible for 






family of receptors which possess 7 transmembrane-spanning 
domains of aminoacids coupled to G-proteins. Once activated, they 
inhibit the enzyme adenylate cyclase, with a consequent reduction 
in the production of cyclic AMP and entry of Ca
2+
 ions together 
with the stimulation of the inwardly rectifying K
+
 channels. These 
processes cause cellular hyperpolarization and inhibit neural 
activity. Thus, the activation of opioid receptors at presynaptic level 
leads to a reduction of neurotransmitter release (Law et al. 2000). 
Opioid receptors are also expressed at postsynaptic level and their 
activation usually produces an inhibitory response. Activation of 
opioid receptors has the potential to produce profound analgesia, 
mood changes, physical dependence, tolerance and a hedonic 
('rewarding') effect. Among all these functions, it is important to 
highlight that sustained opioid treatment produces tolerance and can 
potentially lead to physical dependence (Matthes et al. 1996). 
Desensitization of MOR seems to be the major factor involved in 
the development of tolerance since the evidence for receptor down-
regulation is not consistent (Christie 2008).  
The three families of endogenous peptides POMC, PENK and 
PDYN generate several final active peptides including beta-
endorphin, met- and leu-enkephalin, dynorphins and neo- 
endorphins, respectively, that exhibit different affinities for each 
opioid receptor (Kieffer & Gavériaux-Ruff 2002). Beta-endorphin 
binds with higher affinity to MOR than DOR or KOR. The affinity 
of met- and leu-enkephalin for DOR is 20-fold greater than that for 







Figure 17. Intracellular signal transduction mechanism mediated by opioid 
receptors. 
 
(Akil et al. 1996). All these opioid peptides have an N-terminal 
sequence (Tyr-Gly-Gly-Phe-Met-Leu) indispensable to activate 
opioid receptors (Akil et al. 1996). Neurons containing enkephalins 
have been found in many different brain regions, suggesting that 
these peptides are involved in multiple physiological functions. 
Indeed, enkephalins control emotional responses by acting in limbic 
areas, such as the amygdala, NAc and ventral pallidum and also 
regulate cardiovascular, respiratory, feeding functions by acting on 
autonomic nuclei in the hypothalamus and brainstem. In addition, 
enkephalins mediate pain perception by acting in the spinal cord 
and periaqueductal gray region of the brain. Most enkephalin-
containing neurons have short axons, indicating that enkephalins act 










Figure 18. Distribution of opioid peptide neurons in the a) brain (sagittal 
plane) and b) spinal cord. Densities are represented by symbols of different 
sizes, from low to high. Map of cell bodies expressing opioid peptides is 
evaluated by immunohistochemical and in situ hybridization studies (adapted 








containing the other two types of opioid peptides, beta-endorphin 
and dynorphins, is not as diffuse as that of the neurons containing 
enkephalins. Neurons that contain beta-endorphin are found 
predominately in the hypothalamus and brainstem. The dynorphin-
containing neurons are located primarily in the hypothalamus, NAc 
and caudate-putamen, and are also present in the PFC. In contrast to 
the enkephalin-containing neurons, those contain beta-endorphin or 
dynorphins have long axons that extend to distant brain regions as 
well as to the pituitary gland, brainstem, and spinal cord, indicating 
that beta-endorphin and dynorphins act distant from their points of 
synthesis (Froehlich 1997). Opioid receptors and their endogenous 
ligands have been demonstrated to play an important role in brain 
reward processes and to modulate neurochemical effects of multiple 
drugs of abuse. 
 
3.2 The opioid system in drug addiction 
 
Multiple studies have underlined the important role of opioid 
receptors and their endogenous ligands in opioid, alcohol, nicotine, 
cannabinoid and psychostimulant addiction (Conte-Devolx et al. 
1981; Ghozland et al, 2002; Lee et al.; Charbogne et al. 2014). 
Systemic administration of MOR and DOR agonists produce 
positive reinforcement. These reinforcing effects are due to the 
indirect increase of ventral striatal DA release in the NAc shell (Di 
Chiara & Imperato 1988; Fusa et al. 2005), which is suggested to be 
critical in “drug liking” (Robinson & Berridge 2003; Daglish et al. 






et al. 2012) via the suppression of DA release in the NAc 
(Shippenberg & Elmer 1998; Van Ree et al. 2000). The mechanism 
by which the endogenous opioid system regulates the reinforcing 
properties of drugs is related to the anatomical distribution of opioid 
receptors and neurons containing opioid peptides. MOR and DOR 
are preferentially located at presynaptic GABAergic neurons of the 
VTA. Indeed, the activation of MOR and DOR results in the 
inhibition of GABAergic neurons (Margolis et al. 2008; Johnson & 
North 1992; Spanagel et al. 1992). The consequence of this 
inhibition is a reduction of the inhibitory effect on VTA DA 
neurons which, in turn, is followed by an increased DA release in 
the NAc. Furthermore, the KOR/dynorphin system is mainly 
expressed at DA neurons in the NAc (Svingos et al. 2001; Mansour 
et al. 1994) and the activation of presynaptic KOR inhibits DA 
release in the NAc (Spanagel et al. 1992; Shippenberg et al. 2007). 
In agreement, extracellular DA levels in the NAc are elevated in 
mice lacking KOR (Chefer et al. 2005). 
Pharmacological and genetic studies have suggested a role for 
opioid receptors in the acquisition, maintenance and relapse of drug 
use (Gerrits et al. 2003). The pharmacological administration of 
MOR antagonists or MOR genetic deletion attenuates cocaine-, 
ethanol-, nicotine-, opioid- and THC-induced conditioned place 
preference (Bechtholt & Cunningham 2005; Ghozland et al. 2002; 
Soderman & Unterwald 2008; Becker et al. 2002) and reduces 
cocaine, nicotine, ethanol and amphetamine self-administration 
(Becker et al. 2000; Liu & Jernigan 2011; Tang et al. 2005; Ward et 






Pharmacological and genetic studies have also suggested the 
involvement of DOR in drug reinforcing effects (Le Merrer et al. 
2009a). Naltrindole significantly blocks cocaine- and MDMA-
induced place preference (Suzuki et al. 1994; Reid et al. 1995; 
Belkaï et al. 2009). In addition, DOR antagonists can increase or 
decrease cocaine self-administration in rats depending on the brain 
area microinjected (Ward et al. 2003). Indeed, naltrindole decreased 
cocaine self-administration when injected into the NAc, but it 
increased this behaviour when administered in the VTA and it had 
no effect when injected in the amygdala (Ward & Roberts 2007). 
Different results were obtained in alcohol-seeking behaviour. DOR 
activation in the VTA robustly decreases ethanol consumption in 
rats (Margolis et al. 2008), whereas increased ethanol consumption 
was displayed in constitutive DOR knockout animals (Roberts et al. 
2001). DOR-deficient mice also showed increased operant 
behaviour maintained by nicotine intravenous self-administration, 
although mainly for lower doses of nicotine (Berrendero et al. 
2012). In addition, naltrindole treatment dose-dependently impaired 
nicotine self-administration (Berrendero et al. 2012), while other 
pharmacological studies failed to reveal an effect of naltrindole on 
nicotine self-administration in rats (Liu & Jernigan 2011). DOR 
does not seem to be involved in THC-induced conditioned place 
preference (Ghozland et al. 2002). 
KOR is also involved in the reinforcing effect of several drugs of 
abuse such as cocaine, THC, ethanol and nicotine. Several studies 
have demonstrated that KOR agonists are effective in decreasing 






1992) and the rate of cocaine self-administration in rats and monkey 
(Glick et al. 1995; Negus et al. 1997). In addition, the 
administration of selective KOR agonists decreased amphetamine-
induced enhancement of DA extracellular outflow in the ventral ST 
(Gray et al. 1999). Moreover, KOR has also a critical role in ethanol 
intake. The selective KOR antagonist norbinaltorphimine 
selectively decreased ethanol self-administration in alcohol-
dependent rats (Walker & Koob 2008) and reduction of KOR 
mRNA in the VTA and NAc were reported in rats following 
chronic ethanol exposure (Rosin et al. 1999). In contrast, the role of 
KOR in the rewarding effects of nicotine is difficult to interpret. 
Indeed, a high dose of the KOR agonist U50,488 decreased nicotine 
self-administration, while a low dose tended to increase nicotine 
self-administration in rats (Ismayilova & Shoaib 2010). 
Nevertheless, the selective pharmacological antagonism of KOR 
has no effect on nicotine self-administration (Liu & Jernigan 2012) 
and nicotine conditioned place preference (Jackson et al. 2010). 
KOR is critically implicated in the dysphoric effects induced by 
THC. Indeed, THC-induced conditioned place aversion has been 
abolished in KOR deficient mice, even though THC-induced 
conditioned place preference was not modified (Ghozland et al. 
2002). 
Different drugs of abuse that enhance mesolimbic DA levels also 
increase dynorphin content (Trigo et al. 2010). Indeed, increased 
dynorphin in the NAc (Lindholm et al. 2000), and decreased KOR 
mRNA levels in the VTA and NAc have been reported in rats 






the acute administration of MDMA increases PDYN mRNA in the 
ST and PFC, but not in the NAc (Di Benedetto et al. 2006). 
Similarly, repeated cocaine administration increases the level of 
dynorphin, PDYN and preprodynorphin mRNA in the ST (Trifilieff 
& Martinez 2013). Conversely, a decrease of the dynorphin level 
was observed in the ST of mice for a protracted time (from 30 min 
to 72 hours) following discontinuation of chronic administration of 
nicotine (Isola et al. 2008). The involvement of dynorphin in the 
dysphoric effects of cannabinoids was revealed in mice lacking the 
PDYN gene since THC-induced conditioned place aversion was 
abolished in these mice (Zimmer et al. 2001). Considering these 
data together, the activation of the KOR/dynorphin system in 
regions associated with reward might be part of a protective 
compensatory mechanism to counteract elevated DA level in the 
NAc due to the action of different drugs of abuse (Yoo et al. 2012).  
The regulation of the reinstatement of drug-seeking behaviour by 
the opioid system confirms the central role of this system in 
addiction. The relapse induced by cue-stimuli associated with drug 
use is mainly mediated by MOR and DOR, while stress-induced 
relapse is generally related to KOR/dynorphin system. Thus, the 
MOR antagonist naltrexone inhibits cue-induced reinstatement of 
drugs, such as heroin (Shaham & Stewart 1996), nicotine (Liu et al. 
2008), cocaine (Burattini et al. 2008), methamphetamine 
(Anggadiredja et al. 2004) and alcohol (Ciccocioppo et al. 2002). 
However, naltrexone does not alter the relapse to these drugs when 
it is induced by stress (Shaham & Stewart 1996; Ciccocioppo et al. 






reinstatement of alcohol seeking-behaviour (Ciccocioppo et al. 
2002) and abolished the cocaine reinstated effect of a DOR agonist 
in the conditioned place preference (Kotlinska et al. 2010). 
Furthermore, KOR blockade by specific antagonists or the deletion 
of genes encoding both the endogenous opioid peptide dynorphin or 
KOR inhibits the stress-induced reinstatement of cocaine 
(Beardsley et al. 2005), alcohol (Funk et al. 2014) and nicotine 
seeking behaviour (Jackson et al. 2013). 
Opioid peptides derived from PENK have been postulated to 
mediate the reinforcing effects of many drugs of abuse (Berrendero 
et al. 2005; Marinelli et al. 2005; Shoblock & Maidment 2007). An 
enhancement of PENK expression has been reported in the ST 
following acute or chronic nicotine administration in both mice 
(Dhatt et al. 1995) and rats (Mathieu et al. 1996). Conversely, 
decreased PENK mRNA levels have been found in the caudate-
putamen area in post-mortem brains of humans with a history of 
cocaine abuse (Hurd & Herkenham 1992). More recent studies have 
reported an increase of PENK mRNA levels in caudate-putamen 
after chronic cocaine treatment in rats (Zhang et al. 2012) or no 
change in this brain area, as well as in the NAc and central nucleus 
of amygdala in rat after contingent or noncontingent cocaine 
administration (Ziółkowska et al. 2006). Therefore, changes in 
PENK mRNA level after chronic cocaine exposure are complex and 
unclear. In addition, chronic ethanol exposure in rats increases 
PENK mRNA levels in the central amygdala, but decreases these 






Less consistent changes have been reported for POMC. Thus, no 
changes in POMC mRNA levels have been observed in the 
hypothalamus following chronic cocaine exposure and withdrawal 
(Zhou et al. 2005). In contrast, long-lasting inhibition of POMC 
gene expression in the mediobasal hypothalamus was reported after 
chronic nicotine administration (Rasmussen 1998). Interestingly, 
polymorphisms of the POMC gene might constitute an important 
risk factor for the development of alcohol dependence in humans 
(Zhang et al. 2006). 
In summary, the opioid system has a key role in drug seeking-
behaviour through the modulation of the DA system. In this context, 
the endogenous opioid system more properly seems to mediate the 
emotional hedonic/aversive responses to drugs of abuse. 
 
3.3 The opioid system in the control of eating behaviour 
 
3.3.1 The opioid system in the homeostatic control of food 
intake 
 
Opioid peptides and receptors are located in several brain areas 
related to the regulation of energy homeostasis and exert a crucial 
role in the control of food intake. The opioid system modulates 
feeding mainly in the PVN, LH, ARC, and DMH of the 
hypothalamus (Bodnar 2004a), as well as in the nucleus tractus 
solitarius and the mesolimbic system. Activation of MOR in the 
PVN by local agonist injections produces an increase in food intake. 






reduces deprivation-induced feeding (Bodnar 2004a). Similarly, the 
injection of the MOR agonist DAMGO in the nucleus tractus 
solitarius stimulated food intake, whereas the injection of either the 
DOR agonist DSLET, or the KOR agonist dynorphins A-(1–17) in 
the nucleus tractus solitarius had no effect (Kotz et al. 1997). In 
addition, injections of MOR or DOR, but not KOR agonists in the 
NAc or VTA, stimulated food intake (Bodnar 2004b), highlighting 
that the modulation of the reward system by opioid mechanisms 
participates in feeding behaviour. The precise molecular mechanism 
by which the opioid system modulates food intake is not clearly 
understood, although interactions with melanocortin, NPY, AgRP, 
CART, leptin, PYY, CCK, gherelin, orexin system and insulin 
among others, have been described. Melanocortins are a family of 
proteins that reduce appetite, and their precursor, POMC, encodes 
α-MSH that decreases food intake, and beta-endorphin that 
influences mood and food intake (Pennock & Hentges 2014). In the 
PVH, melanocortins act mainly though two receptors to decrease 
food intake, melanocortin receptor 3 and 4 (Hagan et al. 2001). 
Interestingly, POMC neurons express melanocortin receptors 3 and 
4, but also MOR at pre and post synaptic level. Activation of MOR 
inhibits the release of endogenous opioids and melanocortins, which 
underlines the relationships between these two systems (Pennock et 
al, 2002). The interaction between them has also been supported by 
the observation that the orexigenic effect of beta-endorphin (MOR 
ligand) is blunted by an agonist for melanocortin receptors 3 and 4 
(Grossman et al. 2003). The opioid system also modulates the effect 






(fourth ventricular) and peripheral injections of naloxone blocked 
PYY-induced food intake (Hagan & Moss 1993). Previous studies 
also showed that MOR and DOR, but not KOR agonists, suppress 
K
+
-stimulated release of CCK and substance P from cortical and 
hypothalamic tissues and this suppression was blocked by naloxone 
(Micevych et al. 1982; Micevych et al. 1984).  
The regulation of the effects of orexigenic peptides/hormones by 
the opioid system is also been demonstrated. An important central 
mediator of feeding is NPY. NPY, in the ARC, is a potent orexigen 
factor and its action is mediated by the opioid system especially by 
MOR and KOR, as demonstrated by the fact that KOR and MOR 
antagonists, but not DOR antagonists, blunt NPY-induced feeding 
(Kotz et al. 1993). Moreover, central and peripheral administration 
of naloxone decreases NPY-induced feeding behaviour (Rudski et 
al. 1996; Kotz et al. 1993). It has also been found that long-term 
morphine treatments increased hypothalamic AgRP gene 
expression, whereas short-term treatments decreased leptin 
receptors in the hypothalamus (Anghel et al. 2010). In agreement, 
combination of MOR and KOR antagonist treatment injected into 
the third ventricle significantly reduced feeding elicited by AgRP 
(Brugman et al. 2002). Another central mediator of feeding is the 
orexin system. Hypothalamic injections of orexin increased 
enkephalin gene expression in the VTA, PVH and central nucleus 
of the amygdala. Interestingly, naltrexone also blocked the effects 
of orexin A when administrated in the NAc of rats (Karatayev et al. 
2009). It was also demonstrated that the specific blockade of MOR, 






2010) and regulated ghrelin functions (Kawahara et al. 2013). It is 
well-known that ghrelin stimulates feeding behaviour when injected 
in the VTA or the NAc (Naleid et al. 2005). Systemic ghrelin 
administration followed by consumption of regular food increased 
DA levels in the NAc via preferential activation of MOR, whereas 
systemic ghrelin administration followed by consumption of 
palatable food suppressed the increase in DA levels in the same 
brain area via preferential activation of KOR (Kawahara et al. 
2013). However, pre-treatment with naltrexone in the VTA or NAc 
did not blunt the orexigenic action of ghrelin (Naleid et al. 2005). 
Pharmacological evidence indicates that the endogenous opioid 
system also regulates the effects of insulin. Indeed, subcutaneous 
administration of insulin produced hypoglycemia in rats with a 
concomitant induction of feeding (Levine & Morley 1981). In this 
condition, naloxone significantly suppressed eating during the first 
hour, antagonizing the effects of insulin (Levine & Morley 1981). 
In addition, the MOR antagonist β-funaltrexamine significantly 
inhibited insulin-induced feeding during a long time period (6 
hours). In contrast, insulin hyperphagia was only transiently (2 
hours) inhibited by the selective KOR antagonist nor-
binaltorphamine. However, the DOR-antagonistic action of DALCE 











3.3.2 The opioid system in the hedonic control of food intake 
  
The opioid system also plays an important role in the rewarding 
aspects of eating, modulating the hedonic response promoted by 
palatable food. The opioid system works together with the DA 
limbic system to accomplish this physiological role (Olszewski et 
al. 2011). DA transmission is implicated in the motivation for food, 
while opioids are possibly involved in the hedonic evaluation of 
food (Ackroff & Sclafani 2011; Oliveira-Maia et al. 2011). The 
principal structures involved in these mechanisms are the NAc and 
the VTA. Indeed, activation of the ventral ST opioid system 
encodes the positive effect induced by tasty foods and triggers 
behavioural responses associated with food-seeking. In agreement, 
the shell of the NAc contains a hedonic hotspot in which the 
stimulation of opioid receptors increases the “liking” for food 
reward, measured by the amplification of positive affective 
orofacial reactions to sucrose in rats (Peciña & Berridge 2005). 
Indeed, the MOR agonist DAMGO, the DOR agonist DPDPE and 
the KOR agonist U50488H administered within the rostro-dorsal 
boundaries of the NAc shell enhanced hedonic reactions to sucrose 
“liking” responses, whereas all three opioid receptor agonists 
administered into the caudal half of the medial NAc shell 
suppressed hedonic reactions to sucrose “liking” responses (Castro 
& Berridge 2014). In addition, this response is enhanced with 
DAMGO microinjections in the posterior subregion of the ventral 
pallidum (Smith 2005), which plays a role in amplifying the 






reciprocally activated in the enhancement of “liking” responses 
(Smith & Berridge 2007), such as the rostro-dorsal part of the NAc 
shell projecting to the lateral pre-optic area, anterior and lateral 
hypothalamus and the lateral septum (Zahm et al. 2013).  
Opioids, besides promoting hedonic responses, seem to be also 
involved in learned-associative appetitive processes that underlie 
food acceptance and selection (Cottone et al. 2008) through a 
mechanisms involving orbitofrontal cortex, HCP and amygdala 
circuits (Volkow & Morales 2015). Indeed, several results support 
that opioids influence food intake based on flavour preferences 
(Woolley et al. 2006). A decrease in sucrose preference has been 
observed after systemic treatments with naltrexone (Parker et al. 
1992), whereas morphine injections cause an increase in preferred 
food intake (Glass et al. 1996a). However, the pattern of effects on 
preferred versus non-preferred food depends on the site of 
agonist/antagonist injection: NAc injections of naltrexone decrease 
intake of the preferred food, whereas injections of naltrexone in the 
PVH decrease the intake of both, preferred and not preferred foods 
(Glass et al. 2000). Injections of DAMGO into the NAc 
preferentially increase intake of food with the preferred flavour 
(Woolley et al. 2006). In agreement, the blockade of MOR in the 
shell of the NAc by injection of β-funaltrexamine induced a 
persistent decrease in the consumption of a palatable glucose 
solution, with no effect on the intake of standard chow (Le Merrer 
et al. 2009b). In addition, the administration of the KOR agonist U-






preferred flavour, but increased the intake of the non-preferred 
flavour food (Le Merrer et al. 2009b). 
Several studies also support a role for the opioid system in 
controlling the intake of specific macronutrients. Thus, morphine 
increases fat intake and decreases carbohydrate intake, whereas 
naloxone preferentially decreases fat intake (Marks-Kaufman 
1982). In addition, KOR agonists selectively increased the intake of 
high-fat diet when offered along with a high carbohydrate diet 
(Romsos et al. 1987). 
 
Figure 19. Effects of the opioid system on energy balance. Opioid receptors 
have been found in the hypothalamus (modulating homeostatic signals) and in 
extra-hypothalamic areas such as the mesolimbic DA system (regulating hedonic 






3.3.3 The opioid system in eating disorders 
 
Alterations in the expression of different opioid peptides have been 
reported in neuropsychiatric conditions associated with eating 
disorders such as anorexia, bulimia, BED and obesity. Several 
studies have found that underweight anorexic patients have 
significantly reduced beta-endorphin levels in the cerebrospinal 
fluid compared to healthy volunteers. At the same time, beta-
endorphin levels remain significantly below normal after short-term 
weight restoration (Brewerton et al. 1992). Conversely, dynorphin 
levels have been reported to be normal in the cerebrospinal fluid in 
all stages of anorexic and in bulimic patients (Swedo et al. 1992). 
While there is little evidence of the specific function of the opioid 
system in anorexia, the involvement of this system in binge-eating 
episodes has been better described. A reduction in MOR density in 
the insular cortex has been reported in human patients with bulimia, 
(Nathan & Bullmore 2009). Moreover, bulimic patients showed a 
reduction in the size and frequency of binging and purging 
following naltrexone administration (Kaye et al. 1990; Marrazzi et 
al. 1995). Neuroadaptations of endogenous opioids and receptors in 
the medial PFC, such as increased POMC and reduced PDYN gene 
expression, have been reported in rodents subjected to a binge-
eating regime of intermittent access to highly palatable food (Blasio 
et al. 2014). In addition, the G allele of the OPRM1 (MOR), A118G 
SNP, related to an exaggerated response after MOR activation, was 
associated with higher frequency of BED (Davis et al. 2012). 






regulation of MOR in brain regions relevant for reward processing, 
including ventral ST, insula, and thalamus associated with unaltered 
D2R density (Karlsson et al. 2015). The effects of naloxone and 
naltrexone on feeding behaviour have also been studied in obese 
patients (Lee & Fujioka 2009; Wolkowitz et al. 1988). Both opioid 
antagonists suppressed food intake in these patients, and some of 
the obese patients report decrease in hunger. In spite of these short-
term effects, naltrexone fails to produce consistent weight loss in a 
longer time period (Atkinson et al. 1985; Mitchell et al. 1987). 
However, combination therapy with naltrexone and bupropion, an 
antidepressant that selectively binds to the DA transporter, appears 
to be efficient in obese patients, as previously reported. Taken 
together, these data indicate that the assessment of the opioid 






4. THE ENDOCANNABINOID SYSTEM 
 
4.1 Components and physiological role 
 
The ECS is a neuromodulatory system in the mammalian 
physiology that comprises cannabinoid receptors, their endogenous 
ligands, mainly anandamide (AEA) and 2-arachidonoylglycerol (2-
AG), as well as their synthesis and degradation enzymes 
(Mechoulam & Parker 2013).  
 
4.1.1 Cannabinoid receptors 
 
Two main subtypes of cannabinoid receptor have been identified: 
cannabinoid receptor 1 (CB1R) (Matsuda et al. 1990) and 
cannabinoid receptor 2 (CB2R) (Munro et al. 1993). Both receptors 
belong to the seven transmembrane domain receptor families 
associated with G proteins. CB1R is highly expressed in the central 
nervous system (Herkenham et al. 1991; Tsou et al. 1998) and has 
been found in the basal ganglia (caudate-putamen, globus pallidus, 
ectopeduncular nucleus, substantia nigra) and the molecular layer of 
the cerebellum, explaining the effects of cannabinoids on locomotor 
activity (Compton et al. 1990). High receptor density has also been 
found in the HCP and PFC, indicating that cannabinoids are 
involved in cognition, memory and inhibitory control (Herkenham 
et al. 1991). The expression of CB1R has also been observed in the 






(Compton et al. 1990; Tsou et al. 1998), explaining the role of the 
cannabinoid system in mood and emotional behaviour. In addition, 
CB1R in the NAc is associated with the brain reward system, and 
its expression in the hypothalamus correlates with the role of 
cannabinoids in food intake control and energy homeostasis (Osei-
Hyiaman et al. 2006; Solinas et al. 2008). The presence of CB1R 
has been detected in the thalamus, periaqueductal gray, Rostral 
ventromedial medulla and dorsal horn of the spinal cord, important 
sites in pain transmission pathways (Kano et al. 2009; Tsou et al. 
1998). In all these areas, CB1R is mainly expressed at the 
presynaptic level in GABAergic and glutamatergic neurons 
(Howlett 2002). CB1R has also been found in multiple peripheral 
locations, such as adipocytes (Cota et al. 2003), liver (Osei-
Hyiaman et al. 2006), pancreas (Bermúdez-Silva et al. 2008), lungs, 
smooth muscle, gastrointestinal tract (Calignano et al. 1997), 
vascular endothelium (Liu et al. 2000), human eye (Straiker et al. 
1999), and other peripheral tissues. Peripheral CB1R plays an 
important role in the modulation of metabolism. Thus, the 
activation of CB1R promotes lipogenesis, lipid storage, insulin and 
glucagon secretion, and adiponectin modulation (Bermúdez-Silva et 
al. 2008; Cota et al. 2003; Osei-Hyiaman et al. 2006). Moreover, 
CB1R exerts proinflammatory effects in the cardiovascular system 
(Slavic et al. 2013) and its presence in endothelial cells of various 
vascular beds (Golech et al. 2004) contributes to its vasodilatory 
actions (Wagner et al. 1998). Activation of CB1R in various 
structures of the human eye (Straiker et al. 1999), such as the ciliary 






(Oltmanns et al. 2008; Laine et al. 2003). In addition, the presence 
of CB1R in reproductive organs highlights the involvement of this 
receptor in male fertility and in several critical stages of pregnancy 
in female (Maccarrone et al. 2015). CB1R is also involved in other 
peripheral functions, such as immunosuppression, skin 
proliferation, differentiation and cell survival as well as intestinal 
motility and changes in adrenal functions (Maccarrone et al. 2015; 
Howlett et al. 2004), among others. 
The CB2R has been mainly found in immune cells and tissues, 
namely the tonsils, spleen, thymus and various circulating immune 
cell populations (Galiègue et al. 1995). The presence of CB2R in 
brain neurons has been a controversial topic over the last few years. 
Some studies have reported the expression of CB2R in structures 
such as PFC, ST, HCP, amygdala, brainstem, dorsal root ganglia 
and lumbar spinal cord (Van Sickle et al. 2005; Gong et al. 2006a). 
Moreover, immunohistochemical analysis reveals CB2R 
immunostaining in apparent neuronal and glial cells in a number of 
brain areas in rats (Gong et al. 2006b). Indeed, this receptor can 
modulate neuroinflammatory responses upon microglial activation 
(Atwood & Mackie 2010). The presence of CB2R has also been 
demonstrated at the central level on vascular endothelial cells 
(Golech et al. 2004). The functional role of CB2R in the central 
nervous system has not been yet clarified, although it has been 
demonstrated that activation of CB2R decreases locomotion (Gong 
et al. 2006a), neuropathic and osteoarthritic pain (Racz et al. 2008; 








Figure 20. Schematic representation of the distribution of CB1R and CB2R in the 
brain. CB1R distribution is indicated by circle shapes with low (white), moderate 
(gray) and high (dark gray) expression. Major localization of CB1R (mRNA and 
protein) is in cortical areas, hippocampus, amygdala, striatum, and cerebellum. 
Moderate and low expression levels are observed in thalamic, hypothalamic, and 
brainstem regions. Interestingly, CB2R is expressed in brain areas overall in glial 
cells, although quantitative Real Time Polymerase chain reaction experiments 
also demonstrated the expression of CB2R mRNA in the brainstem, cortex and 
cerebellars granule cells (Van Sickle et al 2005). Amb, ambiguous nucleus; BLA, 
basolateral amygdala; CeA, central amygdala; CPu, caudate-putamen; DB, 
diagonal band; DRN, dorsal raphe nucleus; GP, globus pallidus; Hyp, 
hypothalamus; LC, locus coeruleus; LHb, lateral habenular nucleus; mHb, medial 
habenular nucleus; NAc, nucleus accumbens; OB, olfactory bulb; PAG, 
periaqueductal gray; SNr, substantia nigra pars reticulate; Sol, nucleus of the 
solitary tract; STh, subthalamic nucleus (ventral thalamus); Th, dorsal thalamus; 







regulatory function in drug rewarding effects (Xi et al. 2011a; 
Aracil-Fernández et al. 2012). Stimulation of CB1R and CB2R 



















Figure 21. Schematic representation of the peripheral distribution of CB1R and 
CB2R. The localization of these receptors in different peripheral locations 
highlights their involvement in several physiological functions. 
 
proteins. When the cannabinoid receptor is activated, the βγ subunit 
of the G protein dissociates and the α subunit inhibits the enzyme 






cyclase leads to a decrease of cAMP production from adenosine-5’-
triphosphate, and subsequent PKA activity is inhibited (Bonhaus et 
al. 1998). Reduction of PKA activity promotes intracellular 





and of focal adhesions kinase that is an important factor for 
integrating cytoskeletal changes with signal transduction events. On 
the other hand, the βγ subunit activates G protein-gated inwardly 
rectifying K
+
 channels and inhibits voltage gated Ca
2+
 channels. 
The βγ subunit also activates multiple members of the mitogen-
activated protein kinase family, including extracellular signal-




Figure 22. Cannabinoid receptor signalling. Both CB1 and CB2 cannabinoid 
receptors are associated with Gαi-dependent inhibition of adenylyl cyclase 
activity and Gβγ-dependent activation of the different mitogen-activated protein 






kinase (JNK) as signalling pathways to regulate nuclear 
transcription factors (Howlett 2005). Furthermore, cannabinoids 
could activate protein kinase c signalling in vitro (Hillard & 
Auchampach 1994). The effects of cannabinoids on these multiple 
families of kinases indicate the relevance of changes on protein 
phosphorylation in the mechanism of action of these compounds. 
These cascades of signalling participate in the inhibition of synaptic 
transmission mediated by cannabinoid receptors, consisting in the 
hyperpolarization of the neural membrane and consequent decrease 
of neurotransmitter release. 
Recent evidence suggests the existence of additional cannabinoid-
like receptors, distinct from CB1R and CB2R. Indeed, the orphan 
receptor GPR55 (Sawzdargo et al. 1999) is widely expressed in the 
central nervous system and peripheral tissues and has been 
proposed as a new cannabinoid receptor. This receptor has been 
tentatively classified as a cannabinoid receptor based on its 
activation by THC and synthetic cannabinoids (Lauckner et al. 
2008), although its natural ligand appears to be the 
lysophospholipid, lysophosphatidylinositol (Oka et al. 2007; 
Sylantyev et al. 2013). The role of GPR55 has not been thoroughly 
characterized and it may be involved in pain transmission 
considering its major expression in dorsal root ganglia neurons 
(Lauckner et al. 2008). However, several experiments have also 
demonstrated the role of GPR55 in neuroprotection (Kallendrusch 
et al. 2013), energy homeostasis (Simcocks et al. 2014), 
inflammatory processes (Lanuti et al. 2015; Schicho & Storr 2012), 






Moreover, other G-protein coupled receptors (GPR) GPR1 and 
GPR119, interact with atypical cannabinoids. Besides GPRs, the 
transient receptor potential vanilloid type 1 (TRPV1) channel has 
also been considered as a potential cannabinoid-like receptor (Di 
Marzo & De Petrocellis 2010).  
 
4.1.2 Endogenous cannabinoid ligands 
Endogenous cannabinoid receptor ligands derive from arachidonic 
acid. AEA acts as a partial agonist at CB1R and CB2R and it is an 
endogenous ligand also for TRPV1. AEA is obtained after the 
hydrolysis of N-acylphosphatidylethanolamine by NAPE-PLD 
enzyme. 2-arachidonoylglycerol (2-AG) is the most abundant 
endocannabinoid in the brain and acts as a full agonist for CB1R 
and CB2R. 2-AG is synthesized from AA-containing membrane 
phospholipids through the action of phospholipase C, leading to the 
formation of diacylglycerol and then through the diacylglycerol 
lipases. AEA and 2-AG can be degraded by fatty acid amide 
hydrolase and monoacylglycerol lipase, respectively. AEA and 2-
AG might also become substrates for lipoxygenases (van der Stelt et 
al. 2002), cyclooxygenases-2 (Rouzer & Marnett 2011) and 
cytochrome P450s (Snyder et al, 2010) when monoacylglycerol 
lipase or fatty acid amide hydrolase activity is suppressed. 
Endocannabinoids are not stored and they are generated on demand 
in response to depolarization-induced increases in intracellular Ca
2+
 
(Witting et al. 2004). The principal mechanism by which 








Figure 23. Summary of the major pathways involved in the biosynthesis and 
degradation of: AEA (A) and 2-AG (B). PE, phosphatidylethanolamine; PC, 
phosphatidylcholine; NAT, N-acyl-transferase; NAPEselective phospholipase D, 
N-acylphosphatidylethanolamine hydrolysing phospholipase D; PA, phosphatidic 
acid; FAAH, fatty acid amide hydrolase; phospholipase C; AR-PIP, arachidonic 
acid - containing inositol phospholipids; diacylglicerol, diacylglycerol; MAG, 
monoacylglycerol (Lipina et al. 2012). 
 
 
is through retrograde signalling (Kano et al. 2009). Postsynaptic 
activity leads to the production of endocannabinoids that move 
backwards across the synapse, bind presynaptic cannabinoid 







Figure 24. Overview of the retrograde modulation of neurotransmitter 
release by ECS. The neurotransmitter is released from presynaptic terminals and 
stimulates ionotropic and/or metabotropic receptors. High Ca
2+
 concentration 
stimulates endocannabinoid synthesis in the post synaptic terminal through 
phospholipase C and PLD. 2-AG synthesis could be also mediated by G-protein 
activation, depending on the receptor. Endocannabinoids are released from the 
post synaptic terminal to the synaptic cleft and activate presynaptic CB1R and 
CB2R. Some of the main downstream consequences of CBR activation are: 





 channels, and subsequent inhibition of neurotransmitter release; 
activation of protein kinase cascades, such as mitogen-activated protein kinases 
pathway (adapted from Flores et al. 2013). 
 
There is evidence suggesting that endocannabinoids could also 
modulate synaptic functions in a non-retrograde or autocrine 
manner by engaging TRPV1 and CB1R located within postsynaptic 






indicate that endocannabinoids could act via astrocytes to indirectly 
modulate presynaptic or postsynaptic function (Hegyi et al. 2012; 
Stella 2010). 
Dysregulation in the ECS has been linked to both drug addiction 
and eating disorders (Maldonado et al. 2006; Marco et al. 2012). 
 
4.2 The endocannabinoid system in drug addiction 
 
The ECS is implicated in several phases of the addictive process 
and this system has been considered an important common neuronal 
substrate of addiction (Maldonado et al. 2006). Firstly, the ECS is 
involved in the initial step of addiction, acting as a crucial substrate 
mediating positive reinforcement (Cheer et al. 2007). The role of 
the ECS in brain reward processes is not limited to cannabinoid 
drugs, but also to natural rewards (Sanchis-Segura et al. 2004) and 
to different classes of drugs of abuse including nicotine, 
psychostimulants, alcohol and opioids (Maldonado et al. 2006). 
Genetic deletion of CB1R impairs acquisition of the conditioning 
place preference and self-administration maintained by different 
drugs of abuse (Maldonado et al. 2006). The modulatory role of the 
ECS on the primary rewarding effects of drugs of abuse might 
mainly depend on the ability of this system to regulate DA 
transmission in the mesocorticolimbic circuit (Gardner 2005), and 
in particular the phasic DA release (Cheer et al. 2007). Indeed, 
CB1R negatively modulates the glutamatergic excitatory and 
GABAergic inhibitory synaptic inputs into the DA neurons of the 






of ECS on the modulation of DA activity depend on the functional 
balance between the inhibitory GABAergic and excitatory 
glutamatergic input to the VTA, with the latter being predominant 
(Maldonado et al. 2006). Thus, the endogenous cannabinoid system 
seems to be a crucial substrate mediating the positive reinforcement. 
The ECS is also involved in the motivation to seek the drug by a 
mechanism independent from release of DA in the NAc. CB1R is 
present in the PFC, an important brain area involved in the 
reinforcing value of rewards, in decision making and expectation, as 
well as in the mediation of ‘hedonic experience’ (Kringelbach 
2005). Endocannabinoids could be involved in the motivation to 
obtain the drug by linking reward to a ‘hedonic experience’ 
(Maldonado et al. 2006). This role is highlighted by a reduction of 
the breaking point on a PR schedule task mediated by the blockade 
of CB1R (Solinas et al. 2003) when rodents are trained to self-
administer psychostimulants and opioids (Solinas et al. 2003; Soria 
et al. 2005), which might also be the case for other drugs of abuse. 
Moreover, the ECS plays a role in the reinstatement of drug 
consumption, in which inactivation of CB1R in mice strongly 
reduces drug priming and cue-induced reinstatement of drug-
seeking behaviour of almost all drugs of abuse (De Vries & 





















Figure 25. Possible sites of endocannabinoid action in modulation of drug 
rewarding effects. In the ventral tegmental area (VTA), CB1R is located on 
presynaptic glutamatergic and GABAergic neurons. Activation of CB1R in the 
VTA by endocannabinoids (EC; broken red arrows) produces inhibition of 
GABA release, thus removing the inhibitory effect of these GABAergic cells on 
DA neurons. In addition, the increase of DA neuron activity induces release from 
the DA cells of endocannabinoids that, acting in a retrograde manner on 
presynaptic CB1R, inhibit both inhibitory GABAergic and excitatory 
glutamatergic inputs to VTA DA neurons. Glutamatergic projections from the 
basolateral amygdala (BLA) and hippocampus (HIP), which are involved in 
motivation and memory processes related to drug rewarding effects, are also 
under the control of CB1R, through a presynaptic inhibitory action. In the nucleus 
accumbens (NAc), endocannabinoids behave as retrograde modulators acting 
mainly on CB1R on the axon terminals of glutamatergic neurons. The subsequent 
inhibition of glutamate release inhibits the GABAergic neurons that originate in 
the NAc and project to the VTA, thus indirectly activating VTA DA neurons 







messengers mediate LTP and LTD of synaptic transmission in 
several reward and memory related brain areas, including the NAc, 
PFC, amygdala and HCP (De Vries & Schoffelmeer 2005), as later 
discussed. These effects of endocannabinoids on synaptic plasticity 
might consolidate the reward-driven behaviour required to establish 
the addictive processes (Maldonado et al. 2006). Thus, the ECS 
could represent a crucial neurobiological substrate underlying the 
long‐term behavioural alterations that characterize addiction, such 
as persistent relapse. 
The ECS is also involved in the development of tolerance and 
physical dependence after chronic cannabinoid consumption. 
Tolerance is essentially due to adaptative phenomena consisting in 
pharmacodynamic events such as down-regulation/desensitization 
of cannabinoid receptors, although evidence exists on additional 
pharmacokinetic implications (Gonzalez et al. 2005). Tolerance and 
physical dependence often develop concomitantly and, in some 
cases, the severity of the physical withdrawal syndrome is directly 
related to the magnitude of tolerance. Thus, chronic cannabis use 
leads to adaptative changes in endocannabinoid signalling that 
could contribute to the development of cannabis physical 
dependence (Piomelli 2004). In addition, the ECS is also involved 
in the withdrawal syndrome of several drugs of abuse such as 
morphine, heroin and ethanol, among others (Maldonado et al. 
2006; Naassila et al. 2004). Therefore ECS is an important 






CB1R and endocannabinoids play a crucial role in the modulation 
of brain synaptic functions and plasticity (Castillo et al. 2012). 
Indeed, the ECS induces short-term plasticity by:  
1) depolarization-induced suppression of inhibition through 
modulation of GABA presynaptic release;  
2) depolarization-induced suppression of excitation via inhibition of 
glutamate presynaptic release.  
In addition, the ECS is also responsible for the induction of LTD of 
GABAergic (in the amygdala: Marsicano et al. 2002, and in the 
HCP: Chevaleyre & Castillo 2004) and glutamatergic (in the ST: 
Gerdeman et al. 2002, in the NAc: Robbe et al. 2002 and in the 
cortex: Sjöström et al. 2003) transmission, following the activation 
of postsynaptic mGluR1. It is tempting to speculate that 2-AG may 
be the endocannabinoid mediating this process (Kano 2014). The 
difference between endocannabinnoid-mediated LTD and 
endocannabinnoid-mediated short-term plasticity relies on the 
duration of CB1R activity, which engages distinct signalling events 
in the same target neuron leading to a short or long suppression of 
neurotransmitter release (Diana & Marty 2004). In addition, the 
structural plasticity modification mediated by the ECS has been 
described as a consequence of this synaptic function (Díaz-Alonso 
et al. 2012).  
The potential involvement of CB2R in drug addiction has been 
suggested in the last years. Indeed, a role of CB2R in the rewarding 
and motivational effects induced by drugs of abuse has been 
suggested (Navarrete et al. 2013; Zhang et al. 2014), even though it 






results have been reported in the scientific literature (Katia 2015; 
Onaivi et al. 2008). Indeed, genetic deletion or pharmacological 
blockade of CB2R results in impairment in the acquisition of 
nicotine self-administration and in reduced nicotine withdrawal 
syndrome (Navarrete et al. 2013). However, the activation of CB2R 
does not seem to affect nicotine self-administration and 
reinstatement of nicotine-seeking behaviour in a previous study 
(Gamaleddin et al. 2012a). Moreover, activation of CB2R inhibited 
cocaine self-administration and cocaine-enhanced locomotion (Xi et 
al. 2011b). In agreement, transgenic mice overexpressing CB2R in 
the central nervous system showed a reduction of cocaine-induced 
place preference, self-administration and locomotor sensitization 
(Aracil-Fernández et al. 2012). On the other hand, activation of 
CB2R is involved in cocaine priming-induced reinstatement of 
cocaine-seeking behaviour, but not in cue-induced reinstatement 
(Adamczyk et al. 2012). Furthermore, CB2R expression seems to be 
modified by different drugs of abuse. An increase of CB2R gene 
expression in the whole mouse brain were reported after chronic 
treatment with heroin or cocaine and decreased CB2R gene 
expression in ST and ventral midbrain of mice were revealed after 
chronic ethanol intake (Onaivi et al. 2008). 
In conclusion, the ECS participates in the addictive properties of all 
prototypical drugs of abuse through direct involvement in primary 
drug rewarding effects, in the motivation to seek the drug and in 
relapse to drug-seeking behaviour participating in the motivational 






probably by modulation of the synaptic plasticity underlying 
memory processes. 
 
4.3. The endocannabinoid system in eating behaviour 
 
4.3.1 The endocannabinoid system in the homeostatic control of 
food intake 
 
The ECS is a crucial element in the regulation of energy balance 
and food intake in the central nervous system and peripheral tissues 
(Di Marzo 2008; Heyman et al. 2012; Pagotto et al. 2006). At the 
central level, its role in the homeostatic regulation of food intake is 
due to the expression of the CB1R in hypothalamic circuits 
(Horvath 2003) and in brainstem structures such as the nucleus 
tractus solitarius that can sense signals from different peripheral 
tissues that participate in energy balance (e.g. gastrointestinal tract) 
(Berthoud 2006). In the nucleus tractus solitarius, CB1R is present 
in afferent and efferent neurons (Tsou et al. 1998) modulating both 
glutamatergic and GABAergic transmission in these cells (Roux et 
al. 2009). CB1R expression in vagal afferent neurons is increased in 
fasting and decreased after refeeding under the control of CCK 
(Burdyga et al. 2004). 
CB1R activation in the hypothalamus enhances appetite by 
regulating the response of several orexigenic and anorectic 
mediators (Di Marzo & Matias 2005; Kirkham et al. 2002). Thus, 
CB1R activity enhances the release of several orexigenic agents, 






orexigenic effects of endocannabinoids could also be mediated in 
part by NPY since stimulation or blockade of hypothalamic CB1R 
increases or decreases the level of this peptide, respectively (Verty 
et al. 2004). In addition, CB1R regulates the activation of neuronal 
populations with anorexigenic properties. Indeed, exogenous 
cannabinoids inhibit glutamatergic signalling in POMC neurons via 
CB1R stimulation, thus reducing the release of melanocortins 
(Hentges et al. 2005). Furthermore, CB1R is expressed in CART 
and CRH neurons and the endogenous cannabinoid signalling may 
promote appetite by decreasing these satiety signals (Cota et al. 
2003). Functional interactions between the ECS and the satiety 
system is also supported by the observation that defect in leptin 
signalling is associated with elevated hypothalamic levels of 
endocannabinoids (Di Marzo et al. 2001a).  
At the peripheral level, the ECS is involved in the reduction of 
energy expenditure acting on the adipose tissue, liver, skeletal 
muscle, gastrointestinal tract and pancreas (Matias et al. 2008). 
CB1R activation in the adipose tissue and liver increases expression 
of proteins involved in fatty acid synthesis, leading to enhanced 
lipid levels and fat accumulation (Matias et al, 2008). In the 
endocrine pancreas, cannabinoid receptors modulate insulin 
secretion by regulating glucose-induced Ca
2+
 transients (Li et al. 
2011). Endocannabinoid signalling in the gastrointestinal tract is 
involved in the inhibition of gastric emptying and intestinal motility 
(Davis & Perkins; 2007) as well as the release of enteroendocrine 
peptides such as CCK (Sykaras et al. 2012). In addition, in the small 






feedback mechanism that facilitates food intake (DiPatrizio et al. 
2011). In skeletal muscle cells, endocannabinoids reduce 
mitochondrial activity, insulin signalling and glucose uptake via 
activation of CB1R, possibly through inhibition of IRS1 
phosphorylation and insulin-dependent ERK activation (Lipina et 
al. 2010). 
The role of CB2R in the metabolic control and food intake at the 
central level is still not understood and studies have reported 
contrasting results concerning this issue. Indeed, previous studies 
showed that overexpression of brain CB2R could produce a 
reduction in food intake. This decrease eventually leads to a loss of 
body weight gain and increase basal glucose level, with transgenic 
mice showing chronic hyperglycaemia and glucose intolerance 
(Romero-Zerbo et al. 2012). In the same line, the activation of 
CB2R increases obesity-associated insulin resistance and the 
expression of inflammatory markers in adipose tissue, but not in the 
liver (Deveaux et al. 2009a). On the other hand, the 
pharmacological CB2R antagonist inhibits food consumption in 
mice (Emmanuel S. Onaivi et al. 2008). Moreover, CB2R deficient 
mice fed with a high-fat diet showed a reduction of adipose tissue, 
hepatic inflammation and insulin resistance when compared to wild-
type mice under similar experimental conditions (Agudo et al. 
2010a; Deveaux et al. 2009a).  
All this evidence demonstrates that central and peripheral CB1R act 
in a coordinated fashion to regulate energy homeostasis and eating 
behaviour. More studies are needed to understand the exact 






4.3.2 The endocannabinoid system in the hedonic control of 
food intake 
 
Multiple studies have demonstrated the role of the ECS in the 
modulation of hedonic aspects of eating (Cota et al. 2003). Indeed, 
CB1R is expressed in brain areas directly involved in rewarding 
processes. Microinfusions of AEA in the NAc shell increase 
positive responses to sucrose and enhance the intake of sweet 
solutions (Mahler et al. 2007; Shinohara et al. 2009). In agreement, 
blockade of CB1R activity in the NAc shell of rodents decreases 
palatable food intake (Melis et al. 2007). The ECS in the 
mesocorticolimbic system mediates the motivation to obtain 
palatable food. Indeed, inactivation of CB1R decreases operant 
responses in a PR task maintained by palatable food (Hernandez & 
Cheer 2012). This could be related to the decrease of palatable 
food-induced DA release in the NAc shell due to the blockade of 
CB1R activity (Melis et al. 2007). In contrast, cannabinoid agonists 
increase the hedonic value of food and induce intake in satiated 
animals where the motivation to eat is minimal (Higgs et al. 2003).  
Prolonged consumption of palatable food produces alterations of the 
endocannabinoid signalling, not only in the NAc (Bello et al. 2012), 
but also in several regions of the mesocorticolimbic circuit. A down 
regulation of CB1R expression was found in the HCP (Harrold et al. 
2002), cingulate cortex and VMH (Timofeeva et al. 2009) of 
animals fed a high palatable diet. This effect can be considered to 
be part of a compensatory mechanism aimed to counteract increased 






palatable foods. Moreover, elevated 2-AG and CB1R levels have 
been observed in the central amygdala of rats during abstinence 
from palatable food (Blasio et al. 2013). 
 
The ECS is also involved in the orosensorial aspect of food intake 
making the substances more palatable (Arnone et al. 1997) due to 
the CB1R presence in taste buds, and its activation enhances neural 
responses to sweet foods (Yoshida et al. 2009). Indeed, several 
studies have reported that THC predominantly increased the 
consumption of sweet foods rather than less palatable ones (Koch & 
Matthews 2001). In addition, CB1R is present in the parabrachial 
nucleus, a hindbrain area that integrates taste information. Local 
administration of 2‐AG in this brain area increases intake of 
palatable fat‐rich diet, but not standard chow, revealing a key role 
of the ECS in gating neurotransmission inherent to fat and sweet 
taste (Dipatrizio & Simansky 2008). 
The possible involvement of CB2R in the regulation of the 
reinforcing and motivational properties of food has still not been 
investigated. However, deletion of CB2R seems to be a protective 
factor in the development of diet-induced obesity in rodents, 
although CB2R knockout and wild-type mice showed similar intake 
of palatable high-fat food (Agudo et al. 2010; Deveaux et al. 2009). 
In summary, the ECS participates in the homeostatic, pleasurable 
and motivational aspects of food intake. The extended role of the 
ECS in the control of eating behaviour supports the hypothesis that 









Figure 26. Central and peripheral actions of the endogenous cannabinoid 
system (ECS). Schematic diagram showing the location and function of the ECS 
in different central brain structures and peripheral organs involved in the control 
of food intake and energy metabolism (adapted from Matias et al. 2008). 
 
4.3.3 The endocannabinoid system in eating disorders 
 
The widespread role of the ECS as a modulator of homeostatic and 
hedonic aspects of eating has promoted investigations to understand 






hyperactivation of the ECS is observed in obesity (Matias & Di 
Marzo) and a significant elevation of AEA plasma levels has been 
detected in anorexics, binge-eaters and some obese patients, 
inversely correlated with plasma leptin concentrations (Monteleone 
et al. 2005). Animal studies using CB1R-deficient mice and human 
studies also confirm the important role of this receptor in the 
pathophysiology of obesity and other eating disorders. Indeed, 
elevated levels of CB1R mRNA have been detected in the blood of 
women with anorexia or bulimia (Frieling et al. 2009), as well as in 
the insula, frontal and temporal cortex of these patients (Gérard et 
al. 2011). Clinical trials with the CB1R antagonist rimonabant and 
taranabant have already demonstrated efficacy at reducing food 
intake as well as obesity (Hagmann 2008). However, they produce 
significant side effects, such as depression and suicidal ideation that 
have produced the withdrawal from the market two years after the 
commercialization of rimonabant (Moreira & Crippa 2009). 
Less is known about the function of the CB2R in the 
physiopathological aspect of food intake. No alteration of CB2R 
mRNA expression has been shown in the blood of patients with 
anorexia or bulimia when compared to controls (Frieling et al. 
2009). 
Finally, human genetic studies report a positive association between 
eating disorders and specific polymorphisms of genes encoding for 
different components of the ECS system, such as CB1R 
(Monteleone & Maj 2008), CB2R (Ishiguro et al. 2010) and fatty 






appears to be a modulatory system that integrates different 





































Objective 1. Involvement of MOR, DOR, PENK and PDYN in 
the acquisition and reinstatement of cocaine- and food-seeking 
behaviour. Our aim was to evaluate the participation of the two 
main opioid receptors involved in drug reinforcing effects, MOR 
and DOR, and opioid peptides derived from PENK and PDYN that 
represent their endogenous ligands, in the reinstatement of cocaine- 
and palatable food-seeking behaviour. We have also evaluated the 
impact of the deletion of these opioid components on cue-induced 
reinstatement using c-Fos expression as a marker of neuronal 
activity in main brain areas involved in addiction.  
 
Article # 1: Effects of genetic deletion of endogenous opioid system 
components on the reinstatement of cocaine-seeking behaviour in 





E. Martín-García and R. Maldonado; 
*,#
 Equally contributed to the 
study; Neuropsychopharmacology (2014).  
http://www.nature.com/npp/journal/v39/n13/full/npp2014149a.htm 
 
Objective 2. Validation of a mouse model of addictive-like 
behaviour promoted by palatable food leading to differential 
epigenetic and protein expression changes in specific brain 
reward areas. Our aim was to validate an animal model of eating 
addictive-like behaviour based on the DSM-5 substance use 
disorder criteria using operant conditioning maintained by 
chocolate-flavoured pellets in an outbred mouse population. We 
also evaluated the differential epigenetic and protein expression 




and PFC of mice showing a compulsive eating behaviour 
(vulnerable to addiction) and in mice that did not show this 
behaviour (resistant to addiction). Additionally, we were interested 
in demonstrating the involvement of CB1R in the development of 
eating addictive-like behaviour. 
 
Article # 2: Epigenetic and proteomic expression changes promoted 







, M. Gutiérrez-Martos, E. Martín-García, M. 
Pucci, A. Falconi, C. D’Addario, M. Maccarrone
#





 Equally contributed to the study; 
Neuropsychopharmacology (2015).  
http://www.nature.com/npp/journal/v40/n12/full/npp2015129a.html 
 
Objective 3. Involvement of DOR in the neuroplastic 
mechanisms underlying food reward and seeking behaviour. 
Our aim was to investigate the involvement of DOR in the 
regulation of palatable food rewarding effect by a mechanism that 
implies structural plasticity changes in three brain areas involved in 
addictive processes, PFC, HCP and NAc. 
 
Article # 3: Role of DOR in neuronal plasticity changes promoted 
by food-seeking behaviour. S. Mancino, S. Mendonça Netto, E. 






Objective 4. Involvement of CB2R in the reinforcing effects of 
chocolate flavoured-pellets and eating addictive-like behaviour. 
Our aim was to assess the involvement of CB2R in compulsive 
eating behaviour promoted by highly palatable food using an 
operant model of eating addictive-like behaviour already validated 
in our laboratory.  
 
Title: Involvement of CB2 cannabinoid receptor in eating addictive-
like behaviour. S. Mancino, E. Martín-García, J. Manzanares and R. 























































































Involvement of MOR, DOR, PENK and PDYN in the acquisition 
and reinstatement of cocaine- and food-seeking behaviour. 
 
































































































Supplementary Materials and Methods 
 
Cocaine self-administration apparatus 
Cocaine self-administration training was performed in operant 
chambers (Model ENV-307A-CT, Med Associates, Inc., Georgia, 
VT, USA) equipped with two holes, one randomly selected as the 
active hole and the other as the inactive. Pump noise and a stimulus-
light located above active hole were paired with the delivery of the 
infusion. Chambers had grid floors and were housed in sound- and 
light-attenuated boxes equipped with fans to provide ventilation and 
ambient noise. When mice responded on the reinforced hole, the 
stimulus light went on, and a cocaine (0.5 mg/kg) infusion was 
delivered via a syringe mounted on a microinfusion pump (PHM-
100A, Med Associates, Inc., Georgia, VT, USA) connected via 
Tygon tubing (0.96 mm o.d., Portex Fine Bore Polythene Tubing, 
Portex Limited, Hythe, Kent, UK) to a single channel liquid swivel 
(375/25, Instech Laboratories, Plymouth Meeting, PA, USA), and to 
the mouse intravenous (i.v.) catheter.  
 
Surgery 
Mice were anaesthetized with a ketamine/xylazine mixture (20 
ml/kg of body weight) and then implanted with indwelling i.v. 
silastic catheters as previously described (Soria et al, 2005). Briefly, 
a 6 cm length of silastic tubing (0.3 mm inner diameter, 0.6 mm 
outer diameter) (Silastic®, Dow Corning, Houdeng-Goegnies, 
Belgium) was fitted to a 22-gauge steel cannula (Semat, Herts, UK) 





(Dentalon Plus, Heraeus Kulzer, Wehrheim, Germany) with an 
underlying nylon mesh. The catheter tubing was inserted 1.3 cm 
into the right jugular vein and anchored with suture. The remaining 
tubing ran subcutaneously to the cannula, which exited at the 
midscapular region. All incisions were sutured and coated with 
antibiotic ointment (Bactroban, GlaxoSmithKline, Madrid, Spain). 
After surgery, animals were allowed to recover for 3 days prior to 
initiation of self-administration sessions. The catheter was flushed 
daily with heparinised saline (30 USP units/ml). The patency of i.v. 
catheters was evaluated after the last self-administration session and 
whenever the behaviour appeared to deviate dramatically from that 
observed previously by infusion of thiopental through the catheter. 
If prominent signs of anaesthesia were not apparent within 3s of the 
infusion, the mouse was removed from the experiment. The success 
rate for maintaining patency of the catheter (mean duration of 13 
days) until the end of the cocaine self-administration training was 
88%. 
 
Food maintained operant behaviour apparatus 
Operant responding maintained by food was performed in mouse 
operant chambers (Model ENV-307A-CT, Med Associates, 
Georgia, VT, USA) equipped with two retractable levers, one 
randomly selected as the active lever and the other as the inactive. 
Pressing on the active lever resulted in a pellet delivery together 
with a stimulus-light located above the active lever. Pressing on the 
inactive lever had no consequences. The chambers housed in sound- 





and white noise. A food dispenser equidistant between the two 
levers permitted delivery of food pellets when required. 
 
Immunohistochemistry studies 
Tissue preparation. For c-Fos detection, mice were transcardially 
perfused with 4% paraformaldehyde immediately after the 2h cue-
induced reinstatement session. Subsequently, the brains were 
extracted and postfixed in the same fixative for 4h and 
cryoprotected overnight in a solution of 30% sucrose at 4ºC. 
Coronal frozen sections were made at 30 μm on a freezing 
microtome and stored in a 5% sucrose solution at 4°C until use. 
Immunofluorescence. A previously described protocol (Balerio et 
al, 2004) was adapted for immunofluorescence. Sections were 
incubated with the primary antibody in 3% normal goat serum and 
0.3% Triton X-100 in 0.1 M PB (NGS-T-PB) overnight at 4°C. 
Next day, sections were incubated with the secondary antibody at 
room temperature in NGS-T-PB for 2h. After incubation, sections 
were rinsed and mounted onto glass slides coated with gelatin in 
Mowiol mounting medium. A rabbit polyclonal antiserum (1:1000) 
(Ab-5; Calbiochem) was used for c-Fos detection. Cy3-conjugated 
goat antirabbit (Jackson ImmunoResearch) was used (1:500) as 
secondary antibody.  
c-Fos quantification. The stained sections of the brain were 
analyzed at 40× objective using a Leica DMR microscope equipped 
with a digital camera Leica DFC 300FX. ImageJ software was used 
for the quantification of c-Fos positive nuclei. Three samples of 





analyzed in transformed binary images using a constant region of 
interest (ROI). The threshold was adjusted to distinguish the 






















































                               
 Objective 2 
Validation of a mouse model of addictive-like behaviour promoted 
by palatable food leading to differential epigenetic and protein 
expression changes in specific brain reward areas. 
 
 


















































































Male wild-type CD1 mice used in the fist experiment were 
purchased from Charles River (France). Male CB1 knockout mice 
and their wild-type littermates were used in the second experiment. 
The generation of mice lacking CB1 cannabinoid receptor was 
performed as described previously (Soria et al., 2005). Mice were 
housed individually in controlled laboratory conditions (temperature 
at 21 ± 1°C and humidity at 55 ± 10%) and were tested during the 
first hours of the dark phase of a reversed light/dark cycle (lights off 
at 8.00 hours and on at 20.00 hours). Food and water were available 
ad libitum. Animal procedures were conducted in strict accordance 
with the guidelines of the European Communities Directive 
86/609/EEC regulating animal research and were approved by the 
local ethical committee (CEEA-PRBB). 
 
Operant behaviour apparatus 
Operant responding maintained by food was performed in mouse 
operant chambers (Model ENV-307A-CT, Med Associates, 
Georgia, VT, USA) equipped with two retractable levers, one 
randomly selected as the active lever and the other as the inactive. 
Pressing on the active lever resulted in a pellet delivery together 
with a stimulus-light (associated-cue), located above the active 
lever, while pressing on the inactive lever had no consequences. 





housed in sound- and light-attenuated boxes equipped with fans to 
provide ventilation and white noise. A food dispenser equidistant 




During the operant experimental sessions, animals received after 
active responding a 20 mg standard pellet (TestDiet, Richmond, IN, 
USA) or a 20 mg highly palatable isocaloric pellet (TestDiet, 
Richmond, IN, USA). The standard pellet formula was similar to 
the standard maintenance diet provided to mice in their home cage 
(24.1% protein, 10.4% fat, 65.5% carbohydrate, with a caloric value 
of 3.30 kcal/g). Highly palatable isocaloric pellets presented similar 
caloric value of standard pellets (20.5% protein, 12.7% fat, 66.8% 
carbohydrate, with a caloric value of 3.48 kcal/g) with some slight 
differences in their composition: addition of chocolate flavour (2% 
pure unsweetened cocoa) and modification in the sucrose content. 
Indeed, although the carbohydrate content was similar in standard 
(65.5%) and highly palatable isocaloric pellets (66.8%), the 
proportion of sugars within this carbohydrate amount was different: 
sucrose content in standard pellets was 3.1% of the total 
carbohydrates and 50.1% in highly palatable isocaloric pellets. 
These pellets were presented only during the operant behaviour 
sessions and animals were maintained on standard chow for their 









Establishment of mice subpopulations  
A mouse was considered positive for a particular addiction-like 
criterion when the score for this behaviour was equal or above the 
75th percentile of the distribution achieved by the group showing 
the highest rate of responses that in all the cases corresponded to the 
late training in the chocolate group in the first experiment and in the 
WT chocolate group treated with vehicle in the second experiment. 
Animals were scored for each addiction-like behaviour (three) 
independently and the algebraic sum of scores was calculated. Four 
subgroups of mice were identified depending on the number of 
positive criteria met (0crit, 1crit, 2crit and 3crit) (Figure 3). Based 
on these behavioural results, in the first experiment three different 
animal subgroups were considered for further analysis (behavioural 
and proteomic studies) depending on the diet and criteria met, as 
follows: a) 2-3 criteria chocolate subgroup (n=6), b) 0 criteria 
chocolate subgroup (n=6) and c) 0 criteria standard subgroup (n=6). 
Due to the accomplishment of several criteria of loss of control, we 
considered the chocolate trained mice reaching the 2 criteria as 
addict-vulnerable phenotypes and therefore were included in the 
subgroup with the highest score. For the epigenetic and the 
immunoblot studies, subgroups of mice of a previous study were 
added to obtaining a representative amount of biological samples 
from the mouse brains and the total number of animals used are 





criteria chocolate subgroup (n=16) and c) 0 criteria standard 
subgroup (n=14). 
In the second experiment, the following subgroups were considered 
for the behavioural study: a) 2-3 criteria WT mice treated with 
vehicle (n=5), b) 0 criteria WT mice treated with vehicle (n=5) c) 0 
criteria WT mice treated with rimonabant (3mg/kg; ip.) (n=5) and 
d) 0 criteria CB1KO mice (n=5). 
 
Sample preparation 
All animals were decapitated immediately after the last training 
session. The brains were quickly removed and the following brain 
areas dissected according to the atlas of stereotaxic coordinates of 
mouse brain (Paxinos and Franklin, 1997): PFC, ST, NAc and HCP. 
Brain tissues were then frozen by immersion in 2-methylbutane 
surrounded by dry ice, and stored at -80ºC for later proteomic and 
epigenetic studies. Each brain sample was treated individually. 
Studies of gene expression at the level of transcription and 
translation by quantification of DNA, RNA and proteins were made 
isolating DNA, RNA, and proteins from the selected animals using 
the Nucleo Spin TriPrep kit (Macherey-Nagel GmbH & Co.KG, 
Germany). Isolated DNA and RNA were used for epigenetic studies 




Methylation status of CB1R (CNR1) promoter regions was 





the extraction, 0.5 µg of DNA from each sample was treated with 
bisulfite, using DNA methylation kit (Zymo Research, Orange, CA, 
USA), in according to the manufacturers protocol. Methylation 
analysis was performed by fluorescence-based real-time qRT-PCR, 
using SensiFAST™ SYBR® Kit (Bioline, London, UK), on a DNA 
Engine Opticon 2 Continuous Fluorescence Detection System (MJ 
Research, Waltham, MA, USA). Amplified CNR1 sequence, 
containing 17 CpG sites, was located within 5' upstream region of 
the gene. The amplification program was as follow: 95 °C for 2 
min; 50 cycles at 95 °C for 10 s, 60 °C for 30s.  PCR was also 
performed for non-CpG-containing region of β-Act that served as 
control gene. The primers used for amplification (M: methylation 
specific, U: specific for unmethylated sequence) were the 
following: M_CNR1 (F: 5'-tttatttggtcggtttttttgtc-3', R: 5'-
ctcaccctactctactccctaacg-3'), U_CNR1 (F: 5'-tttatttggttggtttttttgttgt-
3', R: 5'-ctcaccctactctactccctaacac-3') and β-Act (F: 5'-
ggtattgttgataggatgtagaagga-3', R: 5'-tctaaatactaaaattccccttaaacc-3')  
The DNA methylation level was calculated as follows: DNA 
methylation level= (1/1+2-∆Ct). ∆Ct= CtU-CtM (Lu et al., 
2007).The data reported are shown as fold of induction over 
standard food group. 
 
Real-time qPCR (RT-qPCR) 
RT-PCR reactions were performed using the RevertAid H Minus 
First Strand cDNA Synthesis Kit (Thermo Scientific, Waltham, 
MA, USA). The relative abundance of each mRNA species was 





SensiFAST SYBR No-ROX Kit (Bioline) on a DNA Engine 
Opticon 2 Continuous Fluorescence Detection System (MJ 
Research, Waltham, MA, USA). All data were normalized to the 
endogenous reference genes β-actin and GAPDH. The primers used 
for PCR amplification are the following: CB1R (F: 5’- 
ccaagaaaagatgacggcag-3’, R: 5’-aggatgacacatagcaccag-3’); β-ACT 
(F: 5’-tgttaccaactgggacga-3’, R: 5’-gtctcaaacatgatctgggtc-3’); 
GAPDH (F: 5’-aacgggaagctcactggcat-3’, R: 5’-gcttcaccaccttcttgatg-
3’). One μl of the first strand cDNA product was used for 
amplification in triplicate in 20 μl reaction solution, containing 10 
μl of SensiFAST SYBR No-ROX Kit and 10 pmol of each primer. 
The following PCR program was used: 95°C for 10 min, followed 
by 45 amplification cycles of 95°C for 10 sec, 57°C for 30 sec and 
72 for 30 sec. 
 
Proteomic analysis 
Shotgun analysis using high-resolution mass spectrometry together 
with label-free quantification for the analysis of diet-induced 
neuropeptide expression in mice brain was performed. 
Phosphoproteomic and protein analysis were studied in HCP, ST 
and PFC regions. The enrichment in phosphoprotein or 
phosphopeptide content could help to identify the activation of 
particular proteins or pathways. Indeed, a change in 
phosphorylation status may reflect a modification in protein 
activity, and can provide new insights to clarify the intricate cellular 
networks involved in these addiction-like processes (Tannu et al., 





were pooled together in 3 pools of 2 animals per pool in equal 
proportion. Every sample was prepared in triplicate. Precipitated 
protein samples were dissolved in 4% SDS in 0.1 M HEPES 
(pH=8.5) followed by concentration measurement using DC-micro 
plate assay (Bio-Rad, Spain), following manufacturer’s instructions. 
200 ug of each sample of every pooled protein sample were 
subjected to trypsin digestion following the FASP protocol as 
previously described (Wisniewski et al., 2009) for subsequent mass 
of each digested sample was further subjected to phosphopeptide 
enrichment using TiO2. Briefly, TiO2 microcolumns were prepared 
in gel loading tips (0.5 mg) and were equilibrated with loading 
buffer (80 % ACN in water + 6 % TFA). Samples were loaded in 
loading buffer and the columns were washed with 80 % ACN in 
water + 0.1 % TFA. Finally, phosphopeptides were eluted with 30 
µL of elution buffer (5 % NH3 in water) into an eppendorf 
containing 30 µL of 20% formic acid in water. 1ug of the non-
enriched samples and all the samples enriched in phosphorylated 
peptides were run on an LTQ-Orbitrap Velos (Thermo Fisher 
Scientific, United States) fitted with a nanospray source (Thermo 
Fisher Scientific, United States) previous nanoLC separation in a 
EasyLC system (Proxeon, Denmark). Peptides were separated in a 
reverse phase column, 75μm x 150mm (Nikkyo Technos Co., Ltd., 
Japan) with a gradient of 5 to 35% ACN with 0.1% FA in 60 min at 
ion mode with nanospray voltage set at 2.2 kV and source 





using Ultramark 1621 for the FT mass analyzer. An internal 
calibration was performed using the background polysiloxane ion 
signal at m/z 445.120025 as the calibrant. The instrument was 
operated in data-dependent mode. In all experiments, full MS scans 
were acquired over a mass range of m/z 350-2000 with detection in 
the Orbitrap mass analyzer at a resolution setting of 60,000. For 
each MS scan, the twenty most intense ions with multiple charged 
ions above a threshold ion count of 5000 were selected for 
fragmentation with CID at normalized collision energy of 35% in 
the LTQ linear ion trap. All data were acquired with Xcalibur 2.2 
(Thermo Fisher Scientific, United States).  Protein identification 
was performed by Proteome Discoverer software v.1.4.0.288 
(Thermo Fisher Scientific, United States) using MASCOT v2.3 
(Matrix Science, United Kingdom) as search engine and a mouse 
SwissProt database that included the most common contaminants. 
Carbamidomethylation for cysteines was set as fixed modification 
whereas acetylation in protein N-terminal, oxidation of methionine 
and phosphorylation in Ser, Thr and Tyr were set as variable 
modifications (being the latter only set in samples enriched in 
phosphorylated peptides). Peptide tolerance was 7 ppm in MS and 
0.5Da in MS/MS mode, maximum number of missed cleavages was 
set at 3. Peptides were filtered based on the FDR (False Discovery 
rate) lower than 1%. Protein quantification was calculated using the 
R package MSStats (Clough et al., 2012). Two analyses were 
performed with different treatment of the missing values. The 
“strict” analysis considered only features that had at least two 





the features with one or two groups with no values. In this case, a 
value corresponding to the background noise was imputed.  
Immunoblotting 
Proteomic results were validated using immunoblot techniques. For 
immunoblot antibodies anti-CB1R (1:500) (Frontier Institute, 
Japan), anti- alpha syn (1:800) (Cell Signaling, Merck KGaA, 
Germany), anti-DCalmK 2 (1:600) (Abcam, UK), anti-PP1 alpha 
(1:600) and anti-DGKζ (1:500) (Santa Cruz Biology, USA) were 
used (see Supplementary Information). Shortly, proteins from HCP, 
ST and PFC of the three different animal subgroups were processed 
(2-3 criteria chocolate pellets, 0 criteria chocolate pellets, 0 criteria 
standard pellets subgroup). Bound primary antibodies were detected 
with horseradish peroxidase-conjugated antibodies to rabbit, or 
mouse, or goat antibodies (Pierce, diluted 1: 4000) and visualized 
by enhanced chemiluminescence detection (West-Fetmo-
SuperSignaling, Pierce). Western Blotting was performed with 
BioRad Criterion System (Bio-Rad Laboratories Headquarters, 
USA), using precast polyacrylamide 4–20% gradient gel, 13.3 × 8.7 
cm (W × L), for use with Criterion electrophoresis cells. The optical 
density of the immunoreactive bands was quantified after 
acquisition on a ChemiDoc XRS System (Bio-Rad) controlled by 
The Quantity One software v4.6.3 (Bio-Rad). Representative 
cropped immunoblots for display were processed with Adobe 
Photoshop 7.0. For quantitative purposes, the optical density values 
of the specific antibodies were normalized to the detection of 
specific antibodies to GAPDH values in the same sample and 






In the acquisition phase, in the experiment 1 the behavioural data of 
operant responding maintained by food were analysed using three-
way repeated measures analysis of variance (ANOVA) with diet 
(chocolate versus standard food) as between-subject factor and lever 
(active/inactive) and day as within-subjects factors. In the 
behavioural tests to evaluate the addictive-like behaviour, 
comparisons between the subgroups (2-3 criteria chocolate, 0 
criteria chocolate, 0 criteria standard) were made through Mann–
Whitney U test (non-normally distributed data according to 
Kolmogorov test) (Supplementary Information Table S1A). In 
epigenetic study, comparisons among the three subgroups (2-3 
criteria chocolate, 0 criteria chocolate and 0 criteria standard 
pellets) were achieved through Mann–Whitney U test. In the 
immunoblot, analysis of protein changes validation was made using 
a parametric Student t-test.  
In the acquisition phase, in the experiment 2 the behavioural data of 
operant responding maintained by food were also analyzed using 
three-way repeated measures analysis of variance (ANOVA) with 
group (CB1KO versus WT) as between-subject factor and lever 
(active/inactive) and day as within-subjects factors. When the 
pharmacologic treatment started on day 105, data analysis was 
performed considering the between-subject factor group with three 
levels (CB1KO, WT rimonabant and WT vehicle). In the 
behavioural tests to evaluate the addictive-like behaviour, 
comparisons between the subgroups (2-3 criteria WT mice treated 





mice treated with rimonabant and 0 criteria CB1KO mice were 
made through Mann–Whitney U test (non-normally distributed data 
according to Kolmogorov test) (Supplementary Information Table 
S1B).  
Statistical analysis in proteomic was made to compare the following 
subgroups: 1) 2-3 criteria vs. 0 criteria chocolate subgroup, 2) 2-3 
criteria vs. 0 criteria standard subgroup and 3) 0 criteria chocolate 
vs. 0 criteria standard subgroup. Correction for multiple testing was 
performed by adjusting the p-value with a false discovery rate 
(FDR) of 1%. As the features with no values detected were 
considered when comparing the three groups, a value corresponding 
to the background noise was imputed and the results were 
represented in terms of “expression/no expression” for each protein 
(see Supplementary Information Table S3). Differences in the 
significance of some peptides forming part of the same protein were 
also observed. The relationships within the three comparisons were 
analyzed and the following issues were considered: (a) protein 
expression changes in mice trained with chocolate pellets reaching 
0 criteria (resistance to addiction-like behaviour) (b) protein 
expressed only in mice trained with chocolate pellets reaching the 
2-3 criteria (presence in addiction-like subgroup)  (c) proteins 
expressed in mice trained with chocolate and standard pellets with 0 
criteria, but not in chocolate trained mice reaching the 2-3 criteria 
(absence in addiction-like subgroup) (d) protein expression changed 
only in mice trained with chocolate pellets (2-3 criteria or 0 criteria) 
but not in mice trained with standard pellets (palatable food 





was performed and only features that had at least two of three 
values detected in each group were considered (see Supplementary 
Information Table S4). Protein identification was processed by a 
search against a mouse UniProt database. Canonical pathway 
enrichment analyses were performed using Kyoto encyclopaedia of 
genes and genome (KEGG) pathways as well as Gene Ontology 
(GO) enrichment analyses. 
The data are expressed as mean ± SEM, distribution of individual 
data with median and interquartile range or fold change of control 
group. P<0.05 was the criterion for statistical significance for 
behavioural, epigenetic and immunoblot analysis, while p<0.01 was 
used for the proteomic analysis. The statistical analysis was 
performed using the Statistical Package for Social Science program 





The NAc was excluded due to the reduced amount of protein 
obtained in this brain area, which impedes the proteomic studies in 
this animal species. In HCP, changes in the expression of 13 
proteins were revealed in the chocolate trained mice presenting 0 
criteria (resistance to addiction-like behaviour). Moreover, 21 
proteins and 1 phosphoprotein were significantly identified only in 
the chocolate trained mice reaching the 2-3 criteria (presence in 
addiction-like subgroup). Also, 19 proteins and 2 phosphoproteins 





(absence in addiction-like subgroup) (Figure S2B, C). In ST, 
changes in the expression of 16 proteins and 31 phosphoproteins 
were reported in the chocolate trained mice presenting 0 criteria. 
Moreover, 40 proteins and 6 phosphoproteins were modified in the 
chocolate trained mice reaching the 2-3 criteria, whereas 9 proteins 
and 25 phosphoproteins were absent in this group (Figure S2D, E). 
In PFC, changes in the expression of 37 proteins and 26 
phosphoproteins were reported in the chocolate trained mice 
obtaining 0 criteria. Furthermore, 13 proteins and 32 
phosphoproteins were significantly identified in the chocolate 
trained mice reaching the 2-3 criteria, whereas 16 proteins and 14 
phosphoproteins were absent in this subgroup (Figure S2F, G). All 
the proteins and phosphoproteins resulted from the comparisons are 
listed in Table S3 and S4.  
We compared protein expression profiles through analysis of 
canonical pathways enrichment and we validated common proteins 
expressed in the three brain regions related to neurological 
processes. More specifically, due to our results obtained on 
impulsivity like-behaviour (time-out period), we selected alfa-SYN, 
a protein reported to be specially implicated in this behaviour 
(Pena-Oliver et al., 2012). Moreover, we were interested in the 
possible alteration in the expression of proteins involved in synaptic 
plasticity during addictive-like behaviour. Particularly in the 
phenomenon of polarization/depolarization which directly involves 
the PP1alpha protein. In addition, we have selected DCAMKL2 as a 
protein closely related to the possible morphological changes that 





protein directly connected to the endocannabinoid system that 
together with CB1R could be of particular relevance for the 
behavioural alterations reported. As reported in the analysis of 
canonical pathways enrichment, alpha-synuclein (alfa-Syn) peptide  
involved in the “regulation of DA uptake implicated in synaptic 
transmission” pathway was identified in HCP and ST areas of 
chocolate trained mice reaching the 2-3 criteria and in PFC of the 
chocolate trained mice presenting 0 criteria. Protein phosphatase 1 
alpha (PP1alfa) involved in the “long term potentiation” pathway 
was detected in HCP of chocolate and standard subgroup presenting 
0 criteria and in ST of chocolate trained mice reaching 2-3 criteria. 
Moreover, two additional proteins were considered in HCP: 
doublecortin-like kinase 2 (DCalmK 2) involved in the “nervous 
system development” pathway expressed in chocolate trained mice 
reaching the 2-3 criteria and diacylglycerol kinase zeta (DGKζ) 
involved in the “protein kinase C-activating G-protein coupled 
receptor signaling” pathway expressed in the chocolate trained mice 
presenting 0 criteria.  
 
Immunoblotting  
In HCP, changes in the expression of PP1alfa protein were 
validated in the chocolate and standard subgroup presenting 0 
criteria (p<0.05) and the presence of alfa-Syn and DCalmK proteins 
were identified in chocolate trained mice reaching the 2-3 criteria 
(p<0.01). An increased expression of DGKζ protein was also 
revealed in the chocolate trained mice with 0 criteria (p<0.05) 





In ST, change in the expression of PP1alfa protein was validated in 
the chocolate trained mice reaching the 2-3 criteria (p<0.01). 
Decrease of alfa-Syn expression was found in the standard trained 
mice presenting 0 criteria (p<0.05). Interestingly, significant 
expression changes in DCalmK 2 and DGKζ protein were 
additionally revealed in the chocolate subgroup presenting 0 criteria 
(p<0.05) (Figure S3B).  
In PFC, significant increase in alfa-Syn expression was revealed in 
the chocolate group presenting 0 criteria (p<0.05). No changes were 
observed in DCalmK 2, PP1 alfa and DGKζ proteins expression, in 
agreement to the proteomic study (Figure S3C).  
 
 SUPPLEMENTARY FIGURE LEGENDS 
 
Figure S1. Effects of CB1 epigenetic regulation by highly 
palatable food. Immunoblot of CB1 in (A) PFC, (B) HCP, (C) NAc 
and (D) striatum homogenates from mice of 0 criteria standard (n = 
14), 0 criteria chocolate (n = 16) and  2-3 criteria chocolate (n = 13). 
The optical density was normalized to GAPDH in the same 
samples.  
 
Figure S2. Protein expression changes caused by operant 
responding maintained by food: expression / no expression. (A) 
Venn Diagrams of differentially expressed proteins for each 
comparison in the three brain areas. Questions considered: (a) 
protein expression changes in mice trained with chocolate pellets 





protein expressed only in mice trained with chocolate reaching the 
2-3 criteria (presence in addiction-like subgroup) (c) proteins 
expressed in mice trained with chocolate and standard pellets with 0 
criteria, but not in chocolate trained mice reaching the 2-3 criteria 
(absence in addiction-like subgroup) (d) protein expression changed 
only in mice trained with chocolate pellets (2-3 criteria or 0 criteria) 
but not in mice trained with standard pellets (palatable food 
exposure). (B-G) Total number of proteins differentially expressed 
for each comparison in (B) HCP, (D) striatum and (F) PFC. Total 
number of phosphoproteins expressed in (C) HCP, (E) striatum and 
(G) PFC. 
 
Figure S3. Immunoblot and quantification of alpha-synuclein, 
protein phosphatase 1 alpha, doublecortin-like kinase 2 and 
diacylglycerol kinase zeta in (A) HCP, (B) striatum and (C) 
PFC homogenates from mice of 0 criteria standard, 0 criteria 
chocolate and  2-3 criteria chocolate (n =6 mice per group). The 
optical density was normalized to GAPDH in the same samples. 
Data are expressed as mean±SEM. * p<0.05, ** p<0.01, *** 
p<0.001 (2-3 criteria chocolate vs. 0 criteria standard), # p<0.05, ## 
p<0.01, ### p<0.001 (2-3 criteria chocolate vs. 0 criteria chocolate), 
+ p<0.05 (0 criteria chocolate vs. 0 criteria standard). 
 
Table S3 (3.1) Spectral counts of mouse (A) HCP proteins, (B) ST 
proteins, (C) PFC proteins, with 1 or more peptide identifications 
subjected to label-free quantification. Proteins are grouped 





(3.2) Spectral counts of mouse (A) HCP phosphoproteins, (B) ST 
phosphoproteins, (C) PFC phosphoproteins, with 1 or more peptide 
identifications subjected to label-free quantification. Proteins are 
grouped according to their abundance in the four issues considered 
(p<0.01). 
 
Table S4 (4.1) Spectral counts of mouse (A) HCP proteins, (B) ST 
proteins, (C) PFC proteins with 1 or more peptide identifications 
subjected to label-free quantification. Peptides that were 
significantly differentially expressed (p<0.05) are shown. (4.2) 
Spectral counts of mouse (A) HCP phosphoproteins, (B) ST 
phosphoproteins, (C) PFC phosphoproteins with 1 or more peptide 
identifications were subjected to label-free quantification. 
Phosphopeptides that were significantly differentially expressed 









































































































































































Clough T, Thaminy S, Ragg S, Aebersold R and Vitek O (2012) Statistical 
Protein Quantification and Significance Analysis in Label-Free LC-MS 
Experiments With Complex Designs. BMC Bioinformatics 13 Suppl 16:S6.:S6-
13. 
 
Lu L, Katsaros D, de l L, I, Sochirca O and Yu H (2007) Hypermethylation of 
Let-7a-3 in Epithelial Ovarian Cancer Is Associated With Low Insulin-Like 
Growth Factor-II Expression and Favorable Prognosis. Cancer Res 67:10117-
10122. 
 
Paxinos G and Franklin K B J (1997) The Mouse Brain in Stereotaxic 
Coordinates. Academic, San Diego. 
 
Pena-Oliver Y, Buchman V L, Dalley J W, Robbins T W, Schumann G, Ripley T 
L, King S L and Stephens D N (2012) Deletion of Alpha-Synuclein Decreases 
Impulsivity in Mice. Genes Brain Behav 11:137-146. 
 
Soria G, Mendizabal V, Tourino C, Robledo P, Ledent C, Parmentier M, 
Maldonado R and Valverde O (2005) Lack of CB1 Cannabinoid Receptor 
Impairs Cocaine Self-Administration. Neuropsychopharmacology 30:1670-1680. 
Wisniewski JR, Zougman A, Nagaraj N and Mann M (2009) Universal Sample 
























































Involvement of DOR in the neuroplastic mechanisms underlying 















































Role of DOR in neuronal plasticity changes promoted by food-
seeking behaviour. 
 
S. Mancino, S. Mendonça Netto, E. Martín-García, R. Maldonado
 a 
 
ª Departament de Ciencies Experimentals i de la Salut, Universitat 




Correspondence should be addressed to Rafael Maldonado: 





Category of the article: Regular research article 
Number of references: 64 
Words in Abstract: 241 
Words in Article (excluding abstract, references and figure 
legends): 4410 
Number of figures: 4 
Number of tables: 2 










Several lines of evidence support that food overconsumption may 
be related to the role of the endogenous opioid system in the control 
of food palatability. The opioid system, and particularly the delta 
opioid receptor (DOR), plays a crucial role in the regulation of food 
rewarding properties. In our study, we used operant conditioning 
maintained by chocolate-flavoured pellets to investigate the role of 
DOR in the motivation for palatable food and the structural 
plasticity changes promoted by this behaviour. For this purpose, we 
evaluated the specific role of this receptor in the behavioural and 
neuroplastic changes induced by palatable food in the prefrontal 
cortex (PFC), hippocampus (HCP) and nucleus accumbens (NAc) 
in constitutive knockout (KO) mice deficient in DOR. Mutant mice 
and their wild-type littermates were trained to obtain chocolate-
flavoured pellets on fixed ratio 1 (FR1), FR5 and progressive ratio 
(PR) schedule of reinforcement. No significant differences between 
genotypes were revealed on operant behaviour acquisition in FR1. 
DOR knockout mice displayed lower number of active lever-presses 
than wild-type mice on FR5, and a similar decrease was revealed in 
DOR KO mice in the breaking point during the PR. This operant 
training to obtain palatable food increased dendritic spine density in 
the PFC, HCP and NAc shell of wild-type, but these plasticity 
changes were abolished in DOR KO mice. Our results support the 
hypothesis that DOR regulates the reinforcing effects and 
motivation for palatable food through neuroplastic changes in 



























Obesity and overeating are among the most important health issues 
affecting the developed countries (Hill 2006). Genetic 
predisposition and environmental influences are two prominent risk 
factors related to these disorders. Obesogenic environment and the 
high availability of palatable foods contribute to the present high 
rate of obesity. It is estimated that about 13% of the world’s adult 
population (11% of men and 15% of women) was obese in 2014 
and this percentage will tend to increase in the next years (World 
Health Organization WHO; 2014).  
Palatability is an important determinant of the reward value of food 
that can promote the overconsumption leading to overweight and 
obesity. The pleasant experience obtained from palatable food 
contributes to repeat the experience and can result in the 
development of loss of control over intake (Kenny 2011). Food, like 
drugs, activates the mesocorticolimbic system involved in the 
hedonic effect promoted by different rewards and may produce 
neuroadaptive responses in these circuitries by mechanisms that 
resemble drugs of abuse (Volkow et al. 2013). 
The involvement of the opioid system in food hedonic effects has 
been known for several decades (Yeomans & Gray 2002). The 
opioid system is integrated by three different opioid receptors, mu 
receptor (MOR), delta receptor (DOR) and kappa receptor (KOR), 
widely distributed in the central nervous system and located in brain 
areas mediating food intake and reward (Mansour et al. 1995). 





activation increases dopamine (DA) release in the nucleus 
accumbens (NAc) shell (Hirose et al. 2005; Murakawa et al. 2004; 
Okutsu et al. 2006) by decreasing GABA-inhibition in the ventral 
tegmental area (VTA) (Bonci & Williams 1997). MOR and DOR 
are also involved in the inhibitory control process in cortical areas, 
whose dysregulation is associated with addiction and eating 
disorders (Mitchell et al., 2007; Selleck et al., 2015). Although the 
involvement of MOR in eating disorders (Ziauddeen et al. 2012) 
and obesity (Tabarin et al. 2005) is largely demonstrated, little is 
known about the potential implication of DOR in these behaviours.  
Behavioural alterations induced by rewarding stimuli might be 
triggered by plasticity adaptations in neuronal circuitries that seem 
to be mediated by the opioid system (Mazei-Robison & Nestler 
2012). Indeed, this system is implicated in cellular and synaptic 
plasticity through the regulation of glutamatergic and GABAergic 
transmission (Lüscher & Malenka 2011), and structural plasticity 
through long-lasting changes of neuronal morphology (Russo et al. 
2010). Specifically, DOR seems directly involved in long term 
depression (LTD) in hippocampus (HCP) (Piskorowski & 
Chevaleyre 2013) and it is also required to induce long term 
potentiation (LTP) in the lateral perforant path (Bramham et al. 
1991). However, the specific implication of DOR in structural 
plasticity changes has not been clarified. Neuronal and dendritic 
spine morphogenesis underlie experience-dependent brain 
development and information storage (Holtmaat & Svoboda 2009). 
Dendritic spines are highly dynamic structures, and their 





(Lai & Ip 2013). An increase in synaptic strength by induction of 
LTP is generally associated with the enlargement of pre-existing 
spines, the stabilization of newly-formed spines, and the formation 
of new spines increasing the connectivity of neurons (De Roo et al., 
2008). In contrast, a reduction of synaptic strength during the LTD 
is correlated with spine shrinkage and retraction (Lai & Ip 2013). A 
high correlation exists between the physiology of synaptic 
transmission and the shape of the dendritic spine and both 
phenomena could play complementary functions in neuronal 
plasticity (Bosch & Hayashi 2012). 
In this study, we examine the role of DOR in the motivational 
properties and morphological plasticity changes induced by 
palatable food in prefrontal cortex (PFC), HCP and NAc core and 
shell. These regions are crucial for regulating food hedonic aspects 
and dysfunctions of these areas have been related to eating disorders 
(Kelley & Berridge 2002; Volkow et al. 2008). The NAc shell 
participates in the hedonic impact for rewards (Bodnar et al. 2005), 
the NAc core in response-reinforcement learning (Di Ciano & 
Everitt 2001), the PFC in decision-making and inhibitory control 
processes (Volkow et al, 2008) and the HCP in memory processes 






Materials and methods 
 
Animals 
Homozygous knockout (KO) mice deficient in DOR on a C57BL/6J 
background and their respective wild-type littermates were used 
(Filliol et al. 2000). A group of C57BL/6J naïve mice of the same 
age and under the same housing conditions not trained with 
chocolate pellets was added as a control for the synaptic plasticity 
experiment. Mice weighted 31 ± 1.5 g at the beginning of the 
experiment. Mice were housed individually in controlled laboratory 
conditions with the temperature maintained at 21 ± 1ºC and 
humidity at 55 ± 10%, and were tested during the first hours of the 
dark phase of a reversed light/dark cycle (lights off at 8.00 a.m. and 
on at 8:00 p.m.). Food and water were available ad libitum to avoid 
confounding factors linked to deprivation experience (Piazza & Le 
Moal 1998). Animal procedures were conducted in strict 
accordance with the guidelines of the European Communities 
Directive 86/609/EEC regulating animal research and were 
approved by the local ethical committee (CEEA-PRBB). 
 
Operant behaviour apparatus 
Operant responding maintained by food was performed in mouse 
operant chambers (Model ENV-307A-CT, Med Associates, 
Georgia, VT, USA) equipped with two retractable levers, one 
randomly selected as the active lever and the other as the inactive, 





active lever resulted in a pellet delivery together with a stimulus-
light located above the active lever. Pressing on the inactive lever 
had no consequences. The chambers were housed in sound and 
light-attenuated boxes equipped with fans to provide ventilation and 
white noise. A food dispenser equidistant between the two levers 
permitted the delivery of food pellets when required. 
 
Food pellets 
During the operant experimental sessions, animals received after 
each active responding a 20 mg highly palatable isocaloric pellet 
(20.5% proteins, 12.7% fats and 66.8% carbohydrates, with a 
caloric value of 3.48 kcal/g; TestDiet, Richmond, IN, USA) with 
similar caloric value than the maintenance diet provided for mice in 
their home cage (24.1% proteins, 10.4% fats and 65.5% 
carbohydrates, with a caloric value of 3.30 kcal/g; Diets Services, 
Witham, Essex UK) with some slight modifications in its 
composition: addition of chocolate flavour (2% pure unsweetened 
cocoa) and modification in the sucrose content. Indeed, although the 
carbohydrate content was similar in maintenance diet (65.5%) and 
highly palatable isocaloric pellets (66.8%), the sucrose content in 
standard chow was 3.1% of the total carbohydrates and 50.1% in 
highly palatable isocaloric pellets. These pellets were presented 
only during the 1 h daily operant session and animals were 









DOR KO mice and their wild-type littermates were trained in 
operant boxes during 1 h daily sessions to acquire operant 
responding maintained by chocolate-flavoured pellets under FR1 
during 16 consecutive days and FR5 during 95 consecutive days. A 
stimulus light, located above the active lever, was paired 
contingently with the delivery of the reward during the active 
periods. The beginning of each operant responding session was 
signalled by turning on a house light placed on the ceiling of the 
box only during the first 3 sec of the session. A time-out period of 
10 sec was established after each pellet delivery. During this period, 
the cue light was off and no reinforcer was provided after 
responding on the active lever. Responses on the active lever and all 
the responses performed during the time-out period were recorded. 
The criteria for acquisition of operant responding were achieved 
when mice maintained a stable responding with less than 20% 
deviation from the mean of the total number of food pellets earned 
in three consecutive sessions, with at least 75% responding on the 
reinforced lever, and a minimum of 10 reinforcers per session 
(Martín-García et al. 2011). Motivation for food was evaluated in 
each mouse at day 70 of the operant training using the progressive 
ratio (PR) schedule where the response required to earn the pellet 
escalated according to the following series: 1, 5, 12, 21, 33, 51, 75, 
90, 120, 155, 180, 225, 260, 300, 350, 410, 465, 540, 630, 730, 850, 
1000, 1200, 1500, 1800, 2100, 2400, 2700, 3000, 3400, 3800, 4200, 
4600, 5000, 5500. The maximal number of responses that the 





referred to the breaking point. The maximum duration of the PR 
session was 5 h or until mice did not respond on any lever within 1 
h. 
Sample preparation 
Immediately after the last training session, mice were deeply 
anesthetized by intraperitoneal injection (0.2 ml/10 g body weight) 
of a mixture of ketamine (100 mg/kg) and xylazine (20 mg/kg) prior 
to rapid intracardiac perfusion, delivered with a peristaltic pump 
with 10 ml of Na2HPO4/NaH2PO4/NaCl buffer (PBS) 0.1M, pH 
7.5, and followed by perfusion with 40 ml of 4% paraformaldehyde 
(PFA) in PBS 0.1M, pH 7.5. Brains were quickly removed from the 
skull and post fixed in 4% PFA for 10 min. Brain coronal sections 
(100 μm) containing the NAc (from bregma, AP: from 1.54 to 0.98 
mm; ML: ± 0.5 mm; DV: - 4 mm), medial PFC (mPFC) (from 
bregma, AP: from 2.10 to 1.70 mm; ML: ± 0 mm; DV: - 3.5 mm) 
and HCP (from bregma, AP: from 1.58 to 2.06 mm; ML: ± 0 mm; 
DV: -2.8 mm) (Paxinos and Franklin, 1997) were obtained by using 
a vibratome (Leica  VT 1000 S, Nussloch, Germany) and kept in 
PBS 0.1 M until they were processed for fluorescent labelling. 
 
Dendritic spine analysis 
Brain slices were labelled by ballistic delivery of fluorescent dye 
DiI (Molecular Probes, Eugene, OR, USA) using a gene gun 
apparatus (Helios Gene Gun System, Bio-Rad, Deutschland), as 
already reported (Grutzendler et al. 2003), and post fixed with PFA 
overnight at room temperature to further preserve structures and to 





microscope gelatine coated slides and cover slipped with mounting 
medium (Mowiol). Then, images were acquired with confocal 
microscope (Zeiss LSM 510, Germany) with an oil immersion lens 
(63x) to analyze dendritic spine density and structure. 
Individual pyramidal neurons from the mPFC and HCP, and 
medium spiny neurons in the NAc were chosen for spine analysis 
based on several criteria, as described previously (Lee et al. 2006): 
(i) there was minimal or no overlap with other labelled cells, (ii) at 
least three primary dendrites needed to be visible for cells to be 
used for analysis, and (iii) distal dendrites (from secondary 
dendrites to terminal dendrites) were examined. Dendrites from 
medium spiny neurons in the core and shell of the NAc, basilar 
dendrites of pyramidal neurons taken predominantly from the 
prelimbic and infralimbic areas of the mPFC, usually CA1 and CA3 
dendrites of pyramidal neurons of HCP were analyzed. A total of 5 
to 8 mice per experimental group were used and 4 to 11 dendrites 
per brain area and mouse were analyzed (max two 
dendrites/neuron). 
To calculate spine density, a length of dendrite (at least 21 μm long) 
was traced. All images of dendrites were taken at different z levels 
(0.3 μm depth intervals) to examine the morphology of dendritic 
spines. Before the analysis, all images were processed with the 
deconvolution software (Huygens Essential, The Netherlands) that 
reduces the optical noise generated by the contribution of out-of-
focus fluorescent points and by the distortion due to the optical 
instrument. All measurements were made using IMARIS 7 analysis 





automating dendritic spine analysis. Protrusions from dendrites 
were classified into four types based on their morphology pursuant 
to a logarithm program that sorts each spine according to 
parameters as the length spine, the width neck and the width head. 
After visual identification of stubby and headed spines, parameters 
defined by the program identify and distinguish the spine length 
against spine head size, and spine minimum diameter against spine 
head size. Stubby spines stand out from headed spines by the ratio 
spine minimum diameter/spine head diameter, which was equal to 1 
μm for a majority of stubby spines (94%), and less than 1 μm for 
spines with an identifiable neck. After finding an efficient way of 
sorting stubby spines, the program defines parameters to sort out 
large spines. Head size was the first obvious parameter. 
Accordingly, mushroom spines were classified as having width 
head greater than width neck multiplied by 2. The remaining spines 
could be separated on their neck length to head size ratio as thin, if 
the length spine was > 3 μm, and the width head was greater than 
the width neck, or filopodia spines, if the length was > 3 μm and the 
width head was equal to the width neck.  
 
Statistical analysis 
Data obtained during the operant acquisition phase were analyzed 
using three-way repeated measures analysis of variance (ANOVA) 
with manipulandum (active/inactive) and day as within-subjects 
factors and genotype as between-subjects factor. PR and body 
weight data were analyzed using one-way ANOVA between 





Whitney U due to the non-normally distributed data according to 
Kolmogorov test (Supporting Information Table S1A). Structural 
plasticity data were analyzed using one-way ANOVA between 
subjects (genotype). Post-hoc analysis (Newman-Keuls or 
Dunnet’s) was performed when required. All the results are 
expressed as mean ± S.E.M. Differences were considered 
significant at p < 0.05. The statistical analysis was performed using 
the Statistical Package for Social Science program SPSS® 19.0 









Acquisition of operant behaviour to obtain chocolate flavoured-
pellets in DOR and wild-type littermate mice. 
DOR KO and wild-type littermate mice were trained to acquire an 
operant responding maintained by chocolate flavoured-pellets under 
FR1 and FR5 schedule. The acquisition criteria in FR1 were 
achieved after an average of 11.3 ± 1.03 sessions by 28.6% of the 
entire DOR KO group and of 12.6 ± 1.03 sessions by 66.7% of 
wild-type littermates. Chi square test revealed significant 
differences in the percentage of acquisition criteria (χ2 = 9.14, p < 
0.05). Three-way ANOVA revealed a significant main effects of 
genotype, lever and day indicating a continuous operant responding 
for chocolate pellets during the whole training period and 
discrimination between levers [F(1,24) = 44.52, p < 0.001] (Figure 
1). No significant genotype differences were revealed (Table 1). 
The acquisition criteria in FR5 were achieved after an average of 
8.55 ± 5.06 sessions by 78.6% of the entire DOR KO group and of 
6.08 ± 0.71 sessions by 100% of wild-type littermates. Three-way 
ANOVA revealed significant main effects of lever [F(1,24) = 
125.85, p < 0.001] indicating discrimination in the two groups, and 
an interaction between genotype and lever [F(1,24) = 16.95, p < 
0.001], indicating higher number of active lever-presses for wild-
type littermates (Figure 1) (Table 1). Motivation for food measured 
at day 70 on the PR schedule showed a significant decrease in DOR 






Table 1. Operant responding maintained by food during acquisition 
 
                             Three-way ANOVA 
 Acquisition FR1 
 
Acquisition FR5 
 F-value P-value F-value P-value 
Group F(1,24) = 0.40 n.s F(1,24) = 12.44 P < 0.01 
Lever F(1,24)= 44.52 P < 0.001 F(1,24)=125.85 P < 0.001 
Day F(15,360)=13.40 P < 0.001 F(82,1968)=1.97 P < 0.001 
Day × Lever F(15,360) = 9.47 P < 0.001 F(82,1968)=1.87 P < 0.001 
Group × Lever F(1,24) = 7.44 P < 0.05 F(1,24) = 16.95 P < 0.001 
Group × Day F(15,360) = 1.08 n.s F(82,1968)=0.66 n.s. 
Group × Lever 
× Day 
F(15,360) = 1.81 P < 0.05 F(82,1968)=1.04 n.s. 
Three-way ANOVA between-subjects factor and repeated measures in the factors day 
and lever (active/inactive). See materials and methods for details. n.s.: non-significant 
 
 
ANOVA, F(1,24) = 1.03, p < 0.05] (Figure 2A). The number of 
lever-presses during the time-out period was also evaluated as a 
measurement of impulsivity like-behaviour and decreased active 
lever-presses during FR1 and FR5 training sessions were observed 
in DOR KO when compared with wild-type mice [Mann-Whitney 










                                   
 
 
Figure 1. Acquisition of operant training maintained by chocolate-flavoured 
pellets. Mean number of active and inactive lever-presses during the acquisition 
training in FR1 (day 1-16) and FR5 (day 1-95) schedule of reinforcement in DOR 
knockout mice (DOR KO) (n=14) and wild-type littermates (WT) (n=12) trained 
with chocolate-flavoured pellets. Differences are reported as mean ± SEM. ** p < 





No differences in body weight were found between genotypes 
during the FR1 training. As expected, a significant increase of body 
weight was reported during the FR5 training period when compared 






littermates [one-way ANOVA, F(1,26) = 25.87, p < 0.001; F(1,22) 
= 18.32, p < 0.001]. In contrast to the FR1 period, significant 
differences were revealed between DOR KO mice and their wild-
type littermates during FR5 training [one-way ANOVA, F(1,24) = 




Figure 2. Motivation, impulsivity-like behaviour and body weight in DOR 
KO and wild-type littermates (A) Breaking point achieved during the 
progressive ratio (PR) schedule of reinforcement in DOR knockout mice (DOR 
KO) and wild-type littermates (WT). (B) Mean of active lever-presses in the 
time-out period throughout FR1 and FR5 operant training sessions for DOR KO 
and wild-type littermates. (C) Mean of body weight during the entire 
experimental period on FR1 and FR5 schedule for DOR KO and wild-type 
littermates. Data are expressed as mean ± SEM. * p < 0.05 and ** p < 0.01 (DOR 
KO vs. WT); ## p < 0.01 and ### p < 0.001 (FR1 vs. FR5 schedule) (one-way 
ANOVA, PR and body weight, or Mann-Whitney U, impulsive-like behaviour)  


























Figure 3. Neuronal morphological changes induced by chocolate-flavoured 
pellets in DOR and wild-type littermate mice. (A) Total dendritic spine density 
in neurons from the PFC, HCP, NAc shell and NAc core of DOR knockout mice 
(DOR KO) and wild-type littermates (WT) after the operant training to obtain 
chocolate-flavoured pellets respect to naïve mice. (B) Illustration of Dil-labelled 
dendrites of pyramidal neurons from the PFC and HCP and medium spiny 
neurons from the NAc shell and core of naïve wild-type mice and DOR KO and 
wild-type littermate mice trained to obtain chocolate pellets. Data are expressed 
as mean ± SEM. ** p < 0.01 and *** p < 0.001 (vs. wild-type); # p < 0.05 (vs. 
















Operant behaviour to obtain chocolate flavoured-pellets 
modifies structural plasticity in DOR KO and wild-type 
littermates. 
Changes in dendritic spine density were analyzed with ballistic 
labelling with the fluorescent dye Dil in the PFC, HCP, NAc shell 
and NAc core. Significant differences in total dendritic spine 
density in neurons from the PFC, HCP and NAc shell were reported 
between naïve wild-type mice and wild-type mice trained with 
chocolate flavoured pellets [one-way ANOVA, F(1,10) = 5.59, p < 
0.05; F(1,7) = 11.44, p < 0.05; F(1,10) = 6.10, p < 0.05] and 
between wild-type and DOR KO mice trained with these pellets 
[one-way ANOVA, F(1,14) = 33.72, p < 0.001; F(1,8) = 11.69, p < 
0.01; F(1,12) = 20.62, p < 0.001]. Moreover, a significant difference 
in total dendritic spine density in neurons from the PFC was also 
reported between naïve wild-type mice and DOR KO mice trained 
with chocolate pellets [one-way ANOVA, F(1,12) = 9.09, p < 0.05]. 
However, no differences were found between these two groups in 
the HCP, NAc shell and NAc core (Figure 3A).  
Changes in specific types of dendritic spines were also analyzed in 
each brain area. In the PFC, significant differences in thin, 
mushroom and filopodia density were reported between naïve wild-
type mice and wild-type mice trained with chocolate pellets [one-
way ANOVA, F(1,9) = 12.01, p < 0.01; F(1,9) = 14.36, p < 0.01; 
F(1,9) = 29.86, p < 0.05] and in thin, mushroom, filopodia and 
stubby density between wild-type and DOR KO mice trained with 
these pellets [one-way ANOVA, F(1,14) = 17.02, p < 0.01; F(1,14) 









Figure 4. Dendritic density of the different spine types in neurons of (A) PFC 
(B) HCP (C) NAc shell and (D) NAc core of DOR knockout mice (DOR KO) 
and wild-type littermate mice (WT) after the operant training to obtain 
chocolate-flavoured pellets respect to naïve mice. Data are expressed as mean ± 
SEM. * p < 0.05, ** p < 0.01 and *** p < 0.001 (vs. wild-type); # p < 0.05 and ## 






0.05]. In addition, decreased stubby and filopodia spine density was 
reported in DOR KO when compared with naïve wild-type mice 
[one-way ANOVA, F(1,11) = 8.85, p < 0.05; F(1,11) = 15.09, p < 
0.01] (Figure 4A).  
In the HCP, an increase in the density of stubby spines was shown 
in wild-type mice trained with chocolate pellets when compared 
with naïve wild-type mice [one-way ANOVA, F(1,6) = 8.21, p < 
0.05] and DOR KO mice trained with these pellets [one-way 
ANOVA, F(1,8) = 13.42, p < 0.01]. Decreased filopodia density 
was only reported in DOR KO trained with chocolate pellets when 
compared with naïve wild-type mice [one-way ANOVA, F(1,6) = 
6.54, p < 0.05] (Figure 4B). 
In the NAc shell, an increase of filopodia density was observed in 
wild-type mice trained with chocolate pellets with respect to the 
naïve wild-type group [one-way ANOVA, F(1,7) = 7.50, p < 0.05] 
and DOR KO group trained with these pellets [one-way ANOVA, 
F(1,12) = 18.47, p < 0.01]. No significant modifications in the 
different types of spine density were observed between naïve wild-
type mice and DOR KO mice trained with chocolate pellets (Figure 
4C). 
No major modifications were reported among groups in the NAc 
core, although increased mushroom spine density was revealed in 
wild-type mice trained with chocolate pellets when compared with 
the naïve wild-type group [one-way ANOVA, F(1,6) = 6.06, p < 









The present study reveals a novel role of DOR in mediating the 
reinforcing effects, motivation and impulsive-like behaviour 
induced by operant training maintained with chocolate flavoured-
pellets. In addition, prolonged operant training to obtain palatable 
food differently modifies structural plasticity in the PFC, HCP and 
NAc shell of DOR KO mice and their wild-type littermates, which 
suggests a specific involvement of DOR in the plasticity changes 
promoted by this repeated palatable food operant training. 
Our results reveal a critical role of DOR in mediating the 
reinforcing aspects of food-seeking behaviour. During the FR1 
schedule of reinforcement, only 28% of DOR KO mice achieved 
the acquisition criteria in contrast to 66% of wild-type mice. These 
results provide an initial evidence of the role of DOR in the 
acquisition of this operant behaviour. The two genotypes showed 
similar increases in food operant responding across the FR1 period 
suggesting preserved cognitive/learning abilities to acquire the 
food-maintained operant task in DOR-deficient mice. A similar 
performance in operant-responding maintained by high-fat food was 
already previously reported in food-deprived mice, which facilitates 
operant responding (Gutiérrez et al. 2014). These findings ruled out 
a potential learning impairment for operant training in these 
knockout mice. To avoid possible confounding factors, the role of 
DOR in the reinforcing and motivational properties of food 





in mice trained with chocolate pellets and fed ad libitum in their 
home cage, since restrict access to food induces major changes in 
the brain opioid system (Wolinsky et al. 1994). During the FR5 
schedule, DOR KO mice showed less operant responding than wild-
type mice as revealed by the decreased number of active lever-
presses during the whole training period. Similar reduction of the 
operant responding was observed for DOR KO mice during the PR 
schedule. The breaking point is a sensible and validated measure of 
the motivational state of the animal (Arnold & Roberts 1997). 
Therefore, the present result suggests that disruption of DOR 
reduced the motivation for chocolate-flavoured pellets 
consumption. Previous studies have also suggested that DOR 
participates in the rewarding aspects associated with preferred foods 
(Gosnell & Majchrzak 1989), according with the decreased 
motivation toward chocolate pellets of DOR KO animals in our 
experimental conditions. In agreement, central administration of 
DOR agonists increased saccharin solution intake in rats and this 
increase was selective for saccharin, since water intake was minimal 
(Gosnell & Majchrzak 1989). Moreover, non-selective opioid 
antagonists, such as naltrexone and naloxone suppress consumption 
of preferred food, but have smaller effects on non-preferred foods 
further underlying that opioid signalling is involved in determining 
food preference (Leventhal et al. 1995; Cooper 1983; Le Merrer et 
al. 2009c).  
DOR KO animals also decreased active operant responses during 
the time-out period, which is an indirect measure of impulsive-like 





and behavioural disinhibition particularly in the decision-making 
domain (Clark et al. 2006; Verdejo-Garcia et al. 2007). MOR 
activity may be positively correlated with impulsivity traits in 
humans and mice (Love et al. 2009; Olmstead et al. 2009), whereas 
the opposite implication of DOR in impulsivity and inhibitory 
control has been reported (Olmstead et al., 2009). Thus, mice 
lacking DOR appeared more impulsive, in terms of premature 
responses, than wild-type controls when trained to respond for 
sucrose in a signalled nose-poke task (Olmstead et al., 2009). In 
contrast, our results suggest that DOR-deficient mice decrease food-
seeking behaviour and impulsive behaviour promoted by the 
repeated operant training to obtain palatable food. This discrepancy 
could be due to the different experimental conditions used in terms 
of rewards, time of sessions and water restriction. Indeed, the 
previous study found increased impulsivity in response for sucrose 
solution in session lasting 40 min and when the access to water was 
restricted for 2 h per day. These conditions could probably alter 
inhibitory mechanisms, making these mice incapable of refraining 
from doing an anticipated response. Conversely, a more recent 
study suggests that the pharmacological activation of DOR 
increased locomotor activity, although did not increase the rate of 
non-reinforced lever pressing for sucrose (Befort et al. 2011), which 
would suggest that the effect of DOR in impulsive-like behaviour in 
an operant paradigm could be independent of changes in 
locomotion. 
In our study, we observed that mice lacking DOR gained less weigh 





animals. In agreement, mice deficient in DOR resist to weight gain 
after prolonged exposure to high-energy diet (Czyzyk et al. 2012). 
This was attributed to the ability of this receptor to increase the 
energy expenditure and thermogenic activity in the brown adipose 
tissue (Czyzyk et al. 2012).  
Repeated operant training to obtain palatable food changes the 
morphology of dendritic spines in the mesocorticolimbic system 
(Guegan et al. 2013) and leads to a reorganization of synaptic 
connectivity between neurons (Chklovskii 2004). Palatable food-
induced structural plasticity changes in the reward circuit appear to 
be a longer time-dependent process than drug-induced structural 
plasticity changes (Sarti et al. 2007). In our study, structural spine 
density alterations induced by operant training with chocolate-
flavoured pellets were revealed in several brain areas of the reward 
circuit. These morphological spine modifications represent a 
neuronal substrate underlying food experience-induced behavioural 
changes (Butz et al. 2009). These adaptations include changes in 
spine number and shape induced by the synaptic activity. Indeed, 
the density of dendritic spines usually indicates the prevalence of 
excitatory synaptic inputs into a particular neuron (Lai & Ip 2013). 
In this line, an increase of total spine density was found in main 
rewarding brain areas, such as PFC, HCP and NAc shell of wild-
type trained to obtain chocolate pellets when compared with naïve 
and DOR KO mice. In agreement with previous studies (Guegan et 
al. 2013), this increased spine density might be responsible for the 
abnormal behavioural responses observed in wild-type mice trained 





and related impulsivity. In contrast, reduced spine density was 
observed in the PFC of DOR KO mice trained to obtain chocolate 
pellets with respect to naïve wild-type mice. These differences 
could be attributed to the effect of the operant training in the 
absence of DOR since the two genotypes revealed opposite 
modifications in spine density when compared with the non-trained 
naïve group. Changes in the total spine density were not observed in 
the NAc core of DOR KO and wild-type mice, underlying that NAc 
shell and core are involved in different aspects of food seeking 
behaviour, as previously reported (Parkinson et al. 2002; Peciña & 
Berridge 2005). Thus, NAc shell encodes pleasurable sensation 
derived from food consumption (Baldo & Kelley 2007), while the 
NAc core is associated with the elaboration of habit learning 
promoted mainly by conditioned association of natural reward-
related stimuli (Everitt & Robbins 2005). Accordingly, a previous 
study reported that operant training to obtain palatable food does 
not significantly alter dendritic spine density in the NAc core of 
wild-type mice (Guegan et al. 2013).  
Changes in the density of specific dendritic spines were also found 
in the PFC, HCP and NAc shell between genotypes. Operant 
training to obtain palatable pellets increased stubby spine density in 
the HCP and filopodia density in the PFC and NAc shell of wild-
type mice in comparison to the naive group. Interestingly, opposite 
structural changes were observed in DOR KO mice, in which a 
reduced level of stubby spines was observed in the PFC and HCP 
and a decreased filopodia spine density was found in the PFC and 





trained to obtain chocolate pellets. Stubby and filopodia spines are 
recognized as immature spines with low stability, easily turned into 
other spines or eliminated (Kasai et al. 2002). However, filopodia 
spines seem to be implicated in synaptogenesis mechanisms due to 
their elongated morphology that can facilitate axodendritic synaptic 
contacts (García-López et al. 2010). The decreased number of 
stubby spines in the PFC and HCP of DOR KO mice could be 
associated to lower spinogenesis or retraction of the existent spines 
in the memory/learning and inhibitory control circuits and 
decreased levels of filopodia spines could be associated to a 
reduction of synaptic connections in the NAc shell of DOR KO 
mice after this operant training. In this line, spine shrinkages, 
retractions and turnover are generally correlated with LTD activity 
(Lai & Ip 2013). Therefore, we can hypothesized that the lower 
spinogenesis and synaptogenesis in DOR KO mice could be related 
to possible LTD alterations in these brain areas, leading to 
decreased motivation for food and reduced operant response and 
impulsive behaviour. 
Operant training with palatable food also enhanced the density of 
mushroom spines in the PFC and NAc core, as well as thin spines in 
the PFC in wild-type mice trained to obtain chocolate pellets with 
respect to the naive group. In contrast, a decrease of thin and 
mushroom large spines was found in the PFC of DOR KO animals. 
Mushroom spines hold a decreased motility and consequently 
display structural and functional stability (Kasai et al. 2004) and are 
ascribed to mature spines (Nimchinsky et al. 2002) able to maintain 





long-term memory (Kasai et al, 2004). Thin spines maintain 
structural flexibility to enlarge and stabilize into mushroom spines 
making them candidate for ‘learning spines’(Bourne & Harris 
2007b). The decreased density of these large spines observed after 
operant training in DOR KO mice could wane the strength of 
specific synapses in the PFC of these animals. As LTP is generally 
associated with the enlargement and stability of dendritic spines (De 
Roo et al. 2008), the present finding may suggest a LTP alteration 
in the cortical circuit of the mutant mice leading to impairment of 
food-seeking behaviour. 
In conclusion, the present study highlights the role of DOR in the 
reinforcing and motivational properties of food, as well as in 
impulsive responses associated to food-seeking behaviour by a 
mechanism that implies structural plasticity changes in the brain 
reward circuits. This study provides further advances in 
understanding neuroadaptations related to food-seeking behaviours 
that may promote eating disorders and highlights the relevance of 
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Table S1A Normality test 
                                                 Kolmogorov-Smirnov 
    Progressive ratio     Time-out 
 F-value P-value F-value P-value 
WT 
 
  FR1 schedule       -  - F(1,12) = 0.16 n.s 
  FR5 schedule F(1,12) = 0.20 n.s F(1,12) = 0.20 n.s 
 DOR KO    FR1 schedule       -  - F(1,14) = 0.06 n.s 

































































Involvement of CB2 cannabinoid receptor in the reinforcing effects 
of chocolate flavoured-pellets and eating addictive-like behaviour. 
 


























This study was aimed to evaluate the involvement of CB2 
cannabinoid receptor (CB2R) in the reinforcing effects and eating 
addictive-like behaviour promoted by chocolate-flavoured pellets. 
We used a recently validated operant model of eating addictive-like 
behaviour in mice deficient or overexpressing CB2R and wild-type 
littermates (WT). Three hallmarks of addiction were evaluated at 
two different time points during the early and late training period in 
this model: persistence of food seeking during a period of non-
availability of food, motivation for food and perseverance of 
responding when the reward was associated with a punishment. 
Each mouse was classified as resistant (0 criteria) or vulnerable (2-3 
criteria) to this addictive-like behaviour considering these hallmark 
criteria. Our results revealed a significant difference in the 
percentage of mice reaching 0 criteria when compared CB2R 
deficient mice (0%) with control mice (60%) during the early 
period, although no major differences were reported between mice 
overexpressing the CB2 protein (33.3%) and control mice. During 
the late period, a reduced but not significant percentage of CB2R 
knockout mice resistant to addiction was shown, suggesting that 
CB2R seems involved in the predisposition to addiction. Thus, 
CB2R may constitute an interesting potential mechanism involved 








Rewarding foods that usually combine palatability and high energy 
density have become the main driving force promoting overeating 
and body weight gain in the modern society (Alsiö et al. 2012). 
Certain forms of overeating may be mediated by an addictive-like 
process, and individuals may become dependent to these kind of 
highly rewarding foods in some particular conditions (C. Davis et 
al. 2011). Indeed, overeating results of eating behaviour 
disturbances that share neurobiological and psychological 
similarities with substance use disorder (D’Addario et al. 2014). 
Among all the neurotransmission systems orchestrating this 
behaviour, the endocannabinoid system through its two main 
receptors cannabinoid receptor 1 (CB1R) and 2 (CB2R), results 
particularly involved due to its important role in the regulation of 
rewarding responses (Harrold & Williams 2003; Lupica et al. 2004; 
Zhang et al. 2014). CB1R appears to be an important component of 
the neural substrate that mediates the reinforcing properties of drugs 
and palatable foods (Maccioni et al. 2008). The pharmacological 
antagonism or genetic disruption of CB1R reduced the reinforcing 
effects of palatable food and prevented the transition from 
controlled to loss of control over intake (Mancino et al. 2015). 
Several studies suggest the potential involvement of CB2R in 
reward mechanisms by the modulation of brain dopamine (DA) 
related behaviours (Zhang et al. 2014). CB2R seems to be expressed 
in DA neurons of the VTA and functionally modulates DA neuronal 





mechanisms underlying these actions are still unclear (Morales & 
Bonci 2012). Accordingly, the role of this receptor in mediating the 
neurobiological responses of drugs of abuse is not completely 
understood and several contradictory results were reported during 
the last years (Katia 2015; Onaivi et al. 2008). Initial results showed 
increased and decreased CB2R gene expression in mouse striatum 
(ST) and ventral midbrain after chronic heroin treatment and 
ethanol intake, respectively (Onaivi et al. 2008). In addition, recent 
results suggest that the genetic deletion and the pharmacological 
antagonism of CB2R reduce nicotine self-administration and 
nicotine withdrawal syndrome (Navarrete et al. 2013). Conversely, 
it was also shown that neuronal CB2R did not seem to be involved 
in the reinforcing effects of nicotine (Gamaleddin et al. 2012a). 
These discrepant results may be due to the different experimental 
animal species (mice and rats) and differences in the protocol used 
in terms of food restriction regime and schedules of reinforcement 
during the operant training. In addition, cocaine self-administration 
was attenuated in mice overexpressing the CB2R (Aracil-Fernández 
et al. 2012) and after the pharmacological activation of CB2R (Xi et 
al. 2011b; Adamczyk et al. 2012).  
The possible involvement of CB2R in the regulation of the 
reinforcing and motivational properties of food has not been yet 
investigated. However, CB2R seems directly implicated in the 
homeostatic control of food due to its presence in the main 
peripheral tissues responsible for the metabolic control, including 
the liver, adipose tissue, skeletal muscle and pancreatic islets (de 





CB2R may be a key component in the development of obesity-
associated metabolic disorders. Indeed, evidence in mice shows the 
involvement of CB2R in the regulation of body weight gain, 
obesity-associated liver and adipose tissue inflammation, and 
insulin resistance (Agudo et al. 2010a; Deveaux et al. 2009a).  
The aim of our study was to understand the involvement of CB2R 
in the compulsive eating behaviour promoted by palatable food 
using an operant model of eating addictive-like behaviour already 
validated in our laboratory (Mancino et al. 2015). For this purpose, 
we evaluated the persistence of food seeking during a period of 
non-availability of food, the motivation for food and the 
perseverance of responding when the reward was associated with a 
punishment in constitutive transgenic mice overexpressing the 










CD1 wild-type (WT) male mice (n=15) (Charles River, France), 
homozygote CB2R Tg (n=12) and CB2R
 
KO (n=11) mice were 
used. Male CB2R KO mice were initially generated on a C57BL/6J 
congenic background (provided by Nancy E. Buckley, Cal State 
Polytechnic University, Pomona, CA, USA), and the CB2R KO 
founders were crossed with outbred CD1 (Charles River, France) 
background (Buckley et al. 2000) for eight generation. Male mice 
overexpressing CB2R (CB2R Tg) were on a CD1 congenic 
background. These mice were prepared as described elsewhere 
(Racz et al. 2008). Mice weighed 31 ± 5 g at the beginning of the 
experiment. Mice were housed individually in controlled laboratory 
conditions (temperature at 21 ± 1°C and humidity at 55 ± 10%) and 
they were tested during the first hours of the dark phase of a 
reversed light/dark cycle (lights off at 8.00 am and on at 8.00 pm). 
Food and water were available ad libitum in the home cage. Animal 
procedures were conducted in strict accordance with the guidelines 
of the European Communities Directive 86/609/EEC regulating 










Operant behaviour apparatus 
 
Operant responding maintained by food was performed in mouse 
operant chambers (Model ENV-307A-CT, Med Associates, 
Georgia, VT, USA) equipped with two retractable levers, one 
randomly selected as the active lever and the other as the inactive, 
as previously reported (Martín-García et al. 2011). Pressing on the 
active lever resulted in a pellet delivery together with a stimulus-
light (associated-cue), located above the active lever, while pressing 
on the inactive lever had no consequences. The chambers were 
made of aluminium and acrylic, and were housed in sound- and 
light-attenuated boxes equipped with fans to provide ventilation and 
white noise. A food dispenser equidistant between the two levers 




During the operant experimental sessions, animals received a 20 mg 
highly palatable isocaloric pellet (20.5% proteins, 12.7% fats and 
66.8% carbohydrates, with a caloric value of 3.48 kcal/g, TestDiet, 
Richmond, IN, USA) after each active response. Highly palatable 
isocaloric pellets presented similar caloric value to the diet provided 
to mice in their home cage (24.1% proteins, 10.4% fats and 65.5% 
carbohydrates, with a caloric value of 3.30 kcal/g, Special Diets 
Services, Witham, Essex UK) with some slight differences in their 
composition: addition of chocolate flavour (2% pure unsweetened 





carbohydrate content was similar in chow diet (65.5%) and highly 
palatable isocaloric pellets (66.8%), the sucrose content was 
different: in standard chow was 3.1% of the total carbohydrates and 
50.1% in highly palatable isocaloric pellets. These pellets were 
presented only during the operant behaviour sessions and animals 




WT (n=15), CB2R Tg (n=12) and CB2R
 
KO (n=11) mice were 
trained in operant boxes to respond for obtaining chocolate-
flavoured pellets. Animals were trained under a FR 1 schedule of 
reinforcement in 1 h daily session during 5 days, followed by 113 
days of training on a FR 5 schedule. Every self-administration 
session was composed by 25 min of normal delivery of pellets 
(active period), followed by 10 min of non-reinforced active 
responses (pellets-free period), and 25 additional min of active 
period. During the pellets-free period, no pellet reinforcer was 
delivered signalled by the light that illuminated the entire box. A 
stimulus light, located above the active lever, was paired 
contingently with the delivery of the reward during the active 
periods. A time-out period of 10 sec was established after each 
pellet delivery. During this period, the cue light was off and no 
reinforcer was provided after responding on the active lever. 
Responses on the active lever and all the responses performed 
during the time-out period were recorded. The beginning of each 





light placed on the ceiling of the box only during the first three sec 
of the session. The criteria for acquisition of operant responding 
were achieved when mice maintained a stable responding with less 
than 20% deviation from the mean of the total number of food 
pellets earned in three consecutive sessions, with at least 75% 
responding on the reinforced lever, and a minimum of 10 
reinforcers per session (Martín-García et al. 2011). 
Three addiction-like criteria for food-seeking were evaluated as 
previously described (Mancino et al. 2015), at two different time 
points in each mouse, first during the early training sessions (1-24) 
and then during the late training sessions (105-113). The score of 
addiction criteria was attributed considering the responses obtained 
during the late training sessions using the following three 
behaviours resembling DSM-5 criteria for addiction: 
1) Persistence to response: persistence of food seeking behaviour 
even if the food reward is not available. It is measured by the 
number of responses for active lever-presses during the 10 min of 
unavailability of pellets delivery (pellet-free period). The active 
lever responses during the 10 min pellet-free period of the first 3 
consecutive days of the early and late training period were 
evaluated.  
2) Motivation: high motivation for food pellets measured by the PR 
schedule of reinforcement. It was used to evaluate the motivation 
for the food pellet during the early (days 13-15) and late (days 108-
110) period. The response required to earn the pellet escalated 
according to the following series: 1, 5, 12, 21, 33, 51, 75, 90, 120, 





1200, 1500, 1800, 2100, 2400, 2700, 3000, 3400, 3800, 4200, 4600, 
5000, 5500. The maximal number of responses that the animal 
performs to obtain one pellet is the last ratio completed, referred to 
the breaking point. The maximum duration of the PR session was 5 
h or until mice did not respond on any lever within 1 h.  
3) Resistance to punishment: resistance to punishment when food 
pellets intake is maintained despite its negative consequences. Mice 
were placed for one day session in a self-administration chamber 
with a different kind of grid in the floor during the early (days 20-
24) and late (days 111-113) period. This environmental change 
acted as a contextual cue. Mice received an electric foot-shock (0.20 
mA, 2 sec) after 4 responses and received both, an electric foot-
shock (0.20 mA, 2 sec) and a pellet, associated with the 
corresponding conditioned stimulus (cue light), after the 5th 
response. The schedule was reinitiated at the end of the time-out 
period, i.e. 10 sec after the pellet delivery. If mice after the 4th 
response did not complete the 5th response within a min, the 
sequence was reinitiated. 
 
Establishment of mice subpopulations  
 
A mouse was considered positive for a particular addiction-like 
criterion when the score for this behaviour was equal or above the 
75th percentile of the distribution achieved by the control group. 
Animals were scored for each of addictive-like behaviours (three) 
independently and the algebraic sum of scores was calculated. Four 





positive criteria met 0 criteria, 1 criteria, 2 criteria and 3 criteria 
(Figure 5). Due to the accomplishment of several criteria of loss of 
control, we considered mice reaching 2 or 3 criteria as addict-
vulnerable phenotypes and therefore were included in the subgroup 




All animals were decapitated immediately after the last training 
session. The brains were quickly removed and the following brain 
areas dissected according to the atlas of stereotaxic coordinates of 
mouse brain (Paxinos and Franklin, 1997): ST, NAc, prefrontal 
cortex (PFC) and hippocampus (HCP). Brain tissues were then 
frozen by immersion in 2-methylbutane surrounded by dry ice, and 




Data obtained during the operant-acquisition phase were analyzed 
using three-way repeated measures analysis of variance (ANOVA) 
with genotype (WT, CB2R Tg and CB2R
 
KO mice) as between-
subject factor and lever (active/inactive) and day as within-subjects 
factors. Post-hoc analysis (Newman-Keuls) was performed when 
required. Body weight, pellets intake, impulsivity-like behaviour, 
persistence to response, motivation and resistance to punishment 
data were analyzed using Mann–Whitney U test due to the non-





The data are expressed as mean ± SEM (normally distributed data) 
and median and interquartile range (non-normally distributed data). 
Differences were considered significant at p < 0.05. The statistical 
analysis was performed using the Statistical Package for Social 







Acquisition of operant training maintained by food 
WT (n=15), CB2R Tg (n=12) and CB2R
 
KO (n=11) mice were 
trained to acquire an operant responding maintained by chocolate 
flavoured-pellets under FR1 and FR5 schedule of reinforcement. 
The acquisition criteria on FR1 were achieved after 5 sessions by 
0%, 25% and 36.6% of WT, CB2R Tg and CB2R KO mice 
respectively. Chi square test revealed significant differences in the 
percentage of acquisition criteria between the CB2R Tg and WT 
group [χ
2
 = 112495.50, p < 0.001] and between CB2R KO and WT 
mice [χ
2 
= 218176.72, p < 0.001]. On FR1, three-way ANOVA 
revealed a significant interaction between “genotype”, “lever” and 
“day” [F(18,140) = 2.31, p < 0.05], suggesting a progressive 
discrimination between levers (Figure 2). Subsequent post hoc 
analysis (Newman-Keuls) did not show significant differences 
between genotypes.  
The acquisition criteria on FR5 were achieved by the totality of the 
WT, CB2R Tg and CB2R KO mice after an average of 6.27 ± 2.67, 
7.17 ± 2.21 and 5.18 ± 0.52 sessions respectively. During FR5, 
three-way ANOVA revealed significant main effects of “day”, 
“genotype” and “lever” [F(158,2765) = 1.40, p < 0.01], but not 













Figure 1. Experimental design. Experimental sequence of the eating addictive-
like behaviour model. WT (n=15), CB2R Tg (n=12) and CB2R
 
KO (n=11) mice 
were trained for chocolate-flavoured pellets with the presentation of a cue light 
under a fixed-ratio (FR) 1 schedule of reinforcement on 60 min daily sessions 
during 5 days followed by 113 days on a FR5 schedule of reinforcement. Each 
session was composed by 25 min of normal delivery pellets named active period, 
followed by 10 min of pellet-free period in which the persistence to response was 
registered, and other 25 min of active period. In the FR5 two time points were 
considered, early (from day 1 to 24) and late period of training (from day 105 to 
113) to measure the three addictive-like behaviours: 1) persistence to response, 2) 







Figure 2. Acquisition of operant training maintained by food. Mean number 
of active and inactive lever-presses during the acquisition training in the FR1 and 
FR5 schedule of reinforcement in WT (n=15), CB2R Tg (n=12) and CB2R
 
KO 
(n=11) mice. Data are expressed as mean ± SEM. ### p < 0.001 (active lever vs. 
inactive lever) (three-way ANOVA).  
 
Comparisons in body weight, pellets intake and impulsivity-like 
behaviour 
Significant differences in body weight were reported only during 
the late training period (days 105-113) with CB2R Tg
 
mice showing 
lower body weight than WT (p < 0.001) and CB2R KO (p < 0.05) 
mice. A decreased body weight was also observed during the late 














Figure 3. (A-C) Comparisons in body weight, pellets intake and impulsivity-
like behaviour. (A) Mean of body weight during the early and late period of the 
operant training for CB2R Tg, CB2R KO and WT groups that were trained to 
obtain high palatable chocolate-flavoured pellets. (B) Mean number of pellets 
intake during three consecutive sessions in the early and late period of the operant 
training for CB2R Tg, CB2R KO and WT groups. (C) Mean of active lever-
presses during the time-out period during three consecutive days sessions in the 
early and late operant training period for CB2R Tg, CB2R KO and WT groups. 
Data are expressed as mean ± SEM @ p < 0.05, @@ p < 0.01, @@@ p < 0.001 
(early training vs. late training); * p < 0.05, ** p < 0.01 (vs. CB2R Tg), # p < 
0.05, ## p < 0.01 (vs. CB2R KO); + p < 0.05, +++ p < 0.001 (vs. WT) (Mann-






All groups of mice significantly gained weight during the late 
period when compared to the early period of training (days 1-24) (p 
< 0.05) (Figure 3A).  
Pellets intake was significantly increased in CB2R Tg mice when 
compared to WT mice during the early training period (p < 0.01), 
although during the late training period, CB2R Tg mice decreased 
pellets intake with respect to the WT and CB2R KO group (p < 
0.05). Moreover, WT and CB2R KO mice, but not CB2R Tg mice 
significantly increased the amount of pellets intake during the late 
period when compared to the early period (p < 0.001) (Figure 3B).  
Impulsivity-like behaviour was measured by the number of active 
lever-presses during the time-out period. In the early period, CB2R 
Tg mice significantly increased the number of active responses 
when compared with WT mice (p < 0.05). Only WT and CB2R KO 
mice increased the number of time-out active lever-presses during 
the late period when compared with the early period of training (p < 
0.001 and p < 0.01, respectively). During the late period, a 
significant decreased in CB2R Tg mice responses were reported 
with respect to CB2R
 
KO mice (p < 0.05) (Figure 3C).  
 
Differences in operant responding between genotypes in the 
three addiction-like criteria 
All groups of animals were tested for the three behaviours used to 
evaluate the loss of control during the early (days 1-24) and late 
(days 105-113) periods of the operant training. In the persistence to 





increased active lever-presses during the early period when 
compared with WT mice (p < 0.05).  
During the late period, a significant decrease in operant responding 
was observed for CB2R Tg when compared with CB2R
 
KO mice (p 
< 0.05), albeit not significant differences were reported with respect 
to the control group. Furthermore, decreased responses were 
observed for the CB2R Tg group during the late period when 
compared to the early one (p < 0.01) (Figure 4A). 
In the motivation test, CB2R Tg and CB2R
 
KO showed higher 
breaking point during the early period than WT mice (p < 0.05), 
although no significant differences were reported during the late 
period between genotypes. Only WT mice increased the breaking 
point in the late period when compared to the early one (p < 0.01) 
(Figure 4C).  
In the resistance to punishment, only CBR2
 
KO mice increased 
significantly the amount of pellets intake in the foot-shock test 
during the early period with respect to the WT group (p < 0.001). 
No significant differences between groups were reported during the 
late period and a significant decrease in pellets intake was observed 
in CB2R KO mice during the late period with respect to the early 
period (p < 0.001) (Figure 4E).  
 
Calculation of addiction score based on the three addiction-like 
criteria  
All groups of mice were tested for addiction-like criteria during the 
early and late period of training. A mouse was considered positive 





                    MEAN ± SEM                            MEDIAN ± INTERQUARTILES 
Figure 4. (A-F) Differences in operant responding between groups during the 
early and late period of training. (A) in the persistence to response, (C) 
motivation and (E) resistance to punishment for CB2R Tg, CB2R KO and WT 
groups exposed to high palatable chocolate-flavoured pellets expressed as mean ± 
SEM. (B, D, F) Distribution of individual data in the three tests used to measure 
addiction-like criteria during the early and late training of CB2R Tg, CB2R KO 
and WT groups calculated with median and interquartile range. The line indicates 
the 75th percentile of distribution of WT group during the late training period and 
is used as the criterion to attribute one point of the score to each individual 
located equal or above this percentile. @@ p < 0.01, @@@ p < 0.001, @@@ p 
< 0.001 (early training vs. late training); * p < 0.05, (vs. CB2R Tg), # p < 0.05, 







behaviour was equal or major to the 75
th
 percentile of the 
distribution of the WT group (Figure 4B, D, F). All animals were 
divided into 4 subgroups based on the number of criteria for which 
they were scored (Figure 5A). During the early training period 
33.3% of CB2R Tg mice exhibited 0 criteria, 0% reached 1 criteria, 
33.3% got 2 criteria and 33.3% obtained the 3 criteria, while 0% of 
CB2R
 
KO mice reached 0 criteria, 36.4% 1 criteria, 27.8% 2 criteria 
and 36.7 % 3 criteria and finally, 60% of WT mice presented 0 
criteria, 6.7% 1 criteria, 26.7% 2 criteria and 6.7% 3 criteria (Figure 
5B, D, F). Chi square test revealed significant differences in the 
percentage of mice subpopulations reaching the high score (2-3 
criteria) between the CB2R Tg and the control group [χ
2 
= 6.00, p < 
0.05] and between the CB2R KO and the control group [χ
2 
= 4.55, p 
< 0.05]. Interestingly, a significant difference was also shown in the 
percentage of mice subpopulations reaching the 0 criteria between 
the CB2R KO and WT group [χ
2
 = 7.33, p < 0.01].  
During the late training period 16.7% of CB2R Tg mice exhibited 0 
criteria, 58.3% 1 criteria, 16.7% 2 criteria and 8.3% 3 criteria while, 
18.2% of CB2R
 
KO group reached 0 criteria, 45.5% 1 criteria, 
18.2% 2 criteria and 18.2% 3 criteria and finally, 40% of WT mice 
presented 0 criteria, 26.7% 1 criteria, 20% 2 criteria and 13.3% 3 
criteria (Figure 5C, E, G). Chi square test did not reveal significant 
differences in the percentage of mice subpopulations between 





Figure 5. (A) Distribution of animals with different scores for addictive-like 
behaviour. It was calculated as the algebraic sum of the scores obtained in each of the 
three addiction-like criteria during the late training period. The addiction score was 
distributed along a scale from 0 to 3. Data are expressed with median and interquartile 
range. (B-G) Distribution of the different criteria subgroups in percentage. 
Animals were assigned to a criteria subgroup based on the amount of criteria met for 
which they scored equal or above the 75th
 
percentile. Percentage of distribution of 
CB2R Tg animals during the early (B) and late (C) period, percentage of distribution 
of CB2R KO animals during the early (D) and late (E) period and percentage of 









In the present study, we used a reliable model of eating addictive-
like behaviour recently validated in our laboratory (Mancino et al, 
2015) to evaluate the involvement of CB2R in the loss of control 
promoted by long-term operant training maintained by palatable 
food. Extreme subpopulations of mice related to addictive-like 
behaviour were identified among the different genotypes studied. 
The deletion of CB2R leads to a reduction in the percentage of mice 
resistant to develop this addictive-like behaviour, and this effect 
was more evident during the early training period.  
 
A previous study of DSM-based animal model of eating addiction 
revealed a crucial involvement of the CB1R in the addictive-like 
behaviour promoted by palatable food (Mancino et al, 2015). In this 
line, the present study showed a possible opposite involvement of 
CB2R in compulsive food seeking. The genetic disruption or 
overexpression of CB2R has not major consequences in the operant 
behaviour maintained by chocolate-flavoured pellets during the FR1 
and FR5 schedule of reinforcement, although a trend to increase 
active responses was revealed in CB2R KO mice. Previous studies 
reported a different involvement of this receptor in drug operant 
behaviour depending on the drug of abuse used. Indeed, an 
impairment in the acquisition of operant behaviour maintained by 
nicotine was revealed in mice lacking CB2R (Navarrete et al. 2013), 
although nicotine self-administration was not modified by selective 





hand, reduction of cocaine-induced place preference and self-
administration were reported in transgenic mice overexpressing 
CB2R (Aracil-Fernández et al. 2012). Moreover, intra-NAc local 
administration of JWH133, a selective CB2R agonist, dose-
dependently inhibited intravenous cocaine self-administration, 
cocaine-enhanced locomotion, and cocaine-enhanced NAc 
extracellular DA in WT mice, whereas intra-NAc administration of 
AM630, a selective CB2R antagonist, elevated extracellular DA, 
locomotion and blocked the reduction in cocaine self-administration 
produced by systemic administration of JWH133 (Xi et al. 2011b). 
These effects could be related to a possible location of CB2R on 
DA terminals in the NAc (Morales & Bonci 2012) that could 
mediate a decrease in DA release.  
In our experimental conditions, CB2R Tg mice increased the pellet 
consumption during operant training and showed a higher 
impulsive-like behaviour during the early period of training. 
However, an opposite result was observed during the late training in 
which CB2R Tg mice decreased pellets intake and body weight 
when compared to the control group. Previous studies reported that 
CB2R gene expression is increased during obesity (Deveaux et al. 
2009b), although pharmacological CB2R agonism did not affect 
weight gain in obese rats (Jenkin et al. 2014).  
A decreased body weight was observed during the late period in 
CB2R KO with respect to WT mice, even though these two 
genotypes consumed the same amount of food. It was reported that 
CB2R deficient mice, fed with high-fat diet for 15 weeks, 





mechanism that may involve lipid oxidation (Deveaux et al. 2009b). 
In addition, young (2-month-old) CB2R KO mice fed with high-fat 
diet for 8 weeks became obese, but they showed reduced body 
weight gain compared with WT mice under similar feeding 
conditions (Agudo et al. 2010b). In contrast, CB2R KO mice fed 
with standard diet displayed increased body weight gain with age 
(older than 6 months), which was associated with increased food 
intake (Agudo et al. 2010b). Nevertheless, the long-term role of 
CB2R modulation in the control of body weight has not been yet 
fully clarified (Agudo et al, 2010b).  
The increased pellets intake during the late training was also 
associated to an increased impulsivity-like behaviour in CB2R KO 
mice with respect to CB2R Tg mice. CB2R has already been 
proposed to regulate impulsive behaviour, as the treatment with 
selective CB2R agonists reduced cognitive and motor impulsivity, 
accompanied by CB2R down-regulation. In addition, CB2R 
antagonists reduced novelty seeking behaviour in mice (Navarrete 
et al 2012). 
To further explore the role of CB2R in addictive-like behaviour, we 
tested our genetically modified mice for the three criteria of loss of 
behavioural control after palatable food operant training (Mancino 
et al, 2015). During the early period, CB2R Tg mice appear more 
persistent in the response even when the reward was not available 
and more motivated for palatable food with respect to control mice. 
CB2R KO also showed an increased motivation when compared to 
WT mice and seemed to be more perseverant in food-seeking when 





indicate an initial role of CB2R in mediating the loss of control 
promoted by palatable food during the early phase of the operant 
training. The involvement of this receptor in this behaviour is 
highlighted by the higher percentage of CB2R KO and CB2R Tg 
reaching the 2-3 criteria (64% and 67% respectively) than WT mice 
(34%). In addition, significant differences between CB2R KO (0%) 
and control group (60%) in the percentage of mice subpopulations 
reaching 0 criteria were also reported. This result suggests that the 
deletion of CB2R may predispose to develop addictive-like 
behaviour during the early training period, decreasing the 
percentage of mice resistant to this behaviour. 
During the late training, no significant differences were revealed in 
motivation and resistance to punishment, although CB2R Tg mice 
decreased active-lever-presses during the pellets free period when 
compared to WT and CB2R KO mice. In contrast to the early 
period, no major differences between groups were reported in the 
percentage of mice achieving the 2-3 criteria (25% CB2R Tg, 35% 
CB2R KO and 33% WT). Although the percentage of WT and 
CB2R KO mice reaching the 2-3 criteria is mostly similar, a trend 
to decrease the percentage of CB2R KO obtaining 0 criteria 
(18.2%) was revealed when compared to WT mice (40%). These 
results suggest that the deletion of CB2R may produce adaptive 
mechanisms underlying the shift from controlled to loss of control 
over food intake. A possible explanation could be that under our 
experimental conditions a long-term operant training, compensatory 
mechanisms could be activated in mice with genetic manipulations 





In conclusion, the present findings support that CB2R could 
modulate the loss of control promoted by palatable food. The 
possible involvement of this receptor in the vulnerability to develop 
palatable food addictive-like behaviour is suggested by the reduced 
percentage of CB2R KO mice resistant to develop this addictive-
like behaviour, an effect mainly observed during the early training 
period. More studies are needed to clarify the exact involvement of 
CB2R in eating addictive-like behaviour after long-term operant 
training. The use of pharmacological tools targeting CB2R or 
conditional mutants with selective CB2R deletion in particular 
neuronal subpopulations and brain areas of the reward system could 
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A growing body of evidence suggests that some forms of overeating 
disorders should be considered as addictive-like behaviours. Indeed, 
the pattern of food intake observed in certain obese subjects and in 
patients with certain eating disorders, resembles behaviours 
typically endorsed by individuals with substance use disorders 
(Volkow et al. 2008). This similarity may reflect the involvement of 
similar neural systems, including those implicated in regulatory 
self-control and reward (Volkow et al. 2013a). Both, natural 
reinforcers and drugs of abuse activate the mesocorticolimbic DA 
system (Volkow et al. 2008). Indeed, the pleasant experience 
obtained from palatable food and drug consumption positively 
correlates with the amount of DA released in the ventral ST (Alsiö 
et al. 2012). However, the magnitude of the DA response to natural 
reinforcers is usually lower than to drugs of abuse. Nevertheless, 
both stimuli could produce repeated and excessive release of DA in 
the mesocorticolimbic system that, in turn, may induce alterations 
in the reward brain circuits and could trigger complex and long-
lasting neurobiological adaptations (Avena et al. 2009; Volkow et 
al. 2008). Such adaptations may include, at least in part, structural 
modifications in synaptic connections (Kasai et al. 2002; 2004) that 
can make the behaviour increasing compulsive and may lead to 
further loss of control toward drug or food intake (Guegan et al. 
2013; Johnson & Kenny 2010) promoting vulnerability to relapse 
(Volkow & Wise 2005; Martín-García et al. 2011).  
Several neurochemical systems seem to play a critical role in these 
adaptive changes produced by rewarding stimuli. Two of these 




involved in the modulation of the rewarding effects mediated by 
DA (Maldonado & Berrendero 2010). These systems have been 
proposed to play a common role as neurobiological substrates in 
addiction. The aim of the present thesis is to study the involvement 
of the opioid and cannabinoid systems in the compulsive seeking-
behaviour promoted by drugs and palatable food and underlying 
neuroadaptative modifications induced by this behaviour. 
 
The opioid system as a target for cocaine-relapse and food-seeking 
behaviour (article 1 and 3)  
Chronic exposure to prototypical drugs of abuse, including opioids, 
alcohol, nicotine, psychostimulants and cannabinoids has been 
reported to produce time-dependent and region-specific alterations 
in opioid receptor function and expression (Shippenberg et al. 
2008). In a similar way, palatable food produces changes in specific 
opioid components (Chang et al. 2007) that promote food rewarding 
effects (Avena et al. 2008). 
First, we investigated the involvement of several main components 
of the endogenous opioid system (MOR, DOR, PENK and PDYN) 
in the acquisition and reinstatement of cocaine-seeking behaviour 
(article 1). We also studied the role of these opioid components in 
the regulation of the reinforcing effects of high-fat food and 
reinstatement of food-seeking behaviour (article 1). Furthermore, 
we evaluated the specific involvement of DOR in the motivation for 
seeking chocolate-flavoured pellets and structural plasticity changes 





Several studies have underlined the important role of opioid 
receptors and their endogenous ligands in cocaine addiction 
(Charbogne et al. 2014). Thus, acute and chronic administration of 
psychostimulants produce adaptive changes in opioid peptide 
contents and receptor densities depending on the phase of the 
addiction process (Gorelick et al. 2008). Accordingly, acute cocaine 
administration increased MOR mRNA levels in PFC, NAc and 
amygdala (Yuferov et al. 1999). In addition, MOR mRNA levels 
were also increased in the PFC of rats during early withdrawal from 
chronic cocaine administration (Bailey et al. 2005) and enhanced 
beta-endorphin extracellular levels in the NAc were shown during 
cue-induced reinstatement of cocaine-seeking after a short phase of 
abstinence (Dikshtein et al. 2013). Our results showed that various 
components of the opioid system differently mediate cocaine 
motivational effects during the acquisition, maintenance and 
reinstatement of drug-seeking behaviour.  
Multiple studies reveal that MOR plays an important role in the 
reinforcing effects induced by natural rewards and several drugs of 
abuse including cocaine (Le Merrer et al. 2009b). Indeed, selective 
MOR antagonists attenuated cocaine-conditioned place preference 
(Schroeder et al. 2007) and cocaine self-administration in rats 
(Ward et al. 2003). Furthermore, studies with MOR knockout mice 
demonstrated the role of MOR in the reinforcing effects of nicotine 
(Berrendero et al. 2002), THC (Ghozland et al. 2002) and alcohol 
(Becker et al. 2002). However, contradictory results were reported 
in cocaine reinforcement using these genetically modified mice. 




2002), increased (Becker et al. 2002) or decreased (Hall et al. 2004) 
and cocaine self-administration reduced (Mathon et al. 2005) in 
MOR knockout mice. These findings provide an unclear picture of 
the role of MOR in cocaine reinforcement and they are not in 
agreement with previous studies using pharmacological 
manipulations. The discrepancies reported in these studies may be 
due to differences in the genetic background, gender (Anker & 
Carroll 2011) and/or the experimental protocol used. However, 
possible compensatory changes in other neurotransmission systems 
in constitutive knockout mice could also influence the effects of 
cocaine on DA release in the NAc. Despite these inherent 
limitations, we support the hypothesis that the genetic deletion is an 
essential tool for understanding the role of the opioid system in drug 
reward and addictive processes (Lutz & Kieffer 2013b). Indeed, 
pharmacological data in long- term longitudinal studies cannot fully 
reproduce the effects of the deletion of key components of the 
opioid system and cannot provide information about the source of 
endogenous opioid ligands that mediate the behavioural responses 
associated with cocaine rewarding effects.  
In our experimental conditions, no major differences in the 
acquisition of cocaine self-administration were revealed in MOR 
knockout mice, and a tendency to reduce the motivation for cocaine 
was shown in the PR schedule of reinforcement. The discrepancy 
with studies using MOR pharmacological antagonism may support 
the hypothesis of a possible compensatory mechanism after the 




DOR also seems to play an important role in the reinforcing and 
motivational effects of cocaine. In fact, several studies showed a 
diminished release of DA extracellular levels in the NAc of DOR 
knockout mice in response to acute cocaine (Chefer et al. 2004). In 
agreement, studies conducted with pharmacological tools suggested 
that cocaine-induced release of DA in the NAc is partly mediated 
by a DOR-dependent mechanism (Yoo et al. 2012). However, the 
mechanism underlying the role of DOR in mediating cocaine-
induced DA release is still not clear and may depend on the brain 
area analyzed (Ward et al. 2003). Several evidence supported an 
involvement of glutamatergic dependent mechanisms (Fusa et al. 
2005) and a possible MOR–DOR heteromeric interaction (Yoo et 
al. 2012). Our results showed that cocaine self-administration was 
significantly attenuated in DOR knockout mice when trained in 
FR3, but not in FR1, suggesting that the response is impaired only 
when the effort required to obtain the reward is enhanced. A similar 
result was obtained in the operant acquisition maintained by 
chocolate flavoured-pellets (Mancino et al, 2015; in preparation), in 
which DOR-deficient mice decreased active-responses only during 
the FR5 schedule of the operant training. Interestingly, this last 
result could be related to the kind of reinforcer, the palatability 
and/or the caloric content, since no significant differences were 
obtained in DOR knockout mice trained with high-fat food in our 
first study. Other studies showed a decreased operant responding of 
DOR knockout mice when trained to obtain high doses of 
intravenous nicotine in FR1 (Berrendero et al. 2012). In addition, 




cocaine during the PR schedule in our experimental conditions, and 
a similar result was obtained when testing DOR-deficient mice in 
the motivation for chocolate-flavoured pellets (Mancino et al, 2015; 
in preparation). The breaking point is a sensible and validated 
measure of the motivational state of the animal (Arnold & Roberts 
1997) indicating that disruption of DOR reduced the motivational 
properties of cocaine and chocolate-flavoured pellets. All these 
findings highlight the involvement of DOR in the hedonic value and 
the motivational effects of cocaine and palatable food. 
The role of the different families of endogenous opioid peptides in 
cocaine responses is not well understood, although endogenous 
opioid peptides derived from PENK seem to participate in the 
rewarding effects of cocaine and other drugs of abuse, such as 
nicotine (Berrendero et al. 2005; Marinelli et al. 2005). Indeed, it 
was described that DA extracellular levels evaluated by in vivo 
microdialysis in the NAc were reduced in PENK-deficient mice 
after nicotine administration (Berrendero et al. 2005). Moreover, 
long-term cocaine self-administration produced an increased in 
PENK mRNA levels in the ST, NAc, piriform cortex and olfactory 
tubercle and a decrease of these levels in the central amygdala 
(Crespo et al. 2001). In addition, polymorphisms of PENK could be 
involved in the vulnerability of cocaine use disorder (Moeller et al. 
2015). Our results showed an important role of opioid peptides 
derived from PENK in the reinforcing and motivational properties 
of cocaine as revealed by the decreased response of PENK-deficient 




The dynorphin system emerged as a powerful regulator of the 
neurobehavioural consequences of acute and prolonged exposure to 
several illicit drugs, including cocaine (Butelman et al. 2012). 
Indeed, activation of the dynorphin/KOR system produces place 
aversion, social avoidance, and antagonizes the 
reinforcing/rewarding effects of drugs, mainly cocaine, alcohol and 
cannabinoids (Wee & Koob 2010; Mendizábal et al. 2006). Animal 
studies showed that repeated cocaine administration increases levels 
of dynorphin and preprodynorphin mRNA in ST and caudate-
putamen areas (Trifilieff & Martinez 2013). Moreover, selective 
KOR agonists blocked cocaine-induced place preference in rodents 
(Y. Zhang et al. 2004) and decreased cocaine self-administration in 
rats (Schenk et al. 1999) and monkeys (Mello & Negus 1998). In 
contrast, the acquisition of cocaine self-administration and the 
motivation to obtain this drug were not modified in PDYN 
knockout mice in our experimental conditions. In agreement, a 
recent study showed no involvement of the dynorphin/KOR system 
in modulating cocaine self-administration in non-human primates 
(Hutsell et al. 2015). 
A crucial hallmark of addiction is the enduring vulnerability to 
relapse even after long periods of abstinence. The dorsomedial PFC, 
HCP and amygdala and interactions of these regions with the NAc 
core are implicated in the reinstatement of drug seeking produced 
by exposure to stimuli that have previously signalled drug 
administration. In this context, the HCP is important to generate a 
long lasting memory that associates good feelings of drug-intake 




& Grace 2005). These memories, called conditioned associations, 
often lead to drug craving when the addict re-encounters familiar 
environmental circumstances. Different components of the opioid 
system also contribute to reinstatement of cocaine-seeking 
behaviour produced by a cue-stimulus. Previous studies reported 
that the non-selective opioid receptor antagonist naltrexone reduced 
cue-induced cocaine-seeking behaviour in rats, without affecting 
cue-induced sucrose-seeking behaviour (Burattini et al. 2008). 
Evidence that opioid system regulates the reinstatement of cocaine-
seeking behaviour induced by priming or stress was also reported. 
Indeed, repeated treatment with the opioid antagonist naltrexone 
progressively suppressed reinstatement of priming-induced cocaine-
seeking behaviour in rats (Gerrits et al. 2005) and the intra NAc 
injection of selective MOR or DOR agonists reinstated this 
behaviour (Simmons & Self 2009). Moreover, stress causes 
dynorphin release activating KOR in monoamine circuits, which 
results in both potentiation and reinstatement of cocaine and 
nicotine conditioned place preference (Graziane et al. 2013). Our 
results reveal that the reinstatement of cocaine-seeking was 
attenuated in MOR knockout mice. In agreement, pharmacological 
studies showed that the selective MOR antagonist CTAP reduced 
cocaine reinstatement in rats (Tang et al. 2005) and MOR up-
regulation is positively correlated to cocaine craving intensity 
(Zubieta et al. 1996). 
Similarly, in our experimental conditions the reinstatement of 
cocaine-seeking behaviour was significantly reduced in DOR-




deficient ability of DOR knockout mice to form drug-context 
associations rather than deficient reward processes (Le Merrer et al. 
2011). However, pharmacological studies have previously described 
that microinjection of selective DOR agonists in the NAc reinstated 
cocaine-seeking behaviour in rats (Simmons & Self 2009). 
We evaluated the impact of the deletion of the opioid system 
components on neuronal activity in keys brain areas involved in 
addiction during cue-induced reinstatement using c-Fos expression. 
This technique does not provide information about the brain 
pathways involved, but it allows a general simultaneous screening 
of neuronal activity in several brain areas in response to specific 
behaviour. Our results showed that the number of positive c-Fos 
immunostained cells was lower in MOR knockout mice after cue-
induced cocaine reinstatement than in wild-type mice in CA1, CA2 
and CA3 regions of the HCP. This result reflects a decreased 
neuronal activation in brain structures closely involved in memory 
processing after the exposure to the cocaine associated cues when 
the activity of MOR is absent. It could suggest a possible 
implication of MOR in cocaine reinstatement by modifying activity 
of brain areas involved in memory. Furthermore, our study 
demonstrated that cocaine reinstatement decreased the activation of 
positive c-Fos immunostained cells in DOR knockout mice in the 
ST, and in the CA1 region of the HCP. These findings suggest that 
DOR modulates the motivation to obtain cocaine and cocaine 
reinstatement by modifying neuronal activity in brain areas 




In contrast, cue-induced reinstatement of cocaine-seeking behaviour 
was not modified in PENK knockout mice, which suggests that 
other opioid peptides different from those derived from PENK must 
be involved in the reinstatement of cocaine-seeking behaviour. 
However, the number of positive c-Fos immunostained cells was 
decreased in PENK knockout in the ST, amygdala, CA2 and CA3 
regions of the HCP after cue-induced reinstatement. These results 
suggest that the absence of PENK produces changes in several brain 
structures that cause a decrease of neuron activation during the cue-
induced reinstatement session, although these changes may not be 
related with the reinstatement of cocaine-seeking behaviour. 
The reinstatement of cocaine-seeking behaviour was significantly 
increased in PDYN knockout mice, the opposite result to that 
obtained in MOR and DOR knockout mice. In agreement, animal 
studies of cocaine-seeking behaviour reported that the blockade of 
KOR decreased the effects of stress on cocaine-seeking behaviour 
in mice (McLaughlin et al. 2006). Indeed, selective KOR 
antagonists reduced the ability of a footshock stressor to reinstate 
cocaine self-administration in rats (Beardsley et al. 2005), while 
these antagonists had no effects on cue-induced reinstatement of 
nicotine-seeking (Grella et al. 2014). Furthermore, c-Fos mapping 
revealed an opposite result to other lines of opioid knockouts in 
PDYN-deficient mice after cocaine reinstatement. Indeed, the 
number of positive c-Fos immunostained cells induced by cocaine 
reinstatement was enhanced in PDYN knockout mice in the ST, 




neuronal activation in these brain structures related to motor, 
motivation and memory processing.  
In summary, our behavioural and neurochemical results suggest that 
DOR and PENK are involved in the motivation to obtain cocaine, 
and the absence of these opioid components reduces cocaine self-
administration when the effort to obtain the reward is increased. 
Moreover, cocaine reinstatement is reduced in DOR and MOR 
knockout mice, whereas is not modified in the absence of PENK 
and results increased in the absence of dynorphin. Therefore, the 
reduced cocaine reinstatement revealed in MOR and DOR was not 
mediated by the main endogenous ligand of these receptors, 
enkephalins, as the deletion of the two precursors of these 
endogenous opioid peptides, PENK and PDYN, did not mimic this 
behavioural response. In agreement, it was previously demonstrated 
that another MOR and DOR endogenous ligand, beta-endorphin, 
has a crucial role in the rewarding properties of other drugs of abuse 
such as nicotine (Trigo et al. 2009). Thus, further studies are needed 
to investigate the role of this peptide in cocaine addiction and 
reinstatement.  
Previous studies demonstrated the involvement of the opioid system 
in the modulation of the rewarding properties of palatable food 
(Gosnell & Levine 2009; Spangler et al. 2004). Indeed, it is 
currently accepted that the opioid system encodes the 
palatable/hedonic (“liking”) effects of drug and food intake (Zhang 
et al. 2003; Yeomans & Gray 1997), while the motivational 
(“wanting”) aspect is generally exerted by the DA system. In 




the NAc increased sucrose intake in a dose-dependent manner 
(Zhang & Kelley 2002) and POMC mRNA expression was 
increased in the mPFC of rats with chronic access to highly 
palatable food (Blasio et al. 2013). In contrast, the opioid receptor 
antagonist naltrexone did not significantly modify food-seeking 
behaviour (Abdoullaye et al. 2010), nor preference for palatable 
food in rats (Dela Cruz et al. 2012; Baker et al. 2004). However, 
several studies suggested that opioid antagonists preferentially alter 
fat consumption depending on the dose. Indeed, low doses of 
naloxone more specifically reduce fat intake than higher doses 
(Glass et al. 1996a). In our study, the absence of MOR, DOR, 
PENK and PDYN in knockout mice did not modify high fat food-
seeking behaviour, even though these mice were maintained in 
food-deprived conditions. Although restricted access to food may 
facilitate operant responding increasing reinforcer effectiveness and 
the motivation to consume the reward (Raynor & Epstein 2003), 
this condition induces major changes in the central opioid system 
(Wolinsky et al. 1994) making difficult to elucidate opioid system 
functions in food acquisition and reinstatement. Further studies are 
needed to clarify the involvement of this system in high-fat food 
reinforcing effects. 
Our next study investigated the specific involvement of DOR in the 
reinforcing effects, motivation and impulsive-like behaviour 
induced by palatable chocolate food (article 3). In agreement to our 
previous results, several studies did not reveal major implications of 
DOR in the regulation of the rewarding effects promoted by high-




2010). Indeed, the regulation of high-fat food consumption through 
a DOR-dependent mechanism was shown only by the injection of 
high central doses of the DOR antagonist ICI 174,864 that also 
produces motor dysfunction (Islam & Bodnar 1990).  
In our experimental conditions, DOR-deficient mice were trained 
for chocolate-flavoured pellets as a reward and fed ad libitum in 
their home cages with standard diet. As we have previously 
mentioned, our main results are: 1) reduced sensitivity to the 
primary reinforcing effects of chocolate-flavoured pellets, 2) low 
motivation for this reinforcer and 3) reduced impulsive-like 
behaviour displayed by DOR-deficient mice. Impulsivity is a 
predisposing factor associated with the risk of developing addictive-
like behaviour (Jupp et al. 2013). Thus, it can be hypothesized that 
the phenotype of these mice could be potentially associated to a 
protection against developing compulsive-like behaviour over 
palatable food intake. 
A reinforcer is a stimulus that increases the probability of 
strengthening a response and the reinforcer value of that stimulus 
can be defined in terms of the number of responses made to obtain 
it (Epstein et al. 2007). Here, we found that the reinforcing value of 
chocolate pellets was attenuated in DOR-deficient mice during the 
FR5 schedule. Contradictory results were previously reported with 
regards to the involvement of DOR in the reinforcing effects of 
natural rewards. Indeed, chronic administration of the DOR agonist 
SNC80 produced greater reductions in food-maintained responding 
(banana-flavoured food pellets) in monkeys, although cocaine self-




conditions (Do Carmo et al. 2006). When a higher dose of SNC80 
was tested, it eliminated both cocaine- and food-maintained 
responding. These results suggest a non-selective suppression of 
responding for food at the dose in which DOR agonist-induced 
decreases in cocaine self-administration (Do Carmo et al. 2006). 
Similarly, SNC80 decreased response rates maintained by food-
reinforcement in a dose- and time-dependent manner in monkeys 
(Negus et al. 1998; Brandt et al. 2001). On the other hand, region-
specific pharmacological agonisms revealed opposite effects to 
those described. Indeed, selective DOR agonist administration in 
the NAc stimulates palatable feeding (Zhang & Kelley 1997). In 
addition, the intracerebroventricular infusions of DOR agonist, 
DPDPE, enhanced intake at higher (2.5%, 10%), but not lower 
(0.5%), concentrations of sucrose while deltorphin II, increased 
sucrose intake at lower (0.5%, 2.5%), but not higher (10%), solution 
concentrations (Ruegg et al. 1997). Although these findings showed 
a role of DOR in the rewarding aspects of palatable food intake, this 
role still remains unclear since the administration of DOR 
antagonists in the NAc also causes an increase in consumption in 
other studies (Kelley et al. 1996). Moreover, naltrindole, a selective 
DOR antagonist, injected in the ventral pallidum, significantly 
increased the intake of saccharin, but not water (Inui & Shimura 
2014). Conversely, the selective DOR antagonist naltriben reduced 
saccharin responses only with high dose (June et al. 1999). In 
accordance, the constitutive genetic DOR deletion attenuates the 




A differential involvement of DOR in mediating the rewarding 
effects of specific food cannot be discarded to explain the previous 
contradictory results. In fact, the DOR implication in the reinforcing 
properties of chocolate food in our study, but not of high-fat food 
(Gutiérrez-Cuesta et al. 2014; Islam & Bodnar 1990), could suggest 
a possible role for this receptor in mediating this particular food 
preference. Palatability is an important determinant of food reward 
value and it is directly correlated with taste responsiveness that 
promotes food preferences and consumption (Berthoud & Zheng 
2012). In this context, the endogenous opioid system plays an 
important role in the neuronal processing related to palatability. 
Indeed the opioid system seems implicated in increasing the 
consumption of palatable foods, but it has little effect on 
consumption of less pleasant alternative foods (Taha 2010). In this 
line, opioids have been proposed to promote intake of preferred 
foods when choosing between alternatives (Glass et al. 2000). In 
agreement, systemic administration of naltrexone decreased 
preferred food consumption (Glass et al. 1996b) increasing the 
intake of the non-preferred one (Cooper & Turkish 1989). Opioid 
agonists showed a macronutrient-specific effect, increasing food 
intake through preferential increases in fat consumption (Marks-
Kaufman 1982; Zhang et al. 1998; Naleid et al. 2007). Thus, 
systemically administration of morphine preferentially increases fat 
intake (Welch et al. 1994). Although several studies explored the 
effect of opioids on macronutrient preference (fats, carbohydrates 
and proteins) (Marks-Kaufman et al. 1985; Corwin & Wojnicki 




primarily related to the taste or the caloric contenent of these food 
options.  
The potential connection between opioid system and preference for 
chocolate was previously investigated (Drewnowski et al. 1992). A 
previous study reported that enkephalins in the anteromedial 
quadrant of the dorsal neostriatum, but not dynorphins, contributes 
to generating consumption of chocolate. Indeed, rats beginning to 
consume palatable chocolate showed increased extracellular 
enkephalin levels in this brain area (DiFeliceantonio et al. 2012). 
However, the chronic exposure (two weeks) to chocolate liquid 
food reduced enkephalin gene expression in several striatal regions 
of rats (Kelley et al. 2003), as a possible compensatory mechanism 
after chronic chocolate exposure. In addition, epicatechin, a 
flavonoid present in the dark chocolate, seems to have opioid 
receptor binding capacity, specifically with DOR (Panneerselvam et 
al. 2010). In this line, it could be interesting to know which specific 
substances of the chocolate are able to produce rewarding effects. 
Besides the chocolate macronutrient composition, sensory 
properties or psychoactive ingredients such as caffeine and 
theobromine could also contribute to the uncontrolled consumption 
(Bruinsma & Taren 1999). 
 
In our experiment, DOR knockout mice have also shown decreased 
motivation for chocolate-flavoured pellets, in agreement with the 
role of DOR in mediating palatability (Gosnell & Majchrzak 1989). 
In the PR schedule, where the work required to obtain each 




is defined as the last ratio completed. The breaking point is a 
validated measure of the strength of the reinforcer and the 
motivational state of the animal (Arnold & Roberts 1997). Thus, our 
results clearly indicate that the deletion of DOR reduced the 
motivation to obtain palatable food reward. Accordingly, a recent 
study has also reported that the deletion of DOR in mouse forebrain 
GABAergic neurons, mainly in olfactory bulb and ST but not in 
cortex and basolateral amygdala, leads to lower motivation for 
chocolate pellets in an operant paradigm (Chu Sin Chung et al. 
2015). Therefore, these studies provide initial evidence in favour of 
an important role for DOR in processes underlying the motivational 
properties of palatable food intake. 
 
A decreased body weight was found in mice deficient in DOR at the 
end of palatable food operant training in our experimental 
conditions. Accordingly, a previous study showed that DOR 
knockout mice gained less body weight and presented lower fat 
mass than wild-type mice during prolonged exposure to high-fat 
diet, although they were hyperphagic (Czyzyk et al. 2012). This 
reduction of fat mass could be related to the higher energy 
expenditure reported by DOR knockout mice, which was the result 
of an increased activation of thermogenic markers in brown adipose 
tissue (Czyzyk et al. 2012). Taken together these findings highlight 
a role of DOR in the regulation of homeostatic and hedonic 
responses and suggest that DOR inactivation might be effective in 





An involvement of DOR in impulsive-like behaviour induced by 
palatable food was also revealed in our study. Impulsivity has been 
defined as the predisposition toward rapid, unplanned reactions to 
internal and external stimuli without regard for the negative 
consequences of these reactions to themselves or others (Moeller et 
al. 2001). A growing number of studies support a strong association 
between impulsivity and drug (Perry & Carroll 2008) and food-
seeking behaviour (Velázquez-Sánchez et al. 2014). Contradictory 
results have been obtained during the last years about the 
involvement of DOR in impulsive and inhibitory control. Indeed, a 
previous study reported that DOR-deficient mice appeared more 
impulsive, in term of motor responses, than wild-type controls when 
trained to respond for sucrose in a signalled nose-poke task 
(Olmstead et al. 2009). In contrast, our results suggest that DOR-
deficient mice decrease impulsive behaviour promoted by the 
repeated operant training to obtain palatable food. This discrepancy 
may be due to the different reward and experimental protocol used. 
Conversely, another study showed that activation of DOR increased 
locomotor activity, although did not increase the rate of non-
reinforced lever pressing for sucrose (Befort et al. 2011), which 
could suggest that the effect of DOR in impulsive-like behaviour in 
an operant paradigm could be independent of changes in 
locomotion. Moreover, although all these studies focused only on 
one type of impulsivity, the response inhibition or motor 
impulsivity, it is well-known that the construct of impulsivity is 
multidimensional and consists of several different and possibly 




shows that the opioid system also contributes to other types of 
impulsive behaviours. Thus, morphine increases impulsive 
decision-making in different rodent tasks, such as delay discounting 
processes, five-choice serial reaction time task and stop-signal task 
that provide measures of the sensitivity to delayed rewards, 
impulsive choices and response inhibition (Harvey-Lewis & 
Franklin 2015; Pattij et al. 2009; Pitts & McKinney 2005). It should 
not be surprising that different and contrasting results could be 
obtained considering the multiple neural systems involved and the 
different processes participating in impulsive-like behaviours 
(Befort et al. 2011).  
 
In a next step, we have evaluated whether the persistent alterations 
in the reinforcing effects, motivation and impulsive-like behaviour 
revealed in DOR knockout mice and their wild-type littermates 
include structural plasticity changes in the mesocorticolimbic 
system. Several studies reported the involvement of the opioid 
system in synaptic and structural plasticity (Dacher & Nugent 2011; 
Pitchers et al. 2014). Indeed, repeated exposure to exogenous 
opiates caused morphological changes in the VTA (Mazei-Robison 
& Nestler 2012), reduced soma size of DA VTA neurons (Sklair-
Tavron et al. 1996; Spiga et al. 2003; Russo et al. 2007; Mazei-
Robison et al. 2011) and decreased levels of neurofilament proteins 
of the neuronal cytoskeleton in this brain structure (Beitner-Johnson 
et al. 1992). In our study, we observed that repeated operant training 
maintained by chocolate pellets differentially modified spine 




decision-making, learning/memory and motivational processes, in 
DOR-deficient mice and their wild-type littermates when compared 
to non-trained naïve wild-type mice. Indeed, increased total spine 
density was reported in the PFC, HCP and NAc shell of wild-type 
mice trained with palatable food with respect to the non-trained 
naïve wild-type mice and the DOR-deficient group trained with 
palatable food. In contrast, reduced spine density was observed in 
the PFC of DOR knockout mice trained to obtain chocolate pellets 
with respect to non-trained naïve wild-type mice. On the other hand, 
no significant modifications in total spine density were observed in 
the NAc core of all mouse groups. Similar results were obtained in 
a previous study, in which no alteration of dendritic spine density in 
the NAc core area was reported after the training with palatable 
food in wild-type mice (Guegan et al. 2013). These results support 
even more the hypothesis that core and shell structures are involved 
in different aspects of feeding behaviour (Parkinson et al. 2002; 
Peciña & Berridge 2005). In this sense, the NAc core plays a more 
prominent role in the elaboration of habit learning promoted by 
conditioned association of natural reward-related stimuli (Everitt & 
Robbins 2005), while the NAc shell encodes pleasurable sensation 
derived from food consumption, and contributes to motivational 
aspect of food seeking behaviour (Baldo & Kelley 2007). In 
agreement, a recent study reports that during cued food reward 
delivery, DA release increased significantly in the NAc core, but 
not in the shell subregion of rats while, during the extinction period 
(24 h), DA significantly decreased in the NAc core, but not in the 




DA release increased in the NAc core only during signalled reward 
and this increase could be independent of the positive or negative 
hedonic valence of the taste stimulus and probably linked to 
associative learning mechanisms (Day & Carelli 2007). In our study 
increased density of “memory” or mushroom spines is the only 
modification reported in the NAc core between wild-type mice 
trained to obtain palatable food and non-trained naive wild-type 
mice and, although not significant changes were revealed between 
DOR-deficient mice trained with palatable food and non-trained 
naive wild-type mice. These changes are likely due to the training 
effect, although modification in total spine density was not reported 
in this brain area, as previously described.  
Our results highlight the notion that spine formation, turnover and 
morphology are a consequence of the synaptic activity induced by 
the training with palatable food, which activity is central to memory 
formation, learning and motivation and it seems to be mediated by 
DOR. Similar structural plasticity changes in the reward circuit 
induced by chronic exposure to psychostimulants or nicotine were 
hypothesized to participate in the development of the addictive-like 
behaviour (Russo et al. 2010). However, drugs of abuse also 
extensively modify dendritic spine density in the NAc core (Russo 
et al. 2010), suggesting that morphological alterations in this region 
might play a more prominent role in mediating the effects of drugs 
of abuse than palatable food (McFarland et al. 2003). The present 
findings are of relevance to further support the hypothesis that drugs 
and natural rewards, such as palatable food, can influence similar 




palatable food, like drugs of abuse, can potentially alter the 
mechanisms involved in the rewarding processes.  
 
In summary, our results showed a critical role of the opioid system 
in cocaine-reinforcing effects and reinstatement. These results 
suggest that dysregulation of this system may contribute to 
differences in vulnerability to cocaine addiction and relapse. Our 
data also highlighted the role of DOR in the reinforcing effects and 
motivation for palatable food. However, these effects seem to 
depend on the kind of food consumed. In addition, DOR is involved 
in mediating neuroadaptations in principal rewarding areas such as 
PFC, HCP and NAc shell after prolonged operant training 
maintained by chocolate food. To conclude, our results provide 
some advances in the understanding of the common links between 
eating disorders and drug addiction, and highlight the relevance of 
the endogenous opioid system as potential therapeutic targets to 
treat different addictive-like disorders. 
 
Involvement of the CB1R and CB2R in addictive-like behaviour 
promoted by palatable food (article 2 and 4) 
 
Behavioural and neurobiological overlaps have been observed 
between eating and addictive disorders. However, controversial 
arguments about applying the addiction framework to problematic 
eating behaviour are still reported. Although food is necessary for 
survival, the highly palatable processed foods associated with eating 




(Schulte et al. 2015). In this context, the identification of molecular 
factors that could be involved in the loss of control over food intake 
is an important step for further interventions. In this second part of 
the thesis, we first validated an animal model of eating addictive-
like behaviour based on the DSM-5 substance use disorder criteria, 
and we evaluated protein expression changes in the main brain 
regions of the reward system of mice showing a compulsive eating 
behaviour (vulnerable to addiction) and in mice that did not show 
this behaviour (resistant to addiction) (article 2). We also evaluated 
the implication of the CB1R in eating addictive-like behaviour 
through epigenetic, genetic and pharmacological approaches (article 
2). In addition, we investigated the possible involvement of CB2R 
in the vulnerability to develop this addictive-like behaviour (article 
4). 
We assessed addictive-like behaviour using 3 criteria resembling 5 
of the 11 DSM-5 hallmarks of addiction referred to loss of control: 
1) persistence of food-seeking during a period of non-availability of 
food, 2) motivation for food and 3) perseverance of responding 
when the reward was associated with a punishment. These are the 
core components of drug addiction across highly reinforcing 
behaviours and the overconsumption of highly palatable foods can 
result in the same behavioural outcome (Gearhardt et al. 2009a).  
Palatability represents a key factor that influences motivation to 
seek and consume chocolate-flavoured pellets. Despite the 
increased effort required to obtain food (FR5) in our experimental 
conditions, mice trained with palatable food displayed higher levels 




agreement, a previous study showed that palatable pellets improve 
the performance of operant training when compared with standard 
diet (Barbano et al. 2009). Indeed, mice and rats readily acquired 
the operant task reinforced by palatable food and were highly 
motivated to obtain such tastants as measured by the maximum 
number of responses required to earn rewards on fixed and PR 
operant behavioural schedules (Alsiö et al. 2009; Salamone et al. 
2001). These results suggest that palatable food could potentially 
alter the functionality of the brain reward circuit generating a 
pathologic motivational state towards hedonic foods that could 
facilitate compulsive eating in certain patterns of consumption 
(Johnson & Kenny 2010). It is important to emphasize that in our 
study mice were not subjected to a food deprivation regimen, an 
experimental procedure currently used to facilitate operant 
conditioning maintained by food. Therefore, the loss of control over 
palatable food seeking shown in our experiment was not influenced 
by this factor. In our experimental conditions, repeated and long-
term exposure to palatable food produced compulsive seeking 
behaviour in a consistent mouse subpopulation, as evaluated by the 
three criteria of addiction previously mentioned.  
A possible misconception is that all individuals exposed to hedonic 
substances lose control over behaviour. Indeed, highly addictive 
drugs, like cocaine, are used on a regular basis by certain 
individuals, but not all involved individuals become addicted 
(Tossmann et al. 2001; Reboussin & Anthony 2006). Similarly, the 
entire western population is exposed to an energy-dense food 




over food intake and presents overeating and/or eating disorders. 
Genetic vulnerability could play an important role in the 
development of this complex disease. In our experimental 
conditions, only 14.7% of mice trained with chocolate pellets 
reached the 3 criteria of addiction and 7.4% achieved 2 criteria, 
whereas none of mice trained with standard pellets achieved these 
2-3 criteria. This percentage of mice reaching the 2-3 criteria for 
palatable food reflects the high percentage of population with 
vulnerability to develop addiction-like behaviour despite identical 
opportunity to seek for chocolate-flavoured pellets in the whole 
genetically heterogeneous mouse population exposed to this 
experimental model. As expected, mice reaching this high score 
showed highest responses in the three addiction like-criteria tests 
when compared with mice reaching the low score for standard and 
chocolate trained mice. In addition, differences between these 
subpopulations were also revealed in impulsive like-behaviour 
measured by the number of active lever-presses during the time-out 
period. In this line, long-term operant training with palatable pellets 
appears to alter inhibitory control processes and produce an 
unadapted response only in mice reaching the high score. These 
mice showed enhanced operant responses even when no reward can 
be obtained and are incapable of withhold an anticipated response. 
In accordance to our results, a previous work also described the 
emergence of elevated impulsive behaviour with extended period of 
operant training with palatable food (Ghitza et al. 2006; Diergaarde 




palatable food can promote the development of impulsive-like 
behaviours and potentially lead to compulsive food intake.  
 
The identification of a subgroup of mice losing behavioural control 
supports the hypothesis that addictive-like behaviour represents a 
pathologic continuum from controlled to compulsive use that is 
only reached by a limited percentage of users (Piazza & Deroche-
Gamonet 2013). Therefore, inter-individual differences in reaction 
to food could certainly account for the transition from controlled to 
compulsive food intake, similarly to those that facilitate the shift 
from drug use to addiction (Le Foll et al. 2009). However, like other 
common complex disease, addiction has a multifactorial and 
polygenic component that does not conform to a simple Mendelian 
transmission pattern. These complex disorders are likely associated 
with the effects of multiple genes in combination with lifestyle and 
environmental factors (Hamer 2002; Nestler 2014). The persistence 
of maladaptive behaviours suggests that long-lasting changes in 
gene expression occurred within particular regions of the brain in 
these complex diseases. Epigenetics can be viewed as the vehicle 
through which environment interacts with an individual genome to 
determine life-long molecular and behavioural modifications 
(Nestler 2014). Epigenetic mechanisms produced by repeated 
exposure to drugs have been reported to participate in addictive-like 
behaviour (Schroeder et al. 2008), and could also be involved in the 
development of eating addiction. In our study, operant conditioning 
maintained by highly palatable chocolate food produced adaptive 




addiction-like criteria reached by mice. Specifically, mice that 
accomplished the 2-3 criteria showed a significant reduction in 
DNA methylation at CNR1 gene promoter in PFC, which led to an 
up-regulation of CNR1 gene expression and the subsequent increase 
of CB1R protein in the same brain area. Differential changes were 
also observed in CNR1 gene expression in the NAc and HCP of the 
addict-like mice, although they were not functionally relevant since 
no modification was revealed at the CB1 protein level, the ending 
product of this genetic information. Growing evidence supports the 
notion that CB1R plays a crucial role in the reinforcing and 
motivational properties of highly palatable food (Maccioni et al. 
2008) and converging studies have led to hypothesized a link 
between alterations in the ECS and eating disorders. At the 
peripheral level, elevated levels of CB1R mRNA were detected in 
the blood of women suffering from anorexia and bulimia nervosa 
(Frieling et al. 2009) and increased CB1R expression at the central 
level were shown in the insula and frontal and temporal cortex of 
anorexic and bulimic patients (Gérard et al. 2011). A large body of 
evidence also reported that the ECS becomes over activated in 
obesity and that diet-induced obesity elevates HCP levels of 
endocannabinoids and CB1R binding (Thanos et al. 2008; Massa et 
al. 2010). One possible explication to this phenomenon is that 
dietary conditions can influence central and peripheral ECS 
regulation, which could contribute to promote obesity and eating 
disorders (Carr et al. 2008). Indeed, diet-induced changes in the 
ECS affect not only tissues directly involved in the metabolic 




eating and influencing cognitive processes, such as the HCP (Massa 
et al. 2010). Notably, rats exposed to a sweet palatable food diet for 
10 weeks to induce obesity showed a decreased CB1R density in 
the HCP, cortex, NAc and entopeduncular nucleus, and this 
decrease was inversely correlated with the intake of palatable food 
(Harrold et al. 2002). This decrease in CB1R density could be 
interpreted as the resulting effect of an increased activity of these 
receptors by endogenous cannabinoids. In fact, chronic treatment 
with cannabinoid agonists is associated with parallel differentially 
compensatory decreases in CB1R density, CB1R mRNA expression 
and G-protein subunit expression in the forebrain, cerebellum and 
mesencephalon (Rubino et al. 1997; Hoffman & Lupica 2013; 
Breivogel et al. 1999; Fan et al. 1996; Zhuang et al. 1998). As 
already described, the opposite CB1R regulation was found in our 
study, in which CB1R protein level was increased in the PFC of 
addicted animals. This increase could be interpreted as the result, or 
the determinant, of the loss of control over palatable food intake 
presented by this addicted vulnerable subpopulation. Moreover, 
CB1R mRNA levels were also found to be differentially regulated 
depending on the schedule of access to high palatable food. Thus, 
CB1R mRNA levels increased in the nucleus tractus solitarius of 
rats with continuous access to highly palatable sweet for 6 week, 
and decreased in the cingulate cortex of rats with intermittent 
feeding schedule of this palatable food (Bello et al. 2012). 
Our results suggest that long-term daily exposure to palatable food 
leads to alterations of food-seeking behaviour through a CB1R 




dysregulations of the glutamatergic excitatory and GABAergic 
inhibitory synaptic inputs in several brain regions where CB1R acts 
as a regulatory feedback mechanism to modulate synaptic 
transmission (D’Addario et al. 2014). Previous studies proposed a 
bimodal regulation of food intake by CB1R in cortical 
glutamatergic transmission, responsible for the orexigenic effect 
and by CB1R in ventrostriatal GABAergic neurons mediator of the 
hypophagic action by reducing local inhibitory transmission 
(Bellocchio et al. 2010). The cortex contains high levels of CB1R in 
all of its subfields (Glass et al. 1997; Tsou et al. 1998). However, 
the expression pattern of CB1R in the different neuronal 
populations within the cortical subregions is a topic of continuous 
investigation. Almost all cortical neurons expressing CB1R at high 
or moderate levels constitute a subpopulation of GABAergic 
interneurons (Marsicano & Lutz 1999). However, glutamatergic 
neurons in cortical regions contain CB1R at low levels (Monory et 
al. 2006). Although CB1R on cortical glutamatergic cells are less 
abundant, they produce more pronounced effects than on 
GABAergic cells (Steindel et al. 2013). Moreover, anatomical data 
indicate that the predominant localization of CB1R is on axonal 
terminals in all cortical regions examined (Egertová & Elphick 
2000). Considering this evidence, we hypothesized that the CB1R 
epigenetic regulation in PFC and the subsequent translation in 
increased CB1R protein levels found in our study may inhibit the 
primary glutamatergic neuronal output of this region, as already 
described in other studies (Steketee 2003). This CB1R 




glutamate release in the NAc and reduce the activation of NAc 
GABAergic inputs to VTA, removing the inhibitory modulation on 
DA neurons, as already reported (Lupica et al. 2004; Melis et al. 
2004). Hence, CB1R acting indirectly via pre-synaptic neuronal 
inhibition (Szabo et al. 2002), may ultimately affect brain reward 
processes through their ability to enhance extracellular DA levels in 
the NAc (Figure 27) (Fadda et al. 2006; Lecca et al. 2006). This 
hypothesis was supported by data showing that the alterated 
glutamate transmission in the PFC responsible of behavioural 
inhibition (López-Moreno et al. 2008) mediates behavioural 
modifications associate to addiction (Kalivas 2004). Indeed, the 
decreased glutamatergic activation and the functional impairment of 
cortical areas seem to contribute to the impulsive drug intake seen 
in addicted individuals (Volkow & Fowler 2000). This is in line 
with the increased impulsive behaviour observed in mice that 





Figure 27. Schematic representation of the first possible mechanism involved in 
eating addictive-like behaviour mediated by the CB1R. Post-synaptic GABAergic 
medium spiny neurons in the NAc receive glutamatergic, DA and GABAergic 
inputs. Both glutamatergic and GABAergic presynaptic terminals contain CB1R, 
and are thus regulated by endocannabinoids (eCBs). Under physiological 
conditions, CB1R exerts a regulatory modulation of glutamate and GABA release 
in the NAc, and subsequently modulates the activation of the GABAergic 
medium spiny neurons. Long-term training with highly palatable pellets promotes 
an enhanced DA release in the NAc, together with a possible unbalance between 
GABA and glutamate release. This unbalance may be due to the increased CB1R 
expression at the glutamatergic PFC projections toward the NAc able to inhibit 
glutamate release, and thus producing the decrease of the GABAergic tone. This 
lower activation of NAc GABAergic inputs to VTA is followed by an increase in 
the VTA DA neuronal firing responsible of the food rewarding effects. Although 
the system is more complex, this figure would represent a simplified theoretical 
and hypothetical tool to understand the mechanism proposed (adapted from 





On the other hand, we can also hypothesize a different scenario in 
the neurotransmitter systems regulated by CB1R. Indeed, the 
projections from PFC to the NAc and the VTA are both 
glutamatergic (Kalivas et al. 2005). Glutamate transmission exerts a 
potent excitatory effect on DA neurons of the VTA, influencing 
both DA neuron activity and the regulation of the firing properties 
of these neurons (Geisler & Wise 2008). In this context, it was 
reported that acute cocaine sensitizes the glutamatergic input from 
the PFC and enhances the induction of long-term potentiation in DA 
cells (Almodóvar-Fabregas et al. 2002). However, as previously 
described, CB1R in the PFC is more abundant on GABAergic 
interneurons (Steindel et al. 2013).  
On this background, we could hypothesize that the CB1R 
overexpression found in our study is at the GABAergic interneuron 
level of the PFC. This could lead to a reduced GABA release from 
these neuronal subpopulations with the following increase of the 
firing rate of glutamatergic cortical principal neurons in the PFC 
(Figure 28). This increased excitatory transmission projected to the 
VTA, could directly stimulate VTA DA neurons, resulting in a 
major release of DA in the NAc. In support to this second 
hypothesis, several studies report that acute administration of WIN 
55,212-2 into the PFC of rats causes a dose-dependent inhibition of 
the extracellular levels of GABA (Ferraro et al. 2001). At the same 
time, we hypothesized that the over activated cortical glutamatergic 
transmission could stimulate the GABAergic neurons of the NAc as 
a possible mechanism to compensate the excessive DA release. In 




relative level of activation of these inputs under distinct behavioural 
circumstances (Maldonado & Berrendero 2010). In this context, 
several studies also reported that activation of PFC regions could be 
associated with the enhanced desire and craving for the drug 
(Volkow & Baler 2014; Volkow et al. 1991; Volkow & Fowler 
2000). Indeed, the anterior cingulate cortex, ventral orbital cortex 
and amygdala activities are increased during craving for a variety of 
addictive drugs (Goldstein & Volkow 2002). The imbalance in 
glutamatergic transmission is commonly observed in addicted 
individuals and alteration of this excitatory signalling could lead to 
the relapse of drug use (Volkow et al. 2008; Addolorato et al. 2005; 
Volkow & Baler 2014). However, a clear explanation of the 
glutamatergic neurotransmission regulation mediated by CB1R in 
different reward areas within stages of addiction is not yet available. 
Our results together with previous studies suggest that the CB1R 
plays an important role in mediating palatability-induced rewarding 
effects and that its modulation in the PFC could lead to the 






Figure 28 Schematic representation of the second possible mechanism involved 
in eating addictive-like behaviour mediated by the CB1R. Cortical neurons 
express CB1R at GABAergic and glutamatergic interneurons. However, low 
levels of CB1R were found in these glutamatergic terminals, whereas high levels 
were revealed at GABAergic interneurons (Marsicano and Luz, 1999). Under 
physiological conditions, CB1R exerts a regulatory modulation of glutamate and 
GABA release at both levels, and subsequently modulates the activation of the 
glutamatergic principal neurons. Long-term operant training with palatable food 
could promote an increase of CB1R level at cortical GABArgic interneurons 
producing a decrease of GABA release, followed by an increase in the activation 
of glutamatergic principal neurons. This increased excitatory transmission 
towards the VTA could directly stimulate the firing rate of VTA DA neurons with 
the consequent release of DA in the NAc. At the same time, glutamatergic 
projections stimulate GABAergic neurons in the NAc to compensate the 





Pharmacological procedures with a selective CB1R antagonist and 
genetic approaches with constitutive CB1R knockout mice were 
also performed in our study to clarify the involvement of CB1R in 
the development of this eating addictive-like behaviour. The 
pharmacological treatment with the CB1R antagonist rimonabant (3 
mg/kg) reduced food-seeking behaviour, as shown by the lower 
active lever-presses during the FR5 schedule. Moreover, 
rimonabant treatment in the late training period reduced the 
percentage of mice that reached high addiction scores. Thus, none 
of rimonabant treated mice reached the 3 criteria, whereas 67% 
achieved 0 criteria. In contrast, 13% of vehicle treated mice reached 
the 3 criteria and 20% 2 criteria, similarly to the previous 
experiment (14.7% and 7.4%). However, the responses in the three 
behavioural tests were decreased with respect to the previous 
experiment, as expected considering the stressor event that 
represents the repeated intraperitoneal injection. Moreover, mice 
treated with rimonabant reaching the 0 criteria showed decreased 
responses in the three criteria tests, consumed significantly less 
palatable pellets and showed less impulsive-like behaviour when 
compared with mice treated with saline. In support to our results, 
the pharmacological blockade of CB1R reduces the enhanced 
motivation for cocaine developed by rats that have previously 
escalated their cocaine intake (Orio et al. 2009). Several studies also 
showed that blockade of CB1R by rimonabant (3 mg/kg) reduces 
operant responses for palatable food in both FR and PR schedule in 
animals fed ad libitum, while administration of the CB1R agonist 




Moreover, previous studies have also demonstrated that rimonabant 
administration in food-deprived animals decreased operant 
responses and intake of both palatable and non-palatable foods 
(Freedland et al. 2000; Pério et al. 2001), in accordance with the 
well-described role of endocannabinoids in the regulation of 
appetite and orexigenic signalling (Di Marzo & Matias 2005). Thus, 
our results showed that CB1R mediates the reinforcing effects and 
the motivation for palatable food. Similarly, CB1R knockout mice 
trained with chocolate-flavoured pellets significantly reduced 
operant seeking-behaviour during the FR1 and FR5 in our 
experimental conditions compared to wild-type mice. The decreased 
operant responses obtained in these knockout mice do not seem to 
be a consequence of a learning/memory impairment as reported in a 
previous study conducted in our laboratory demonstrating that the 
self-administration of natural rewarding stimuli, such as water and 
standard food, was not altered in CB1R knockout mice (Soria et al. 
2005). Moreover, the percentage of CB1R knockout mice that 
reached addiction criteria was significantly lower than WT mice, 
and none of CB1R knockout mice reached the 3 or 2 criteria in the 
late training period. These CB1R knockout mice also showed 
decreased operant responses during the time-out period, which can 
be related to reduced impulsive behaviour with respect to wild-type 
mice. In agreement, the administration of CB1R agonists and 
antagonists enhanced and decreased, respectively, certain forms of 
impulsive-like behaviours (McDonald et al. 2003; Pattij et al. 2007). 
In summary, the pharmacological or genetic disruption of CB1R 




prevented the transition to addiction that evolves from controlled to 
compulsive intake. 
Hedonic food consumption does not only depend on the functional 
expression and activity of the CB1R in the reward 
mesocorticolombic pathway, but also it depends on interactions 
between CB1R and homeostatic signals involved in the modulation 
of the appetite (Cristino et al. 2014). Indeed, homeostatic and 
hedonic neural circuits are closely interlinked and the CB1R, at 
central and peripheral level, is involved in the regulation of 
appropriate responses in terms of food intake and energy 
homeostasis. Thus, the endocannabinoid signalling in the 
hypothalamus seemed to be inversely correlated with leptin plasma 
levels (Di Marzo et al. 2001b). Such a tight cross-talk between the 
ECS and leptin also affects the activity of the brain reward system. 
Indeed, obese rats with defective leptin signalling showed increased 
CB1R expression in frontal, limbic and striatal brain structures 
(Thanos et al. 2008). Moreover, the endocannabinoid signalling in 
the small intestine serves as an orosensory positive feedback 
mechanism that facilitates reward intake (DiPatrizio et al. 2011). 
Therefore, it is possible that the deletion of this receptor leads to a 
decrease of the incentive value and appetite for chocolate food in 
mice reaching the low score under our experimental conditions. 
This relationship between the network governing energy and 
rewarding homeostasis has profound implications for the prevention 
and treatment of various eating disorders, including some forms of 





Epigenetic studies can help to clarify gene regulation involved in 
the development of behaviours, but cannot provide insight of post–
translational modifications in the protein product. Therefore it is 
necessary to evaluate the proteome in order to understand the 
intricate neuro-adaptive machinery involved in addictive processes 
and to know whether palatable food, a reinforcer experienced daily, 
causes molecular adaptations in terms of protein expression 
modification. Palatable diets in the modern environment may be 
harmful not only because of ensuing weight gain and the associated 
health risks, but also because adaptations have occurred in the 
neurobiology of the individual, driving the overeating of palatable 
food away from voluntary control into compulsivity (Alsiö et al. 
2009). Proteomic studies contribute greatly to understand gene 
functions and offer the potential to provide a global view of the 
neurobiological changes underlying addiction and to identify key 
proteins involved in compulsive drug and food overintake (Lull et 
al. 2010). However, technical limitations of proteomic studies were 
reported in terms of sensitivity and lagging technological 
capabilities in this field (Lull et al. 2010). Addiction science 
typically focuses on neuronal populations, although these cells 
comprise only 20-30% of the total cellular population in the brain 
tissue (Singh et al. 2003) and the neuronal spatial distribution 
makes difficult to ensure that the entirety of cell population is 
subjected to proteomic analysis (Lull et al. 2010), which represent a 
limitation in the use of proteomic tools in neuroscience. 
Additionally, rarer proteins are often masked by more abundant 




Moreover, the proteomic technique used in the present study did not 
allow the entire detection of the membrane proteins since the 
technique is focused principally in metabolic cell processes. 
Nonetheless, proteomic studies have revealed in our experimental 
conditions differential changes in protein expression and in the level 
of phosphorylation of synaptic proteins depending on the 
experimental subgroup and the brain area analyzed (Table S3 and 
S4 of the article 2). We distinguished between proteins and 
phosphoproteins because the enrichment in phosphoprotein or 
phosphopeptide content could help to identify the activation of 
particular proteins or pathways. Indeed, phosphorylation is a key 
reversible modification occurring mainly on serine, threonine or 
tyrosine residues as a post-translational modification that can 
regulate enzymatic activity, subcellular localization, complex 
formation and degradation of proteins (Delom & Chevet 2006). A 
change in phosphorylation status may reflect a modification in 
protein activity, and can provide new insights to clarify the intricate 
cellular network involved in these addictive-like processes.  
Protein expression profiles were compared in the three brain regions 
studied and several changes in the expression of proteins involved 
in structural, transport, motor, signal transducer, catalytic processes 
were identified within subgroups as result from the list of proteins 
(Table S3, S4 of the article 2). Changes in the expression of proteins 
related to intracellular trafficking and cell organelles, Golgi 
apparatus and endoplasmic reticulum, allow proposing effects on 
the development of neuronal growth cones, axonal positioning and 




2012). Modifications in the expression of proteins involved in the 
cell adhesion and structural and motor activity of the cytoskeleton 
microfilaments allow to hypothesize regulation of the spine growth, 
synapse morphology and formation of new synapses (Matus Ortega 
et al. 2012.; Gu & Zheng 2009). Expression changes in proteins 
involved in signal transducer could suggest an alteration in the 
synaptic transmission. Modifications in the expression of proteins 
related to lipid and cholesterol metabolisms suggest changes in 
neuronal functions, plasticity and central nervous system 
myelination, similar to changes described after the administration of 
drugs of abuse (Samaha et al. 2004). In this line, all the proteomic 
data were compared to previous studies with drugs of abuse in order 
to identify similar molecular targets underlying addictive-like 
behaviours.  
Specific common proteins in the three brain areas selected, related 
to impulsive-like behaviour, synaptic plasticity and cannabinoid 
signalling were validated by immunoblot techniques: α-synuclein 
(α-Syn) (impulsive control: Ambermoon et al. 2011), protein 
phosphatase 1α and doublecortin-like kinase 2 (PP1α, DCalmK 2) 
(synaptic plasticity processes: Edelman et al. 2005; Hou et al. 2013) 
and diacylglycerol kinase zeta (DGKζ) (regulation of the 
endocannabinoid activity: Liu et al. 2001). Immunoblot remains the 
staple for confirming and validating proteomic results and it is a 
useful tool for measuring total levels of a specific protein (Lull et al. 
2010). However, the major limitations to antibody-based 
immunoblot confirmations are the relatively low throughput nature 




increased α-Syn level was revealed in the HCP of mice reaching the 
high score and in the PFC of mice with low score trained with 
chocolate pellets, while a decreased expression of the same protein 
was found in the ST of mice trained with standard pellets. α-Syn is 
an important regulator in DA transmission. It interacts with the DA 
transporter, and regulates DA neurotransmission and synaptic 
strength of DA neurons (Boyer & Dreyer 2007). Our data and the 
literature support the idea that a positive correlation exists between 
drug and palatable food over intake and increased α-Syn levels. 
Indeed, α-Syn seems implicated in impulsive control disorder, such 
as drug addiction (Pena-Oliver et al. 2012), and it is expressed in 
axons and presynaptic terminals of neurons located in brain areas 
responsible for emotions and memory, mainly in the HCP (Taguchi 
et al. 2014). Mice deficient in this protein showed impaired spatial 
learning and working memory (Kokhan et al. 2012). In agreement, 
our results showed increased α-Syn protein expression in the HCP 
of the addict-like group, which it leads to speculate not only 
enhanced impulsivity in these mice, but also a greater learning 
ability. Nevertheless, future studies are needed to determine 
whether the increased α-Syn protein levels induced by drug and 
palatable food is one of the adaptive mechanisms to mediate 
addiction. 
Protein expression modifications associated with synaptic and 
structural plasticity changes are also reported in our study. Synaptic 
plasticity and structural neuronal reorganization underlie learning 
and memory functions. In this line, the characterization of addiction 




evaluate the effects of drugs on the cellular events, cascade 
signalling and proteins related to synaptic plasticity (Thomas et al. 
2008). The molecular mechanisms involved in the structural 
adaptations induced by the synaptic activity are still not completely 
understood (Lamprecht & LeDoux 2004). Here, we focus only on 
two proteins that could contribute to mediate some of the 
behavioural changes that define addiction. Indeed, we found 
increased DCalmK 2 expression in HCP and ST of mice reaching 
the 2-3 criteria and 0 criteria trained with chocolate, respectively. 
This protein is generally involved in the maturation of dendritic 
spines and this process could underlie eating addiction. 
It is well-known that structural plasticity modifications could spring 
from neuronal activities. Therefore, PP1α expression changes, a 
protein involved in synaptic plasticity, were also analyzed and an 
opposite regulation in the expression of this protein was found 
between HCP and ST in addict-like mice. This protein seems to be 
important for triggering LTD through the DA-induced 
phosphorylation of DARPP-32 (Yan et al. 1999). The DA DARPP-
32 signalling pathway integrates glutamate and DA signals in 
midbrain DA neurons regulating fronto-striatal functions and 
plasticity, and it was related to several behavioural alterations 
including drug addiction (Albert et al. 2002; Svenningsson et al. 
2005; Fernandez et al. 2006).  
An overexpression of DGKζ protein was selectively observed in 
HCP and ST of chocolate trained mice obtaining 0 criteria. DGKζ 
seems to modulate the cannabinoid signalling (Gantayet et al. 




DGKζ and CB1R in specific brain areas under our experimental 
conditions, although more studies are needed to confirm this 
hypothesis.  
Although the relative importance for these protein adaptations 
largely remains to be determined, they likely represent the sustained 
molecular changes underlying the behavioural outcome of repeated 
training with palatable food. These adaptations could play important 
roles in the development of the compulsive food-seeking and –
taking behaviours characteristic of addiction. 
In conclusion, our research validated for the first time an operant 
model of eating addiction in a heterogenic mouse population 
allowing to identify extreme subpopulations, vulnerable or resistant 
to addiction. We detected in these subpopulations specific 
epigenetic and proteomic alterations in HCP, ST, NAc and PFC. 
Changes in DNA methylation at CNR1 gene promoter and its 
encoding transcript were observed in PFC. The involvement of the 
CB1R in the development of this addictive-like behaviour was also 
demonstrated by using genetic and pharmacologic approaches. 
Moreover, we identified proteins expressed in different 
subpopulations of mice that have allowed formulating novel 
hypotheses on the molecular mechanisms orchestrating eating 
addiction. These changes could participate in the biological 
substrate underlying the behavioural alterations that could 
eventually lead to eating-related disorders and provide an important 
advance in understanding the mechanisms engaged in hedonic 





Our previous study revealed a crucial involvement of the CB1R in 
the addictive-like behaviour promoted by palatable food. In our 
following study (article 4), we investigated the possible implication 
of CB2R in the compulsive palatable food consumption using the 
same behavioural model. Previous studies reported that CB2R 
might be associated with addiction vulnerability due to its possible 
involvement in the modulation of the reward system (Zhang et al. 
2014). It was hypothesized that CB2R could be present in local DA 
terminals of the NAc and here it may inhibit DA release (Morales & 
Bonci 2012). Alternatively, CB2R may influence the activity of 
NAc resident GABA medium spiny neurons or cholinergic neurons, 
as well as glutamatergic inputs (from the PFC, HCP and others) that 
could regulate either release of DA or the activity of the GABA 
medium spiny neurons (Morales & Bonci 2012). Another 
possibility is that modulation of the secretion of cytokines by 
activation of CB2R in microglia may influence DA levels or 
neuronal signalling (Morales & Bonci 2012). In this regard, 
emerging evidence suggests that under normal conditions microglia 
plays an important role in remodelling synaptic circuits, influencing 
synaptic structure and establishing dynamic interactions with 
presynaptic and postsynaptic neuronal elements (Tremblay et al. 
2011). However, whether and which neurons express CB2R under 
normal conditions is still a matter of debate. Further studies are 
required to determine how CB2R modulates DA neurotransmission 
and finding the precise distribution of CB2R within the NAc is 
crucial to answer this question. Accordingly, contradictory results 




by CB2R with different drugs of abuse. Indeed, attenuation of 
nicotine seeking-behaviour was revealed in mice lacking CB2R 
(Navarrete et al. 2013), although no modification of this behaviour 
after selective CB2R agonist or antagonist injections was reported 
in rats (Gamaleddin et al. 2012b), maybe due to the use of different 
experimental conditions. Moreover, the down-regulation of CB2R 
expression in midbrain appeared to facilitate alcohol reinforcing 
effects (Onaivi et al. 2008; Ishiguro et al. 2007) and polymorphisms 
in the CB2R gene could influence alcoholism vulnerability 
(Ishiguro et al. 2007). Furthermore, reduction of cocaine-induced 
place preference and self-administration were reported by 
transgenic mice overexpressing CB2R (Aracil-Fernández et al. 
2012) and intra-NAc local administration of JWH133, a selective 
CB2R agonist, dose-dependently inhibited intravenous cocaine self-
administration, cocaine-enhanced locomotion, and cocaine-
enhanced NAc extracellular DA in wild-type, but not in CB2R 
knockout mice (Xi et al. 2011b). In addition, activation of CB2R by 
JWH133 inhibited VTA DA neuronal firing during cocaine self-
administration in wild-type mice (Zhang et al. 2014). The possible 
explanation of these last findings could be that the inhibitory effect 
of JWH133 on cocaine consumption may be mediated by activation 
of CB2R at the presynaptic level on the ventral DA projection in the 
NAc. Our results using a natural reward showed that the genetic 
disruption or overexpression of CB2R had not major consequences 
in the operant behaviour maintained by chocolate-flavoured pellets 
during the FR1 and FR5 schedule of reinforcement. In this line, no 




of the CB2R antagonist SR144528 in mice deprived of food for 24 
hours were found in a previous study (Wiley et al. 2005). However, 
a significant increase in food intake was reported in rats that 
received intra-cerebroventricular injections of the CB2R antagonist 
AM 630 following a 12-hr fast was described (Werner & Koch 
2003). In our experimental conditions, we show that CB2R does not 
seem particularly involved in the reinforcing properties of palatable 
food, although a trend to increase active responses was reported 
only by CB2R knockout mice. Although no significant differences 
in the acquisition were revealed between genotypes, this does not 
mean that this receptor is not involved in addictive-like behaviour. 
In fact, addiction is not just the taking of the drug, but it is also 
measured by the appearance of drug-related behavioural problems 
and high motivation for the drug (Piazza & Deroche-Gamonet 
2013). When all groups of mice were tested for the three criteria of 
addiction (Mancino et al, 2015), significant differences were 
obtained during the early period for mice overexpressing or 
deficient of the CB2R compared to the control group. The main 
differences were obtained during the early training period when a 
higher percentage of CB2R knock-out and CB2R Tg reaching the 2-
3 criteria (64% and 67% respectively) was revealed in comparison 
to wild-type mice (34%). In addition, significant differences in the 
percentage of mice subpopulations reaching the 0 criteria between 
the CB2R knockout (0%) and control group (60%) were reported 
during this early period. This result suggests that the deletion of 
CB2R may predispose to develop addictive-like behaviour during 




to this behaviour. Specifically, this finding means that CB2R could 
participate in the vulnerability to addiction. Nevertheless, addiction 
is a behaviour appearing only after an extended access to drugs 
(Deroche-Gamonet et al. 2004) and this high vulnerability revealed 
in CB2R knockout mice to develop addictive behaviours just during 
the early training period could be an ambiguous phenomenon. 
Indeed, after long operant training maintained with palatable food a 
similar percentage of addict-like mice was revealed between CB2R 
knockout and the control group (36% and 33% respectively), 
although a trend to decrease the percentage of CB2R-deficient mice 
reaching 0 criteria (18%) was revealed when compared to the 0 
criteria control mice (40%). This result could suggest that the 
deletion of the CB2R is involved in producing the adaptive process 
occurring during the transition to addiction, making animals more 
vulnerable to loss of control over food intake. However, the lack of 
significant results between the two groups in the late phase of the 
operant training could be influenced by compensatory mechanisms 
activated in mice with genetic manipulations of CB2R that could 
minimize the differences between genotypes. Moreover, it should 
also be considered that constitutive CB2R knockout mice presented 
increased vulnerability to stressful stimuli, whereas transgenic mice 
overexpressing CB2R resistant to these stressful stimuli, as revealed 
in the light-dark box and elevated plus-maze test (Ortega-Alvaro et 
al. 2011). This vulnerability to stressful stimuli could have affected 
the performance of CB2R knockout mice in our operant paradigm. 
In summary, the present findings support the notion that the activity 




behaviours promoted by palatable food, and this effect was more 
pronounced during the early period of the operant training. More 
studies are needed to clarify the exact involvement of CB2R in 
eating addictive-like behaviour after long-term palatable food 
operant training.  
 
Finally, our results demonstrated that CB1R could participate in the 
biological substrate underlying the behavioural alterations during 
eating-addictive disorders, although the precise CB1R circuits 
involved must be still clarified. Moreover, our study also revealed 
the participation of CB2R in palatable food reward properties. 
However, numerous questions remain open with regards to possible 
mechanisms involved in this response. The generation of 
conditional mutants with selective CB2R deletion in particular 
neurons will be essential to further advance in this topic and to 














































The results obtained in the present thesis allow to draw the 
following conclusions: 
 
1.  The endogenous opioid system is critically involved in 
cocaine reinforcing effects and reinstatement of cocaine-
seeking behaviour.  
 
2. Opioid peptides derived from PENK acting on DOR have an 
important role in cocaine reinforcing properties.  
 
3. MOR and DOR, and endogenous opioid peptides different 
from enkephalins are crucial for cue-induced reinstatement 
of cocaine-seeking behaviour by modulating neuronal 
activation of brain areas involved in the control of motor, 
motivation, and memory processes, while opioid peptides 
derived from DYN have an opposite role to MOR and DOR 
in the control of cocaine reinstatement. 
 
4. The absence of basal tone of MOR, DOR, PENK and PDYN 
in mice did not modify high-fat food-seeking behaviour.  
 
5. DOR seems implicated in the reinforcing effects, motivation 
and impulsive behaviour induced by operant training with 







6. DOR mediates structural plasticity changes in PFC, HCP 
and NAc shell triggered by prolonged operant training with 
chocolate palatable food. 
 
7.  Training with palatable food induced structural plasticity 
changes in the mesocorticolimbic circuit similar to those 
produced by addictive drug exposure. However, these 
alterations require more time to take place than those 
produced by drugs of abuse. 
 
8. We validated an animal model of eating addictive-like 
behaviour based on the DSM-5 substance use disorder 
criteria using operant conditioning maintained by chocolate 
pellets in an outbred mouse population allowing to identify 
subpopulations of addict-like and non-addict-like mice. 
 
9. Specific proteins in the HCP, ST and PFC regions related to 
impulsive-like behaviour (α-Syn), synaptic plasticity (PP1α, 
DCalmK 2) and cannabinoid signalling  (DGKζ) could be 
involved in the neurobiological changes leading to eating 
addictive-like behaviour.  
 
10. Reduction in DNA methylation at CNR1 gene promoter in 
PFC of addict-like mice represents an important adaptive 







11.  CB1R is involved in the development of addictive-like 
behaviour promoted by palatable food. Indeed, CB1R 
deletion or pharmacological antagonism leads to reduced 
percentage of mice that accomplish addiction criteria after 
long-term training to palatable food. 
 
12. CB2R could be involved in the loss of control over 
consumption promoted by the operant training with 
palatable food.  
 
13. The deletion of CB2R could predispose to generate 
addictive-like behaviour decreasing the percentage of mice 
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